% Exported from Psilocybin Research Publication Tracker
% Tracker site: https://psilocybin-research.com
% Publication tracker: https://psilocybin-research.com/
\documentclass[11pt]{article}
\usepackage[T1]{fontenc}
\usepackage[utf8]{inputenc}
\usepackage{enumitem}
\usepackage[hidelinks]{hyperref}
\usepackage[margin=1in]{geometry}
\title{Psilocybin and Psilocin Research Export}
\author{Psilocybin Research Publication Tracker}
\date{2026-08-23}
\begin{document}
\maketitle
\noindent Exported from \href{https://psilocybin-research.com}{psilocybin-research.com}. Records: 980.

\begin{enumerate}[leftmargin=*]
\item Back AL, McGregor BA, Billingsley L, Blom D, Callan G, Myers S, Guy J, Kumar S, Layer M, Levin J, Perez J, Thompson P, Salmonson K, Whinney J, Thorn LL (2026). \textit{Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1177/28314425251404460}{doi:10.1177/28314425251404460}.
\item Cruz L, Beserra FR, Freind JMK, Rodrigues SE, Mograbi DC (2026). \textit{Music Playlist Use in Clinical Trials of Psychedelic Assisted Psychotherapy: A Systematic Review.}. Journal of clinical psychology. [published; PubMed]. \href{https://doi.org/10.1002/jclp.70167}{doi:10.1002/jclp.70167}.
\item Canady Valerie A. (2026). \textit{JAMA study examines Oregon's psilocybin services model}. Mental Health Weekly. [published; Crossref]. \href{https://doi.org/10.1002/mhw.34984}{doi:10.1002/mhw.34984}.
\item Centre for Addiction and Mental Health (2026). \textit{Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07211438}{source link}.
\item Clark Rachel N (2026). \textit{The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A Narrative Review}. Lynchburg Journal of Medical Science. [published; Crossref]. \href{https://doi.org/10.63932/3067-7106.1087}{doi:10.63932/3067-7106.1087}.
\item Michael J. Broman, Jhuma N. Acharya, Kaltum Ahmed, Stacey B. Armstrong, Alan K. Davis (2026). \textit{The Abuse Liability of Classic Psychedelics: A Methodological Critique and Assessment of the Quality of Evidence of Recent Studies}. Current Addiction Reports. [published; OpenAlex]. \href{https://doi.org/10.1007/s40429-026-00774-8}{doi:10.1007/s40429-026-00774-8}.
\item COMPASS Pathways (2026). \textit{A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07570654}{source link}.
\item Christopher P. Albertyn, Ron Shore, Linda E. Carlson, Erika Dyck, David Clements (2026). \textit{Assessing Canadian Policy Readiness for Psychedelic-Assisted Therapy in Cancer Care}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.21983116}{doi:10.5281/zenodo.21983116}.
\item Strika-Bruneau L, Elhssaini C, Fauvel B, Kervadec E, Bezo A, Amirouche A, Benyamina A, Romeo B. (2026). \textit{Psilocybin-assisted psychotherapy for substance use disorders as a complex intervention: A systematic review of efficacy, mechanisms and psychotherapeutic frameworks.}. Journal of psychopharmacology (Oxford, England). [published; Europe PMC]. \href{https://doi.org/10.1177/02698811261473436}{doi:10.1177/02698811261473436}.
\item Charles Raison (2026). \textit{An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07719088}{source link}.
\item Region Skane (2026). \textit{The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07169747}{source link}.
\item University of Wisconsin, Madison (2026). \textit{Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06692192}{source link}.
\item Nathan Brashares Sackett (2026). \textit{PsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06853912}{source link}.
\item Brigham and Women's Hospital (2026). \textit{Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07296094}{source link}.
\item NYU Langone Health (2026). \textit{Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06349083}{source link}.
\item The University of Texas Health Science Center, Houston (2026). \textit{Acceptability \& Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06706232}{source link}.
\item Roswell Park Cancer Institute (2026). \textit{Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06827054}{source link}.
\item Claudio N Soares (2026). \textit{A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06969170}{source link}.
\item Saanvi Gutta (2026). \textit{Psychedelic Therapy for Depression}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.21893916}{doi:10.5281/zenodo.21893916}.
\item Nicky Mehtani, MD, MPH (2026). \textit{Psilocybin Recovery Intervention for Stopping Methamphetamine Use}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07756736}{source link}.
\item COMPASS Pathways (2026). \textit{A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05711940}{source link}.
\item COMPASS Pathways (2026). \textit{A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05624268}{source link}.
\item University of Colorado, Denver (2026). \textit{A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07516405}{source link}.
\item University Health Network, Toronto (2026). \textit{Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06506019}{source link}.
\item Ham R, Gardner J, Carter A, Liknaitzky P. (2026). \textit{'So many relationships in the room': Participant perspectives on the affordances and challenges of co-therapy in psychedelic assisted therapy.}. Psychology and psychotherapy. [published; Europe PMC]. \href{https://doi.org/10.1111/papt.70098}{doi:10.1111/papt.70098}.
\item Dean JG, Hurwitz E, Furnish T, Castellanos J, McKinty A, Farrell B, Barrows D, Peck SK, Trim J, Samadhi E, Renwick G, Mudge R, Vieten C, Cuccurazzu B, Coleman P, Lin A, Geyer MA, Zeidan F, Halberstadt AL. (2026). \textit{Feasibility and Tolerability of Psilocybin for Phantom Limb Pain.}. The journal of pain. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jpain.2026.106404}{doi:10.1016/j.jpain.2026.106404}.
\item Bhagavan C, Carter O, Nielsen G, Berlowitz D, Issak S, Braat S, Zaloumis S, Attard Z, Oliver G, Mayne D, Rucker J, Butler M, Dandash O, Bryson A, Kanaan RA. (2026). \textit{Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study.}. CNS drugs. [published; Europe PMC]. \href{https://doi.org/10.1007/s40263-026-01326-4}{doi:10.1007/s40263-026-01326-4}.
\item National Institute on Aging (NIA) (2026). \textit{Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07721467}{source link}.
\item Trent Emerick (2026). \textit{Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07406828}{source link}.
\item Centre for Addiction and Mental Health (2026). \textit{Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06731621}{source link}.
\item University of Southern California (2026). \textit{An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06233344}{source link}.
\item Yvan Beaussant, MD, MSci (2026). \textit{Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06001749}{source link}.
\item Schaefer DA, Agrawal M, Mazzola E, Leff MK, Leeks C, Kematick BS, Beaussant Y. (2026). \textit{Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary Analysis.}. Journal of pain and symptom management. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jpainsymman.2026.07.030}{doi:10.1016/j.jpainsymman.2026.07.030}.
\item Yale University (2026). \textit{Psilocybin as a Treatment for Chronic Pain in Smokers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07118332}{source link}.
\item Boehnke KF, Pouyan N, Aday JS (2026). \textit{Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians.}. Drugs. [published; PubMed]. \href{https://doi.org/10.1007/s40265-026-02339-5}{doi:10.1007/s40265-026-02339-5}.
\item Lu S, Zhang Z, Xue X, Jiang Y, Zhang C, Liu P, He D, Shen W, Yang S, Wang F (2026). \textit{Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus.}. Hearing research. [published; PubMed]. \href{https://doi.org/10.1016/j.heares.2026.109701}{doi:10.1016/j.heares.2026.109701}.
\item Graham M, Ge Y, Pacula RL, Pessar SC, Wilkins C, Hall W, Hammond D (2026). \textit{A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study.}. The International journal on drug policy. [published; PubMed]. \href{https://doi.org/10.1016/j.drugpo.2026.105348}{doi:10.1016/j.drugpo.2026.105348}.
\item University of Washington (2026). \textit{A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07336238}{source link}.
\item Joshua Rosenblat (2026). \textit{Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07737990}{source link}.
\item Tel-Aviv Sourasky Medical Center (2026). \textit{Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07737054}{source link}.
\item Armstrong Stacey B., Levin Adam W., Sepeda Nathan D., Shaub Hillary, Hunter Taweh, Douglas Angela, Lancelotta Rafaelle, Davis Alan K. (2026). \textit{Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial}. Communications Medicine. [published; Crossref]. \href{https://doi.org/10.1038/s43856-026-01767-4}{doi:10.1038/s43856-026-01767-4}.
\item Centre for Addiction and Mental Health (2026). \textit{Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06512220}{source link}.
\item Centre for Addiction and Mental Health (2026). \textit{Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06518720}{source link}.
\item Scottsdale Research Institute (2026). \textit{An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07275970}{source link}.
\item University of Wisconsin, Madison (2026). \textit{Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05866471}{source link}.
\item Centre for Addiction and Mental Health (2026). \textit{Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06299319}{source link}.
\item Danial Beniameen, Armya Beniameen (2026). \textit{A Systematic Review of EEG Predictors and Correlates of Psilocybin’s Treatment in Depression}. Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal. [published; OpenAlex]. \href{https://doi.org/10.26685/urncst.1027}{doi:10.26685/urncst.1027}.
\item Nicholas Vucak, Raimondo Bruno, Julio Quealy, James G. Casimaty, Susan L. Rossell, D Castle, Nicola Acevedo (2026). \textit{Integration in classic psychedelic-assisted therapies for mental health conditions: A scoping review}. Psychedelics. [published; OpenAlex]. \href{https://doi.org/10.1016/j.psyche.2026.100030}{doi:10.1016/j.psyche.2026.100030}.
\item Parr BA, Young WB, Silberstein SD (2026). \textit{Comparing synthetic and biological therapy for the treatment of cluster headache: what is needed and when?}. Expert review of neurotherapeutics. [published; PubMed]. \href{https://doi.org/10.1080/14737175.2026.2706794}{doi:10.1080/14737175.2026.2706794}.
\item Cervera-Sanchez Miguel Benjamin, San-Juan Daniel, Díaz-Peregrino Roberto, Camacho-Castillo Evelin Zulema, Bringas-Ortiz Sthefany Anahi, Padilla-Cabezutd Christian (2026). \textit{Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations}. British Journal of Clinical Pharmacology. [published; Crossref]. \href{https://doi.org/10.1002/bcp.70690}{doi:10.1002/bcp.70690}.
\item Johns Hopkins University (2026). \textit{PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07610135}{source link}.
\item Levy-Cooperman N, Sellers E, Glue P, Szeto I, Brown D, Jarecki-Smith J, Tyler WJ, McDonnell MB. (2026). \textit{A randomized, double-blind, placebo-controlled single-ascending-dose study to identify a non-hallucinogenic dose of psilocybin in healthy adults}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.64898/2026.07.16.26358273}{doi:10.64898/2026.07.16.26358273}.
\item Bartosz Niciński, Magdalena Kloc, Ewa Wiench, Natasza Millan, Aleksandra Blicharz, Wojciech Kozdraś, Lidia Kozaczko, Gabriela Szewczyk, Elżbieta Bukowczan, Alicja Zając, Damian Broda, Alicja Benecka (2026). \textit{Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of Depression}. Zenodo (CERN European Organization for Nuclear Research). [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.21406174}{doi:10.5281/zenodo.21406174}.
\item Johns Hopkins University (2026). \textit{Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06067737}{source link}.
\item Jakub Bajer, Aleksandra Włodarczyk, Hubert Kulawinek, Julia Obersztyn, Krzysztof Kasparek, Marta Czech, Grzegorz Kasparek, Adrianna Szczecińska, Wiktoria Glanert, Aleksandra Mliczek, Piotr Mrozek (2026). \textit{Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2026.94.73071}{doi:10.12775/jehs.2026.94.73071}.
\item Dougherty Robert F., Modlin Nadav Liam, McGowan Niall M., Staples Patrick, Williams Ella, Clarke Patrick, Shafiei Mario, Leininger Carly, Alti Merve, Croal Megan, Marwood Lindsey, Kirlić Namik, Ryslik Gregory A., Goodwin Guy M. (2026). \textit{Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder}. Journal of Psychopharmacology. [published; Crossref]. \href{https://doi.org/10.1177/02698811261464988}{doi:10.1177/02698811261464988}.
\item Yale University (2026). \textit{Mechanistic Studies of Psilocybin in Headache Disorders}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06464367}{source link}.
\item Gary Enos (2026). \textit{National bill seeks to jump-start psychedelic treatment for veterans}. Alcoholism \& Drug Abuse Weekly. [published; OpenAlex]. \href{https://doi.org/10.1002/adaw.34973}{doi:10.1002/adaw.34973}.
\item Thomas CW, LaMalfa KS, Whelan TP, Blackmore T, Golden CT, Pizzagalli DA, Bergman J, Gilmour G, Kangas BD (2026). \textit{Psychedelics produce enduring enhancement of reward responsiveness in male rats.}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/s41386-026-02475-2}{doi:10.1038/s41386-026-02475-2}.
\item Bruyère Health Research Institute. (2026). \textit{PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07063862}{source link}.
\item Ottawa Hospital Research Institute (2026). \textit{PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04754061}{source link}.
\item Raul Edison Luna Lazo, Nicole Milagritos Cardoso Azorza, Jatziri Yanina Vilca Yanac, Ahmad Kassem El Zein, Omar Abraham Ramírez Paucar, Luana Mota Ferreira, Roberto Pontarolo (2026). \textit{Therapeutic potential of psilocybin in the pharmacological treatment of obsessive-compulsive disorder: a scoping review protocol.}. Open MIND. [published; OpenAlex]. \href{https://doi.org/10.17605/osf.io/guqxr}{doi:10.17605/osf.io/guqxr}.
\item University Health Network, Toronto (2026). \textit{Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06341426}{source link}.
\item Yale University (2026). \textit{Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06624137}{source link}.
\item Douglass Hannah M., Spriggs Meg J., Godfrey Kate, Danby Jennifer L., de Magalhaes Frederico J. C., Macdonald Lauren, Alderton Kirsty L., Archer Stephanie, Ahmad Kirran, Martell Jonny, Frias Jennifer T., Sawicka Gabriela, Read Tim, Blemings Allan, Lafrance Adele, Nicholls Dasha, Erritzoe David, Park Rebecca J., Nutt David J., Carhart-Harris Robin L. (2026). \textit{Psilocybin therapy for adult females with anorexia nervosa: pilot study}. The British Journal of Psychiatry. [published; Crossref]. \href{https://doi.org/10.1192/bjp.2026.10687}{doi:10.1192/bjp.2026.10687}.
\item University of Wisconsin, Madison (2026). \textit{Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04161066}{source link}.
\item Matthew A. Boehm, Oriana Mayorga (2026). \textit{Policy Considerations for Psychedelics in Research and Medicine - What’s Next on the Schedule?}. Journal of Science Policy \& Governance. [published; OpenAlex]. \href{https://doi.org/10.38126/jspg280103}{doi:10.38126/jspg280103}.
\item Koning Elena, Richard Jérémie, Keshen Aaron (2026). \textit{Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions}. International Journal of Eating Disorders. [published; Crossref]. \href{https://doi.org/10.1002/eat.70164}{doi:10.1002/eat.70164}.
\item Meyer Thomas D, Vale Lauren N, Ibrahim Maya, Olmos Carolina, Quevedo João, Soares Jair C (2026). \textit{Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study}. BMJ Open. [published; Crossref]. \href{https://doi.org/10.1136/bmjopen-2026-118471}{doi:10.1136/bmjopen-2026-118471}.
\item Sunstone Medical (2026). \textit{A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06902974}{source link}.
\item Bender DA, Nayak SM, Siegel JS, Hellerstein DJ, Ercal BC, Lenze EJ (2026). \textit{Provider perspectives on challenges in treatment during psychedelic therapy.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-025-06907-7}{doi:10.1007/s00213-025-06907-7}.
\item Grant Jon E., Boutouis Sophia, O’Brien Margaret, Avila Laurie, Neelapu Megha, Ehsan Dustin (2026). \textit{An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder}. Clinical Neuropharmacology. [published; Crossref]. \href{https://doi.org/10.1097/wnf.0000000000000683}{doi:10.1097/wnf.0000000000000683}.
\item Orsini DK, Wong S, Di Luch S, Chan B, Vasudeva S, Lovell GFM, Le GH, Jones BDM, Chisamore N, Mollica A, Johnson DE, Kaczmarek ES, Goel A, Burke MJ, Mansur R, McIntyre RS, Husain MI, Rosenblat JD (2026). \textit{Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.}. JAMA psychiatry. [published; PubMed]. \href{https://doi.org/10.1001/jamapsychiatry.2026.0255}{doi:10.1001/jamapsychiatry.2026.0255}.
\item Hoyer D (2026). \textit{Psychedelics, entactogens and psychoplastogens for depression and related disorders.}. British journal of pharmacology. [published; PubMed]. \href{https://doi.org/10.1111/bph.70088}{doi:10.1111/bph.70088}.
\item Wittenkeller L, Gudelsky G, Winhusen TJ, Amato D (2026). \textit{Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology.}. British journal of pharmacology. [published; PubMed]. \href{https://doi.org/10.1111/bph.70181}{doi:10.1111/bph.70181}.
\item Sjöström David, Schau Rybäck Olea, Claesdotter Knutsson Emma, Kajonius Petri, Jensen Sondén Oskar, Carlbring Per, Björkstrand Johannes, Movahed Rad Pouya (2026). \textit{Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults”}. PLOS One. [published; Crossref]. \href{https://doi.org/10.1371/journal.pone.0352246}{doi:10.1371/journal.pone.0352246}.
\item Estela-Fernandez CA, Mohamed Yousif Elsheikh R, Beatrice DB, A Alhendal A, Irene Ewe C, Montesinos SY, Wensel J, Mishra AP, Yousif AA, Ali HT (2026). \textit{Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations.}. Neuropsychiatrie: Klinik, Diagnostik, Therapie und Rehabilitation: Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater. [published; PubMed]. \href{https://doi.org/10.1007/s40211-026-00584-4}{doi:10.1007/s40211-026-00584-4}.
\item Stefanie Enriquez Geppert, Lisa Bevers, Arvid Rosander, Peter Fodran, Vince Polito (2026). \textit{Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development}. University of Groningen research database (University of Groningen / Centre for Information Technology). [published; OpenAlex]. \href{https://research.rug.nl/en/publications/370a82bd-d8db-4a02-b644-bf0c9131680b}{source link}.
\item Johns Hopkins University (2026). \textit{5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05452772}{source link}.
\item Guidetti C, Fava M, Papakostas GI (2026). \textit{Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-026-03722-0}{doi:10.1038/s41380-026-03722-0}.
\item Claudino Dos Santos JC, Bolan SJ, Lodetti G, Viana GL, Rico EP, Gonçalves CL (2026). \textit{Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challenges.}. Journal of psychiatric research. [published; PubMed]. \href{https://doi.org/10.1016/j.jpsychires.2026.06.035}{doi:10.1016/j.jpsychires.2026.06.035}.
\item Mauro Pettorruso, Giacomo d’Andrea, Antonio Inserra, Clara Cavallotto, Stefano Censi, Étienne Billard, Antonio Di Stefano, Luisa De Risio, Maria Giulia Tullo, Claudio D’Addario, Giorgio Di Lorenzo, Richard G. Wise, Stefano L. Sensi, Francesca Zoratto, Giovanni Martinotti (2026). \textit{Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care}. Translational Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1038/s41398-026-04203-2}{doi:10.1038/s41398-026-04203-2}.
\item University Health Network, Toronto (2026). \textit{Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07048743}{source link}.
\item University of Virginia (2026). \textit{Psilocybin-Assisted Therapy for Prolonged Grief}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06724289}{source link}.
\item University Health Network, Toronto (2026). \textit{Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06416085}{source link}.
\item Low ZXB (2026). \textit{Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2026.111717}{doi:10.1016/j.pnpbp.2026.111717}.
\item Frick A, Blest-Hopley G, Grin M, Erritzoe D, Nutt D, Carhart-Harris R. (2026). \textit{Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9880403/v1}{doi:10.21203/rs.3.rs-9880403/v1}.
\item Leeman Lawrence, Armstrong Maya, Menashi Dara, Nayo-Washington Hanifa, Marseille Elliot, Herrera Janus, Romero Crystal, Page-Reeves Janet (2026). \textit{Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico}. Frontiers in Public Health. [published; Crossref]. \href{https://doi.org/10.3389/fpubh.2026.1845943}{doi:10.3389/fpubh.2026.1845943}.
\item SAIMSARA (2026). \textit{Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARA}. SAIMSARA Journal. [published; Crossref]. \href{https://doi.org/10.62487/saimsara7a54f680}{doi:10.62487/saimsara7a54f680}.
\item Labra-Lorenzana Angel, Lima-Sánchez Dania Nimbe, Delaflor-Wagner Christian Alejandro, Martínez-Hernández Diana, Ramos-Jiménez Christian, Toledo-Lozano Christian Gabriel (2026). \textit{Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-Analysis}. Psychiatry International. [published; Crossref]. \href{https://doi.org/10.3390/psychiatryint7030137}{doi:10.3390/psychiatryint7030137}.
\item Julia Osipowska, Marlena Kwolek, Alicja Judzińska, Bartosz Piech, Kamila Sobczyńska, Justyna Ignarska, Magda Terbosh, Sabina Kubicz `Mzabi, Emilia Trojanowska, Magdalena Dubaj (2026). \textit{THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.2(50).2026.5605}{doi:10.31435/ijitss.2(50).2026.5605}.
\item Robin Carhart-Harris, PhD, MA (2026). \textit{Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-sampling}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05698511}{source link}.
\item Tarbi Elise C., Bhatia Ian, Balach Nabil, Buehler Suzannah, Demeo-Meres Magdalena, Gramling Cailin, Thambi Tej, Hart Julia, Reblin Maija, Rizzo Donna M., Gramling Robert, Agrawal Manish, Manetta Emily (2026). \textit{Developing Methods for Observing Awe Narration in Psilocybin-Assisted Therapy}. Healthcare. [published; Crossref]. \href{https://doi.org/10.3390/healthcare14111589}{doi:10.3390/healthcare14111589}.
\item University of Calgary (2026). \textit{The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06768944}{source link}.
\item Kelly JR, Sheridan C, Iusan P, Coakley L, Burke L, Brennan C, MacDonald A, Ivers JH, Trepel D, Tormey G, Finnegan M, Young GW, Harkin A (2026). \textit{Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.}. The international journal of neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1093/ijnp/pyag028}{doi:10.1093/ijnp/pyag028}.
\item Gaurav Uppal, Naima Gul, Asha Dhandapani, Sathyan Soundararajan, Khushboo Kansal (2026). \textit{From Altered States to Altered Trajectories and From Molecules to Meaning: A Network Meta Analysis Mapping Comparative Efficacy of Psychedelic Assisted Therapies in Modern Psychiatry}. BJPsych Open. [published; OpenAlex]. \href{https://doi.org/10.1192/bjo.2026.11141}{doi:10.1192/bjo.2026.11141}.
\item Canady Valerie A. (2026). \textit{Psilocybin shows rapid relief for depression symptoms}. Mental Health Weekly. [published; Crossref]. \href{https://doi.org/10.1002/mhw.34890}{doi:10.1002/mhw.34890}.
\item Patil Shivaputra A., Hunsberger Holly C. (2026). \textit{Psilocybin: Chemical Foundations and Emerging Therapeutic Potential}. Mini-Reviews in Medicinal Chemistry. [published; Crossref]. \href{https://doi.org/10.2174/0113895575429775260119043318}{doi:10.2174/0113895575429775260119043318}.
\item Yonezawa Kengo, Hirata Mayuko, Takano Hiroaki, Kusudo Keisuke, Tomiyama Sota, Harada Lisa, Suzuki Kouta, Nutt David J., Uchida Hiroyuki, Tani Hideaki (2026). \textit{Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations}. Psychiatry and Clinical Neurosciences. [published; Crossref]. \href{https://doi.org/10.1111/pcn.70042}{doi:10.1111/pcn.70042}.
\item Varela YM, de O Tavares VD, Delgado LM, de Faria HAT, Menezes LQ, Almeida RM, Agrícola P, de Carvalho BS, Bienemann B, Falchi-Carvalho M, Cavalcanti-Ribeiro P, Palhano-Fontes F, Fernandes-Osterhold G, de Araujo DB, Galvão-Coelho N (2026). \textit{Mapping cognitive-behavioral approach in psychedelic-assisted treatment: a systematic review across phases with classic and non-classic psychedelics.}. European archives of psychiatry and clinical neuroscience. [published; PubMed]. \href{https://doi.org/10.1007/s00406-025-02188-5}{doi:10.1007/s00406-025-02188-5}.
\item Egger K, Bozsak R, Aicher HD, Sari H, Poetzsch SN, Rominger A, Martin-Soelch C, Smallridge JW, Dornbierer D, Quednow BB, Scheidegger M, Cumming P (2026). \textit{Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [F]FDG-PET study.}. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. [published; PubMed]. \href{https://doi.org/10.1177/0271678x261454172}{doi:10.1177/0271678x261454172}.
\item Houff Jenna, Williams Andrew, Allen Obie, Gisabella Barbara, Pantazopoulos Harry, Del Arco Alberto (2026). \textit{Psilocybin Decreases Preference for Large Rewards Accompanied by Increased Activity of Parvalbumin Neurons With Perineuronal Nets in the Medial Prefrontal Cortex}. European Journal of Neuroscience. [published; Crossref]. \href{https://doi.org/10.1111/ejn.70574}{doi:10.1111/ejn.70574}.
\item Poppe C, Lyck L, Bechtold L, Repantis D (2026). \textit{Expectations and Motivations for Participation in Clinical Trials Utilizing Psychedelics for Treatment-Resistant Depression: A Qualitative Study.}. Brain and behavior. [published; PubMed]. \href{https://doi.org/10.1002/brb3.71544}{doi:10.1002/brb3.71544}.
\item Rosa WE, Napolitano S, McAndrew N, Jenkins B, Lichtenthal WG, Applebaum AJ, Breitbart W, Agrawal M (2026). \textit{Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy Among Patients with Advanced Cancer and Depression: Rationale and Preliminary Evaluation of MCP-PSIL.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1177/28314425251363983}{doi:10.1177/28314425251363983}.
\item L Belinger, N M Rieser, E J E Engeli, L Becciolini, M Clamote, M Pribis, F Saissi, G.A. Florineth, N L Hehl, M Herdener, K H Preller (2026). \textit{Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers.}. Open Access CRIS of the University of Bern. [published; OpenAlex]. \href{https://doi.org/10.48620/98266}{doi:10.48620/98266}.
\item Atiq Mazen A., Weisman Eli, Guerra Rodrigo B., Martinez Luis Luna, Yaden David B., Barrett Frederick S., Nayak Sandeep, Sayali Ceyda (2026). \textit{Psilocybin-induced neurocardiogenic syncope: a case report}. Psychopharmacology. [published; Crossref]. \href{https://doi.org/10.1007/s00213-026-07079-8}{doi:10.1007/s00213-026-07079-8}.
\item Mertens Lea J., Betzler Felix, Brand Manuela, Evens Ricarda, Jungaberle Andrea, Jungaberle Henrik, Kärtner Laura, Majić Tomislav, Schmitz Christian N., Ströhle Andreas, Scharf Dennis, Spangemacher Moritz, Wolff Max, Assadi Zahra, Bahri Scharif, Becher Lilith, Färber Luca V., Harder Henry, Kirchen Niklas, Kulakova Eugenia, Kunz Linda C., Meijer Andy, Rohrmoser Barbara, Wellek Stefan, Berger Moritz M., Koslowski Michael, Gründer Gerhard (2026). \textit{Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial}. Psychotherapy and Psychosomatics. [published; Crossref]. \href{https://doi.org/10.1159/000552272}{doi:10.1159/000552272}.
\item Laursen DRT, Salazar J, Jürgens G, Hróbjartsson A (2026). \textit{Active placebo control interventions in pharmacological trials: a scoping review of the development process and a terminological analysis.}. Journal of clinical epidemiology. [published; PubMed]. \href{https://doi.org/10.1016/j.jclinepi.2026.112345}{doi:10.1016/j.jclinepi.2026.112345}.
\item Dallas T Mason (2026). \textit{Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic Potential}. Digital Showcase Research, Scholarship, \& Creative Works (University of Lynchburg). [published; OpenAlex]. \href{https://digitalshowcase.lynchburg.edu/dmscjournal/vol8/iss1/6}{source link}.
\item Rachel N Clark (2026). \textit{The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A New and Promising Approach}. Digital Showcase Research, Scholarship, \& Creative Works (University of Lynchburg). [published; OpenAlex]. \href{https://digitalshowcase.lynchburg.edu/cgi/viewcontent.cgi?article=3694\&context=dmscjournal}{source link}.
\item University of New Mexico (2026). \textit{Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07506395}{source link}.
\item Washington University School of Medicine (2026). \textit{A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07582120}{source link}.
\item Yngwe Hampus, Plavén-Sigray Pontus, Ekman Carl Johan, Henje Eva, Berglund Anders, Tiger Mikael, Beckman Maria, Lundberg Johan (2026). \textit{Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression}. JAMA Network Open. [published; Crossref]. \href{https://doi.org/10.1001/jamanetworkopen.2026.12589}{doi:10.1001/jamanetworkopen.2026.12589}.
\item Alan Davis (2026). \textit{Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07216404}{source link}.
\item Jacob Cohen, Peter Parbo, Per Trads Ørskov, Dirk Wildgruber, Benjamin Kreifelts, ulrich kirk, Oke Gerke, Martin Korsbak Madsen, Mikael Palner (2026). \textit{Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial.}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/3b9fx\_v1}{source link}.
\item Walters CK, Chetty S, Rants’o TA, Gossayn S, Lerotholi LJ. (2026). \textit{Safety and Efficacy of Psilocybin in the Management of Treatment-Resistant Depression: A Systematic Review}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9283280/v1}{doi:10.21203/rs.3.rs-9283280/v1}.
\item Jessie Kim, Liam Lochhead, Cory R. Weissman (2026). \textit{From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical Practice}. Pharmacology Research \& Perspectives. [published; OpenAlex]. \href{https://doi.org/10.1002/prp2.70262}{doi:10.1002/prp2.70262}.
\item University Medical Center Groningen (2026). \textit{The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06782724}{source link}.
\item Reid Matthew, Weisman Eli, Martinez Luis Luna, Coon William, Barrett Frederick (2026). \textit{1080 Psilocybin Elicits Non-Linear Night to Night Changes in Sleep Spectral Power}. SLEEPJ. [published; Crossref]. \href{https://doi.org/10.1093/sleep/zsag091.1079}{doi:10.1093/sleep/zsag091.1079}.
\item Centre for Addiction and Mental Health (2026). \textit{Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05710237}{source link}.
\item Hendricks Peter S., Lappan Sara N., Shelton Richard C., Lahti Adrienne C., Cropsey Karen L., Johnson Matthew W., Bradley Melissa, Simonsson Otto, Davis Lori L., Grossman Daniel H., Ortiz Cynthia E. (2026). \textit{Psilocybin in the Treatment of Cocaine Use Disorder}. JAMA Network Open. [published; Crossref]. \href{https://doi.org/10.1001/jamanetworkopen.2026.11029}{doi:10.1001/jamanetworkopen.2026.11029}.
\item Sunstone Medical (2026). \textit{A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05947383}{source link}.
\item University of North Carolina, Chapel Hill (2026). \textit{Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06303739}{source link}.
\item Stanford University (2026). \textit{A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07479550}{source link}.
\item Usona Institute (2026). \textit{A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04353921}{source link}.
\item University of Washington (2026). \textit{A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07565909}{source link}.
\item Bradley Ellen, Kelley D Parker, Picard Martin, Szigeti Balazs, Sakai Kimberly, Fernandes Gisele, Ostrem Jill, Tanner Caroline, Finley Patrick, Ludwig Connie, Llerena Katiah, Busby Zach, McKernan Amber, Zuzuarregui Jose Rafael, Bock Meredith, Wang Aliss, Penn Andrew, Woolley Josh, O'Donovan Aoife (2026). \textit{356. Psilocybin Therapy is Associated With Decreases in Markers of Mitochondrial Stress and Inflammation in an Open-Label Clinical Trial of Parkinson’s Disease}. Biological Psychiatry. [published; Crossref]. \href{https://doi.org/10.1016/j.biopsych.2026.03.590}{doi:10.1016/j.biopsych.2026.03.590}.
\item Greenway KT, Garel N, Dinh-Williams LL, Thibault Lévesque J, Kaelen M, Dagenais-Beaulé V, de la Salle S, Erritzoe D, Looper K, Turecki G, Rej S, Richard-Devantoy S (2026). \textit{The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression.}. The British journal of psychiatry: the journal of mental science. [published; PubMed]. \href{https://doi.org/10.1192/bjp.2025.102}{doi:10.1192/bjp.2025.102}.
\item Uyar A, Forbrich L, Lueken U, Evens R (2026). \textit{Landscape analysis of pre-registered clinical trials involving classical psychedelics.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251371690}{doi:10.1177/02698811251371690}.
\item Scholle P, Wenke Š, Nekovářová T, Zaytseva Y, Tylš F, Brunovský M, Horáček J, Andrashko V, Koudelka V, Viktorinová M, Viktorin V, Hájková K, Kuchař M, Páleníček T (2026). \textit{The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251389552}{doi:10.1177/02698811251389552}.
\item Kerr-Gaffney J, Myrtle S, Askari F, Bird C, Modlin NL, Young AH, Rucker J (2026). \textit{Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251408769}{doi:10.1177/02698811251408769}.
\item Lewis BR, Reid MJ, Novick AM, Byrne K, Niciu MJ, Fonzo GA, Meyer TD, Feifel D, El-Mallakh RS, Soares J, Suppes T, Barrett FS (2026). \textit{Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251413490}{doi:10.1177/02698811251413490}.
\item Goldy SP, Sepeda ND, Hilbert SN, Bari BA, Garcia-Romeu A, Gukasyan N, Barrett FS, Yaden DB, Nayak SM (2026). \textit{Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2026.117010}{doi:10.1016/j.psychres.2026.117010}.
\item Moreno Francisco A., Allen Katja E., Wiegand Christopher B., Dunne Rajan, Prickett James I., Bayze Brian, Allen John J. B. (2026). \textit{A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder}. Journal of Psychopharmacology. [published; Crossref]. \href{https://doi.org/10.1177/02698811261424214}{doi:10.1177/02698811261424214}.
\item Mertens Lea J., Koslowski Michael, Betzler Felix, Brand Manuela, Evens Ricarda, Kärtner Laura, Jungaberle Andrea, Jungaberle Henrik, Majić Tomislav, Schmitz Christian N., Ströhle Andreas, Scharf Dennis, Spangemacher Moritz, Wolff Max, Assadi Zahra, Bahri Scharif, Becher Lilith, Färber Luca V., Kirchen Niklas, Kulakova Eugenia, Kunz Linda, Meijer Andy, Rohrmoser Barbara, Wellek Stefan, Berger Moritz M., Gründer Gerhard (2026). \textit{Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression}. JAMA Psychiatry. [published; Crossref]. \href{https://doi.org/10.1001/jamapsychiatry.2026.0132}{doi:10.1001/jamapsychiatry.2026.0132}.
\item Brusky B, M'Bailara K, Alla F, Barrault M (2026). \textit{Psychological support in psychedelic-assisted therapy clinical trials: A systematic review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811261424204}{doi:10.1177/02698811261424204}.
\item Beidas Zeina, Ragnhildstveit Anya, Blackman Adam, Anderson Thomas, Fewster Emily, Syed Omer A., Sobolenko Valentyne, Kanca Ismail Kaan, Son Tatiana, Farb Norman, Petranker Rotem (2026). \textit{Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM}. BJPsych Open. [published; Crossref]. \href{https://doi.org/10.1192/bjo.2026.12000}{doi:10.1192/bjo.2026.12000}.
\item Nayak SM, Sepeda ND, Dick MN, Tiwari P, Zahid Z, Sayalı C, Weiss BM, Yaden DB, Garcia-Romeu A, Barnett BS, Barrett FS. (2026). \textit{Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.64898/2026.04.28.26351625}{doi:10.64898/2026.04.28.26351625}.
\item University Hospital, Basel, Switzerland (2026). \textit{Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05883540}{source link}.
\item Portland VA Research Foundation, Inc (2026). \textit{Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04982796}{source link}.
\item Kyle Greenway (2026). \textit{Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07373535}{source link}.
\item Cahuasqui-Mendoza Deivid Antonio (2026). \textit{Psilocybin as an alternative to conventional treatments: A systematic review}. Gaceta Médica de Caracas. [published; Crossref]. \href{https://doi.org/10.47307/gmc.2026.134.s2.32}{doi:10.47307/gmc.2026.134.s2.32}.
\item University of Colorado, Denver (2026). \textit{Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06430541}{source link}.
\item Khosravi Mohsen, De Berardis Domenico, Tusconi Massimo (2026). \textit{The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes}. Mental Wellness. [published; Crossref]. \href{https://doi.org/10.4081/mw.2026.40}{doi:10.4081/mw.2026.40}.
\item Siti Nashria Rusdhy, Andrian Fajar Kusumadewi, Carla Raymondalexas Marchira, Mustika Suci Mahardikaningrum, Teresa Lalita Wiryarini, Devira Ayu Wulandari (2026). \textit{Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled Trials}. Open Access Indonesian Journal of Medical Reviews. [published; Crossref]. \href{https://doi.org/10.37275/oaijmr.v6i2.883}{doi:10.37275/oaijmr.v6i2.883}.
\item Bhagavan C, Dandash O, Carter O, Bryson A, Kanaan RA. (2026). \textit{Sustained Effects of Low-to-Moderate Doses of Psilocybin on Brain Connectivity}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.64898/2026.04.17.26351147}{doi:10.64898/2026.04.17.26351147}.
\item Gondi CS, Gnanamony M, Gondi TP, Nersesyan L, Demirkhanyan L (2026). \textit{Psychedelics and Autism Therapy: A Review of Current Research and Future Directions.}. Current issues in molecular biology. [published; PubMed]. \href{https://doi.org/10.3390/cimb48040417}{doi:10.3390/cimb48040417}.
\item Klintefors P, Bhagavan C, Kanaan R, Bryson A, Berlowitz D, Attard Z, Carter O. (2026). \textit{Psilocybin’s Kinematic Effect on Manual Dexterity}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9291780/v1}{doi:10.21203/rs.3.rs-9291780/v1}.
\item Back Anthony L., McGregor Bonnie A., Thorn Leslie L., Harvey Kalin, Blom Dianna, Callan George, Guy John, Kumar Sameet, Hershberg Rob, Layer Melissa, Levin Jackie, Myers Susanna, Perez Juliana, Salmonson Kathy, Thompson Peter, Whinney Joseph (2026). \textit{A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience}. Frontiers in Public Health. [published; Crossref]. \href{https://doi.org/10.3389/fpubh.2026.1810904}{doi:10.3389/fpubh.2026.1810904}.
\item Section for Affective Disorders; Northern Stockholm Psychiatry (2026). \textit{CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06319378}{source link}.
\item University Hospital, Basel, Switzerland (2026). \textit{Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06180759}{source link}.
\item Schindler EAD, Gottschalk CH, Pittman BP, D'Souza DC (2026). \textit{Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial.}. Headache. [published; PubMed]. \href{https://doi.org/10.1111/head.70024}{doi:10.1111/head.70024}.
\item Weiser S, Jung S, Bardl B, Kufs JE, Janevska S, Valiante V, Hoffmeister D, Regestein L (2026). \textit{Psilocybin Production With Genetically Modified Aspergillus nidulans Under Pressurized Conditions.}. Biotechnology and bioengineering. [published; PubMed]. \href{https://doi.org/10.1002/bit.70137}{doi:10.1002/bit.70137}.
\item Swieczkowski Damian, Kwaśny Aleksander, Sadko Krzysztof, Cubała Wiesław Jerzy (2026). \textit{Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols}. European Neuropsychopharmacology. [published; Crossref]. \href{https://doi.org/10.1016/j.euroneuro.2025.112746}{doi:10.1016/j.euroneuro.2025.112746}.
\item Olejnik P, Kamińska K, Gołembiowska K, Kasarełło K (2026). \textit{Effects of psilocybin and chronic mild stress on microglial activation in rat spinal cord: an ex vivo analysis.}. Pharmacological reports: PR. [published; PubMed]. \href{https://doi.org/10.1007/s43440-026-00824-y}{doi:10.1007/s43440-026-00824-y}.
\item Žuljević Marija Franka, Mijatović Antonija, Orhanović Renata, Goasdoué Glenn, Gujinović Diana (2026). \textit{Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin}. Journal of Clinical Epidemiology. [published; Crossref]. \href{https://doi.org/10.1016/j.jclinepi.2026.112170}{doi:10.1016/j.jclinepi.2026.112170}.
\item Downar J, Lapenskie J, Anderson K, Parsons G, Polskaia N, Lalumiere G, Lawlor P (2026). \textit{PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial.}. Palliative medicine. [published; PubMed]. \href{https://doi.org/10.1177/02692163261416269}{doi:10.1177/02692163261416269}.
\item Kazdan J, Ladha KS, Husain MI (2026). \textit{Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action.}. Pharmacology research \& perspectives. [published; PubMed]. \href{https://doi.org/10.1002/prp2.70238}{doi:10.1002/prp2.70238}.
\item Marazziti D, Gambini M, Gurrieri R, Russomanno G, Sità G, Pescini E, Digiuseppe FR, Mucci F (2026). \textit{Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations.}. Expert opinion on pharmacotherapy. [published; PubMed]. \href{https://doi.org/10.1080/14656566.2026.2654682}{doi:10.1080/14656566.2026.2654682}.
\item Kenji Hashimoto, Feyza Arıcıoğlu, Mesut Çetin (2026). \textit{Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric Disorders}. Psychiatry and Clinical Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.65801/pcp.3512}{doi:10.65801/pcp.3512}.
\item Sunnybrook Health Sciences Centre (2026). \textit{Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06072898}{source link}.
\item Indiana University (2026). \textit{Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07499583}{source link}.
\item Federal University of Latin American Integration (2026). \textit{Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06898606}{source link}.
\item Aly Shah Aziz (2026). \textit{Classic psychedelic medicines for adolescent refractory mental health disease}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2026.00452}{doi:10.1556/2054.2026.00452}.
\item Broc A Pagni, Stephen Ross, Sarah Mennenga, Snehal R Bhatt, Richard J. Zeifman, Petros Petridis, Brennan Carrithers, Lindsay Worth, Samantha Podrebarac, Lindsey Owens (2026). \textit{Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/7xfek\_v1}{source link}.
\item Skalski Piotr, Pękacka-Falkowska Katarzyna, Pluto-Prądzyńska Agnieszka, Owecki Michał K. (2026). \textit{Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD)}. Brain Sciences. [published; Crossref]. \href{https://doi.org/10.3390/brainsci16040358}{doi:10.3390/brainsci16040358}.
\item Anders Fink-Jensen, MD, DMSci (2026). \textit{The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05416229}{source link}.
\item Medical University of Vienna (2026). \textit{Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07490353}{source link}.
\item Bhagavan C, Carter O, Bryson A, Dandash O, Kanaan R (2026). \textit{Psychedelics in functional disorders: A scoping review.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2026.111642}{doi:10.1016/j.pnpbp.2026.111642}.
\item Gustavo Vazquez (2026). \textit{Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06818994}{source link}.
\item Sungheetha Akey, Rajesh Sharma R., Aroba Oluwasegun Julius, Mahapatra Sheila, Mahendhiran P. D. (2026). \textit{Explainable AI framework for psilocybin depression treatment optimization}. Frontiers in Computer Science. [published; Crossref]. \href{https://doi.org/10.3389/fcomp.2025.1652190}{doi:10.3389/fcomp.2025.1652190}.
\item Alessandra Linardi, Ariadiny Lima Caetano, Rodrigo Portes Ureshino (2026). \textit{Editorial: Psychedelic substances and neurological diseases: from basics to clinical application}. Frontiers in Pharmacology. [published; OpenAlex]. \href{https://doi.org/10.3389/fphar.2026.1816812}{doi:10.3389/fphar.2026.1816812}.
\item Crocq MA, Auby P (2026). \textit{The renaissance of research on psychedelics in child and adolescent psychopharmacology.}. Child and adolescent psychiatry and mental health. [published; PubMed]. \href{https://doi.org/10.1186/s13034-026-01069-6}{doi:10.1186/s13034-026-01069-6}.
\item Wood BJ, Vest MF, Carfagno C, Bartley KR, Sharma P, Halberstadt AL, Blough BE, Murnane KS (2026). \textit{Differential Effects of Acute and Chronic Fluoxetine on Psychedelic-Induced Behavior in Mice: Implications for Clinical Trials.}. ACS pharmacology \& translational science. [published; PubMed]. \href{https://doi.org/10.1021/acsptsci.5c00484}{doi:10.1021/acsptsci.5c00484}.
\item Yale University (2026). \textit{Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06442423}{source link}.
\item Gregorio GD, Basset S, Manmohan H, Nixon WC, Pogaku A, Zhou J, Sanderson DJ, Lengieza ML, Bocchio M. (2026). \textit{Age moderates the relationship between psychedelics use and mental health in naturalistic settings}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9022170/v1}{doi:10.21203/rs.3.rs-9022170/v1}.
\item Johnson Matthew W., Naudé Gideon P., Hendricks Peter S., Garcia-Romeu Albert (2026). \textit{Psilocybin or Nicotine Patch for Smoking Cessation}. JAMA Network Open. [published; Crossref]. \href{https://doi.org/10.1001/jamanetworkopen.2026.0972}{doi:10.1001/jamanetworkopen.2026.0972}.
\item Psyence Australia Pty Ltd (2026). \textit{A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07072728}{source link}.
\item Alexander WB, Hansen ED, Anderson BT, Zarrabi AJ, Rogers AH, Loewen G, Ficarro ZR, Alexander MH, Schaefer D, Case AA (2026). \textit{Meaning and Psychedelics in Palliative Care: A Narrative Review.}. Journal of pain and symptom management. [published; PubMed]. \href{https://doi.org/10.1016/j.jpainsymman.2025.10.015}{doi:10.1016/j.jpainsymman.2025.10.015}.
\item Keshen A, Touyz S, Lacroix E, Hay P, McElroy SL (2026). \textit{Innovative Pharmacological Approaches to Eating Disorder Treatment.}. The Psychiatric clinics of North America. [published; PubMed]. \href{https://doi.org/10.1016/j.psc.2025.08.014}{doi:10.1016/j.psc.2025.08.014}.
\item van der Meer PB, Schukking N, Dik M, van Reemst A, Fuentes JJ, Kaptein AA, Schoones JW, Verboeket S, de Waal MM, Goudriaan AE, Kramers C, Schellekens A, Bossong MG, Somers M, Batalla A (2026). \textit{Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1177/28314425251364182}{doi:10.1177/28314425251364182}.
\item Ana Deutsch, Luis E. Contreras, Sarah Kratina, Leah M. Mayo (2026). \textit{A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations}. Therapeutic Advances in Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/20451253261433836}{doi:10.1177/20451253261433836}.
\item C Faria, Diana Dias da Silva, João José Sousa (2026). \textit{Psilocybin-assisted therapy for major depressive disorder: implications for clinical effectiveness, health economics, and regulatory decision-making}. Instituto Politécnico do Porto. [published; OpenAlex]. \href{https://doi.org/10.26537/prpaeh.v4i3.7173}{doi:10.26537/prpaeh.v4i3.7173}.
\item Gearin A, Docherty J, Sun X, Cheung EH, Tanuseputro P (2026). \textit{Psychedelic therapy and cultural humility.}. Translational psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41398-026-03913-x}{doi:10.1038/s41398-026-03913-x}.
\item Centre for Addiction and Mental Health (2026). \textit{Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive Impairment}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06041152}{source link}.
\item Garcia-Romeu Albert, Naudé Gideon P., Rebman Alison W., So Sara, Yaffe Abigail, Geithner Ian, Kozero Erica A., Yang Ting, Soloski Mark J., Aucott John N. (2026). \textit{Pilot study of psilocybin in patients with post-treatment lyme disease}. Scientific Reports. [published; Crossref]. \href{https://doi.org/10.1038/s41598-026-38091-9}{doi:10.1038/s41598-026-38091-9}.
\item Johns Hopkins University (2026). \textit{Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06005662}{source link}.
\item Petranker R, Farb N, Syed O, Li E, Shore D, Anderson T, Blackman A. (2026). \textit{Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-8319478/v1}{doi:10.21203/rs.3.rs-8319478/v1}.
\item Christina Chwyl, Alissa Bazinet, Adie Wilson-Poe, Kim Hoffman, Kellie Pertl, Sara McCrimmon, Philip Korthuis, Jason Luoma (2026). \textit{Ethical Complexities and Best Practices in Informed Consent for Psychedelic Services: A Qualitative Study on Expert Perspectives}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/mdz73\_v2}{source link}.
\item Jordan McDowell, Jada Middleton, Alanna Bluett, Alisa Kozachenko, Bayan Attar, Yuvraj Singh Saini, Jennifer Burke, Cayden McPhee, Mutahera Mutahera, Talya Ahmed, Nabila Ibrahim, Gilbert Atukwatsibwe, Sulabha Adhikari, Mohammad Esmaili, Jean-Vital Yambayamba (2026). \textit{Effects of Psilocybin and Select Pharmaceutical Interactions}. MacEwan University Student eJournal. [published; OpenAlex]. \href{https://doi.org/10.31542/bcek6t76}{doi:10.31542/bcek6t76}.
\item Khan Z, Weaver S, Dando RV, Schlag AK, Neill JC, Wainwright V (2026). \textit{Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis.}. Qualitative health research. [published; PubMed]. \href{https://doi.org/10.1177/10497323261419338}{doi:10.1177/10497323261419338}.
\item Beidas Z, Ragnhildstveit A, Blackman A, Anderson T, Fewster E, Syed OA, Sobolenko V, Kanca IK, Jaglinska M, Son T, Farb N, Petranker R (2026). \textit{Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial.}. BJPsych open. [published; PubMed]. \href{https://doi.org/10.1192/bjo.2025.10968}{doi:10.1192/bjo.2025.10968}.
\item MycoMedica Life Sciences PBC (2026). \textit{A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07050368}{source link}.
\item Johns Hopkins University (2026). \textit{Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07053917}{source link}.
\item Amanda L. Elyse (2026). \textit{Psilocybin and Animal Testing: Charting an End to the Use of Animals in Drug Development Research}. Digital Commons at University of Maryland Carey Law (University of Maryland Francis King Carey School of Law). [published; OpenAlex]. \href{https://digitalcommons.law.umaryland.edu/cgi/viewcontent.cgi?article=1002\&context=jhclp\_online\_issue}{source link}.
\item Rafael Lancelotta, Paul Nagib, Stacey B. Armstrong, Adam W. Levin, A. B. Davis (2026). \textit{Development and assessment of a psychedelic-assisted therapy music playlist for clinical trials: Theory, intentionality, and metrics}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2026.00462}{doi:10.1556/2054.2026.00462}.
\item Centre for Addiction and Mental Health (2026). \textit{Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07405606}{source link}.
\item University of California, Los Angeles (2026). \textit{Psilocybin-Assisted Cognitive Behavioral Therapy for Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07281352}{source link}.
\item Matthew Hicks, Olivia Hicks, Ryan Bradley, Heather Zwickey (2026). \textit{Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2026.00485}{doi:10.1556/2054.2026.00485}.
\item Hadassah Medical Organization (2026). \textit{Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07079930}{source link}.
\item TRYP Therapeutics (2026). \textit{A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06206265}{source link}.
\item Nantes University Hospital (2026). \textit{Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER: a Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07391332}{source link}.
\item Liu Junhong, Wang Yuanyuan, Xia Ke, Wu Jinfeng, Zheng Danhao, Cai Aoling, Yan Haitao, Su Ruibin (2026). \textit{Acute psilocin increased cortical activity in rat}. Frontiers in Neuroscience. [published; Crossref]. \href{https://doi.org/10.3389/fnins.2026.1593703}{doi:10.3389/fnins.2026.1593703}.
\item Vale LN, Ibrahim M, Fávaro-Pereira L, Soares JC, Meyer TD (2026). \textit{Contemplating versus having used psychedelics in bipolar disorder - What makes the difference?}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2025.120437}{doi:10.1016/j.jad.2025.120437}.
\item Swainson J, Brietzke E, Khullar A, McIntyre RS, Soares CN (2026). \textit{Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models.}. Canadian journal of psychiatry. Revue canadienne de psychiatrie. [published; PubMed]. \href{https://doi.org/10.1177/07067437251389090}{doi:10.1177/07067437251389090}.
\item Do A, Cloutier L, Hébert-Tremblay L, Thauvin C (2026). \textit{Psilocybin use in bipolar disorder: A comprehensive review.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2025.120485}{doi:10.1016/j.jad.2025.120485}.
\item Hirsch D, Reed J, Naqvi A, Ngor A, Dugan L, Costa K, Ganasi RS, Truman K, Danovitch I, IsHak WW, Hedrick R (2026). \textit{Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010-2025): 15 Years of Progress (or Lack Thereof).}. CNS drugs. [published; PubMed]. \href{https://doi.org/10.1007/s40263-025-01248-7}{doi:10.1007/s40263-025-01248-7}.
\item Van Ameringen M, Patel V, Patterson B, Hopkinson P, Rahat M (2026). \textit{New treatments for OCD? Evidence for cannabinoids and psychedelics.}. Journal of psychiatric research. [published; PubMed]. \href{https://doi.org/10.1016/j.jpsychires.2025.11.021}{doi:10.1016/j.jpsychires.2025.11.021}.
\item Reid MR, Song J, Boehnke KF, Buchanan NT, Aday JS (2026). \textit{Disengaged: A systematic review of community engagement in psychedelic-assisted therapy research.}. Neuroscience and biobehavioral reviews. [published; PubMed]. \href{https://doi.org/10.1016/j.neubiorev.2025.106516}{doi:10.1016/j.neubiorev.2025.106516}.
\item Marques MG, Patarroyo-Rodriguez L, Singh B (2026). \textit{Psilocybin and Bipolar Depression: Promise and Prudence.}. CNS drugs. [published; PubMed]. \href{https://doi.org/10.1007/s40263-025-01255-8}{doi:10.1007/s40263-025-01255-8}.
\item Haghdoost F, Bahceci D, Delcourt C, Wijeratne T, Jensen RH, Cincinnato C, Tomlinson S, Wold B, Polito V, Carcel C, Ashraf U, Jenkins B, Petersen AS, Ray JC, Schindler EAD, Tsang B, Gianacas C, Rodgers A (2026). \textit{Patient perspectives on research gaps in cluster headache.}. Headache. [published; PubMed]. \href{https://doi.org/10.1111/head.70031}{doi:10.1111/head.70031}.
\item Ham R, Gardner J, Carter A, Liknaitzky P (2026). \textit{Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy.}. Brain and behavior. [published; PubMed]. \href{https://doi.org/10.1002/brb3.71262}{doi:10.1002/brb3.71262}.
\item Anna Maria Komarczewska, Filip Matusiak, Klaudia Brzoza, Michał Kociński, Patryk Iglewski, Michał Pietrasz (2026). \textit{Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects}. Quality in Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/qs.2026.51.68216}{doi:10.12775/qs.2026.51.68216}.
\item Łukasz Deska, Cezary Kosmecki, Dawid Głaz, Natalia Kamińska, Wojciech Sołtys, Magdalena Stolarczyk, Maksymilian Głaz, Mateusz Stronczyński, Aleksandra Jagura-Sukiennik, Julia Wawerska (2026). \textit{PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.1(49).2026.4711}{doi:10.31435/ijitss.1(49).2026.4711}.
\item Adam Wolski, Ewa Szplit, Mikołaj Franciszek Patalong, Roman Cemaga, Mateusz Kubicki, Przemysław Kołodziej, Natalia Bruska, Bartłomiej Błaszkowski, Andrii Bilyk, Katarzyna Więckowska (2026). \textit{Psychedelics in psychiatric treatment: a literature review}. Quality in Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/qs.2026.50.68013}{doi:10.12775/qs.2026.50.68013}.
\item Fernando Mora López, Johynny Solís Solís, Ekaterina Daniela Hernández Baker, Olger Herrera Barboza, David Diaz Polo, Daniela Consumi Cordero (2026). \textit{The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence}. Zenodo (CERN European Organization for Nuclear Research). [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.18375715}{doi:10.5281/zenodo.18375715}.
\item Rishika Scott, James Smith (2026). \textit{The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression}. Emerging Minds Journal for Student Research. [published; OpenAlex]. \href{https://doi.org/10.59973/emjsr.317}{doi:10.59973/emjsr.317}.
\item NYU Langone Health (2026). \textit{A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06796062}{source link}.
\item Tripdatabase (2026). \textit{Is psilocybin only effective as part of psychotherapy?}. Zenodo (CERN European Organization for Nuclear Research). [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.18339347}{doi:10.5281/zenodo.18339347}.
\item Jakub Klepacz, Radosław Swędrak, Marzena Swojnóg, Zuzanna Dobrakowska (2026). \textit{THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.1(49).2026.4582}{doi:10.31435/ijitss.1(49).2026.4582}.
\item Florineth, Gianluca Andri, Klima, Isabell, Boeker, Anna Laura, Catzeflis, Polina, Wopfner, Alexander, Denier, Niklaus, Bracht, Tobias, Adorjan, Kristina, Pfammatter, Mario, Müller, Felix, Soravia, Leila Maria (2026). \textit{Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.}. Open Access CRIS of the University of Bern. [published; OpenAlex]. \href{https://doi.org/10.48620/94398}{doi:10.48620/94398}.
\item Anthony L. Back, Bonnie A. McGregor, Leslie Lazar Thorn, Kelsey K. Baker, T. Gooley, Mendel Kaelen, Kalin Harvey, John M. Guy, Susanna Myers, Juliana Pérez, Peter Thompson, Lindsay Billingsley, Cheryl Sesnon (2026). \textit{Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/28314425251413856}{doi:10.1177/28314425251413856}.
\item Benjamin Kelmendi, Thomas Adams, Terence Ching, Rachael Grazioplene, Stephen Kichuk, Geena Fram, Prerana Patel, Jeff Eilbott, Elizabeth D’Amico, Sarah Shnayder (2026). \textit{Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/atfum\_v1}{source link}.
\item Zaynab Khan, Sterre Weaver, Rachael V. Dando, Anne Katrin Schlag, Joanna; id\_orcid 0000-0002-2717-9739 Neill, Verity; id\_orcid 0000-0002-9876-250X Wainwright (2026). \textit{Sense-making around psilocybin in UK women experiencing cancer-related existential distress: An Interpretative Phenomenological Analysis}. Research Explorer (The University of Manchester). [published; OpenAlex]. \href{https://research.manchester.ac.uk/en/publications/6f070f13-96c6-4cc4-9e40-f2837bdb79b3}{source link}.
\item Mitchell J, Neitzke-Spruill L, Mathai DS, Robinson JO, Kavan Z, Averil LA, McGuire AL (2026). \textit{From trials to clinics: investigators' perspectives on translating psychedelic research into clinical care.}. Translational behavioral medicine. [published; PubMed]. \href{https://doi.org/10.1093/tbm/ibag027}{doi:10.1093/tbm/ibag027}.
\item Florineth GA, Klima I, Boeker AL, Catzeflis P, Wopfner A, Denier N, Bracht T, Adorjan K, Pfammatter M, Müller F, Soravia LM (2026). \textit{Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.}. JAMA network open. [published; PubMed]. \href{https://doi.org/10.1001/jamanetworkopen.2025.54843}{doi:10.1001/jamanetworkopen.2025.54843}.
\item Marta Gómez Álvarez, Javier Calleja-Conde, Víctor Echeverry-Alzate (2026). \textit{Psychedelics and Mental Health: Psilocybin and Depression. A Sistematic Review}. Open Science Framework. [published; OpenAlex]. \href{https://doi.org/10.17605/osf.io/yu3n9}{doi:10.17605/osf.io/yu3n9}.
\item E. Lopez, J O Lundberg, F. Hieronymus, M. Beckman, H. Yngwe, C.J. Ekman, M. Tiger, N. Edvall (2026). \textit{Symptom-level antidepressant response to psilocybin: exploratory outcomes comparing psilocybin treatment to niacin}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2026.106904}{doi:10.1016/j.nsa.2026.106904}.
\item Yosr Ziadi, Taehwan Park (2026). \textit{Cost-Effectiveness of Psilocybin-Assisted Therapy (PAT) for Patients with Treatment-Resistant Depression}. Open MIND. [published; OpenAlex]. \href{https://doi.org/10.17605/osf.io/nrt59}{doi:10.17605/osf.io/nrt59}.
\item Stefan Jerotić, Olga Čolović, Nađa Marić (2026). \textit{Psychedelic-assisted psychotherapy: Clarifying the role of the "psychotherapy"}. Medicinska istrazivanja. [published; OpenAlex]. \href{https://doi.org/10.5937/medi0-62051}{doi:10.5937/medi0-62051}.
\item Hannah Whitmore, Maria Mangini, Heather Leutwyler, Brian Anderson (2026). \textit{Facing Mortality Together: A Constructivist Grounded Theory Analysis of Group Psilocybin Therapy Among Older Long-Term AIDS Survivor Gay Men}. Palliative Medicine Reports. [published; OpenAlex]. \href{https://doi.org/10.1177/26892820251401798}{doi:10.1177/26892820251401798}.
\item L.J. Mertens, M. Koslowski, F. Betzler, M. Brand, R. Evens, L. Krätner, A. Jungaberle, H. Jungaberle, T. Majić, C.N. Schmitz, A. Ströhle, D. Scharf, M. Spangemacher, M. Wolff, Z. Assadi, B. Scharif, L. Becher, L.V. Färber, N. Kirchen, E. Kulakova, L. Kunz, A. Meijer, B. Rohrmoser, S. Wellek, M. Berger, G. Gründer (2026). \textit{Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE): Results of a randomized active placebo-controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2025.105779}{doi:10.1016/j.nsa.2025.105779}.
\item L. Marwood, M. Young, J. Chai-Rees, S. Mistry, S. Maxwell, G.M. Goodwin (2026). \textit{The impact of COMP360 psilocybin on anhedonia: post-hoc analyses from a phase IIb randomised controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2025.106572}{doi:10.1016/j.nsa.2025.106572}.
\item N. Mcgowan, J. Rucker, R. Yehuda, M. Agrawal, H. Simmons, S. Das, G. Goodwin (2026). \textit{An open-label study of single-dose COMP360 psilocybin for post-traumatic stress disorder: safety, tolerability, and secondary efficacy outcomes}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2025.106821}{doi:10.1016/j.nsa.2025.106821}.
\item Jensen, Hailey A (2026). \textit{Psilocybin Treatment for Refractory Depression: A Clinical Review}. Digital Commons - Gardner-Webb University (Gardner-Webb University). [published; OpenAlex]. \href{https://digitalcommons.gardner-webb.edu/pa-department-journal-of-medical-science/63}{source link}.
\item Cuttler C, Stueber A, Simone J, Mayo LM (2026). \textit{Down the Rabbit Hole: A Large-Scale Survey of Psychedelic Users' Patterns of Use and Perceived Effects.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2025.2452226}{doi:10.1080/02791072.2025.2452226}.
\item Gushken F, Fidalgo TM, Tardelli VS (2026). \textit{Characteristics of Ongoing Clinical Trials for Cocaine Use Disorder Registered on Global Clinical Trial Databases.}. Journal of addiction medicine. [published; PubMed]. \href{https://doi.org/10.1097/adm.0000000000001580}{doi:10.1097/adm.0000000000001580}.
\item Aghajanian S, Shafiee A, Parvizi Omran S, Rezaei Nejad A, Jafarabady K, Kohandel Gargari O, Rajai S, Mohammadi I, Bahrami Babaheidari T, Bakhtiyari M (2026). \textit{Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811241287542}{doi:10.1177/02698811241287542}.
\item Foster K, Morrison I, Daniel S, Antoine J, Thankappan B, De La Haye W, Tyler M, Grant C, Delgoda R (2026). \textit{Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi.}. Journal of AOAC International. [published; PubMed]. \href{https://doi.org/10.1093/jaoacint/qsaf072}{doi:10.1093/jaoacint/qsaf072}.
\item McGowan NM, Rucker JJ, Yehuda R, Agrawal M, Modlin NL, Simmons H, Tofil-Kaluza A, Das S, Goodwin GM (2026). \textit{Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251362390}{doi:10.1177/02698811251362390}.
\item Marek GJ, Makai-Bölöni S, Umbricht D, Christian EP, Winters J, Dvorak D, Raines S, Hughes ZA, Austin EW, Klein AK, Leong W, Krol FJ, Graaf AJV, Juachon MJ, Otto ME, Borghans LGJM, Jacobs G, Kruegel AC, Sporn J (2026). \textit{A novel psychedelic 5-HT receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251378512}{doi:10.1177/02698811251378512}.
\item Hutchison KE, Hooper JF, Karoly HC (2026). \textit{Psilocybin Outside the Clinic: Public Health Challenges of Increasing Publicity, Accessibility, and Use.}. JAMA psychiatry. [published; PubMed]. \href{https://doi.org/10.1001/jamapsychiatry.2025.3038}{doi:10.1001/jamapsychiatry.2025.3038}.
\item Konstantinou GN, Rosenblat J, Hales S, Husain MI, Blumberger DM (2026). \textit{Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety.}. General hospital psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.genhosppsych.2025.12.005}{doi:10.1016/j.genhosppsych.2025.12.005}.
\item Matos ARS, Silva AC, Rego L, Fernandes R, Gonçalves S (2026). \textit{Psilocybin-assisted therapy for individuals with palliative care needs: A systematic review of safety and efficacy.}. Palliative medicine. [published; PubMed]. \href{https://doi.org/10.1177/02692163251383335}{doi:10.1177/02692163251383335}.
\item Dwyer J, Johnston RB, O'Callaghan C, Ross M (2026). \textit{Stepping back into life: How Psychedelic Assisted Psychotherapy transforms the way of life of the terminally ill.}. General hospital psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.genhosppsych.2025.12.002}{doi:10.1016/j.genhosppsych.2025.12.002}.
\item Rasheed S, Arif R, Raza AA, Samadi A (2026). \textit{Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder.}. Annals of medicine and surgery (2012). [published; PubMed]. \href{https://doi.org/10.1097/ms9.0000000000004349}{doi:10.1097/ms9.0000000000004349}.
\item Freitas da Costa B, Hartmann P, Pagnin D (2026). \textit{Pharmacological Management of Anxiety in End-of-Life Care: A Systematic Review of Benzodiazepines, Opioids, and Psilocybin.}. Human psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1002/hup.70032}{doi:10.1002/hup.70032}.
\item Spiti A, Caldirola D, Perna G (2026). \textit{New Antidepressant Development in the Treatment of Depression.}. Advances in experimental medicine and biology. [published; PubMed]. \href{https://doi.org/10.1007/978-981-95-6872-7\_23}{doi:10.1007/978-981-95-6872-7\_23}.
\item Raza M, Kaur J (2026). \textit{A Promise Without Panacea: Psychedelic-Assisted Therapies in Modern Psychiatry.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.102421}{doi:10.7759/cureus.102421}.
\item Evans M, Charrette A (2026). \textit{Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility.}. Frontiers in neuroscience. [published; PubMed]. \href{https://doi.org/10.3389/fnins.2026.1816932}{doi:10.3389/fnins.2026.1816932}.
\item Geraci J, Viirre E, Qorri B, Pani L (2026). \textit{Psychedelics and the quantum brain: a falsifiable hypothesis on Posner molecules and spin-dependent pharmacology.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2026.1777613}{doi:10.3389/fphar.2026.1777613}.
\item Kervadec E, Bezo A, Serreau R, Strika-Bruneau L, Fauvel B, Amirouche A, Benyamina A, Romeo B (2026). \textit{Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives.}. Journal of clinical psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1097/jcp.0000000000002197}{doi:10.1097/jcp.0000000000002197}.
\item Rotem Petranker (2025). \textit{Microdosing Psychedelics to Improve Mood}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05259943}{source link}.
\item Cervera-Sanchez MB, San-Juan D, Díaz-Peregrino R, Camacho-Castillo EZ, Bringas-Ortiz SA, Padilla-Cabezutd C. (2025). \textit{Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure Risks}. Authorea Preprints. [preprint; Europe PMC]. \href{https://doi.org/10.22541/au.176701186.65064859/v1}{doi:10.22541/au.176701186.65064859/v1}.
\item Houff J, Williams A, Allen O, Gisabella B, Pantazopoulos H, Del Arco A. (2025). \textit{Psilocybin decreases reward-seeking behavior accompanied by increased activity of parvalbumin neurons with perineuronal nets in the medial prefrontal cortex}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.64898/2025.12.22.696123}{doi:10.64898/2025.12.22.696123}.
\item Manasicha Wongpaiboon, Jackson L. Shelton, Eric Delgado Rendon, Maddison Vail (2025). \textit{A Systematic Review of the efficacy, safety, and Tolerability of Psychedelics in the Treatment of post-traumatic Stress Disorder}. Current Treatment Options in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1007/s40501-025-00373-w}{doi:10.1007/s40501-025-00373-w}.
\item Bhagavan C, Carter O, Nielsen G, Berlowitz D, Issak S, Braat S, Zaloumis S, Attard Z, Oliver G, Mayne D, Rucker J, Butler M, Dandash O, Bryson A, Kanaan RA. (2025). \textit{A Randomised, Triple-Blind, Dose-Finding Study of the Impact of Psilocybin on Motor Function in Healthy Participants}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.64898/2025.12.22.25342874}{doi:10.64898/2025.12.22.25342874}.
\item NYU Langone Health (2025). \textit{Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07296328}{source link}.
\item Carlson LE, Richardson H, Shore R, Albertyn CP, Balneaves LG, Bates A, Burnell M, Chochinov HM, Clements D, Deleemans J, Horlock H, Mathews J, McKenzie M, Savard C, Soares CN, Tu W, Williams M (2025). \textit{The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview.}. Current oncology (Toronto, Ont.). [published; PubMed]. \href{https://doi.org/10.3390/curroncol33010007}{doi:10.3390/curroncol33010007}.
\item Bukovsky D, Amaev A, Song J, Kyte S, Carmona-Torres E, Ueno F, Deluca V, Strafella AP, Husain MI, Graff-Guerrero A, Gerretsen P (2025). \textit{Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2025.111541}{doi:10.1016/j.pnpbp.2025.111541}.
\item Qinqing Chen, Peiyuan Chen, Tao Wei, Sunita Chamyuang, Bai-Xiong Chen (2025). \textit{From fungi to pharmacy: Applied technologies in psilocybin production and its therapeutic applications}. Creative Science. [published; OpenAlex]. \href{https://doi.org/10.55674/cs.v18i1.264689}{doi:10.55674/cs.v18i1.264689}.
\item Brar G, Burke T, Gribben AD, Harrington C, Thuery G, Kelly JR (2025). \textit{Psilocybin reporting in media (PRiMe) for the treatment of depression.}. Irish journal of psychological medicine. [published; PubMed]. \href{https://doi.org/10.1017/ipm.2025.10142}{doi:10.1017/ipm.2025.10142}.
\item M. H. M. Wickramasekara, G. D. M. C. Gonapaladeniya (2025). \textit{Psychedelic-Assisted Therapy (Pat): A New Frontier in Mental Health Treatment}. The journal of desk research review and analysis.. [published; OpenAlex]. \href{https://doi.org/10.4038/jdrra.v3i2.87}{doi:10.4038/jdrra.v3i2.87}.
\item Kittur ME, Burgos M LA, Jones BDM, Blumberger DM, Mulsant BH, Rosenblat JD, Husain MI (2025). \textit{Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2025.119952}{doi:10.1016/j.jad.2025.119952}.
\item Ledwos N, Baer J, Husain MI, Blumberger DM, Patterson R, Hollingdrake E, Cheung E, Hawco C, Zrenner C, Zrenner B, Feusner JD, Rossell SL, Castle DJ, Zai G (2025). \textit{Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study.}. BJPsych open. [published; PubMed]. \href{https://doi.org/10.1192/bjo.2025.10895}{doi:10.1192/bjo.2025.10895}.
\item Jungwirth J, Westenhöfer S, Aicher H, Provaznikova B, Kronenberg G, Seifritz E, Prinz S, Olbrich S. (2025). \textit{Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-8079137/v1}{doi:10.21203/rs.3.rs-8079137/v1}.
\item Suspène J, Huet S, Berteina-Raboin S, Benyamina A, Baril P, Morisset-Lopez S, Serreau R. (2025). \textit{Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review}. Qeios. [preprint; Europe PMC]. \href{https://doi.org/10.32388/xcfsag.2}{doi:10.32388/xcfsag.2}.
\item NYU Langone Health (2025). \textit{A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05398484}{source link}.
\item Spohn, Kyle (2025). \textit{Magic Mushrooms as Medicine: What the United States Can Learn from Jamaica’s Unregulated Psilocybin Industry as FDA Approval Nears}. eYLS (Yale Law School). [published; OpenAlex]. \href{https://repository.law.miami.edu/umialr/vol57/iss1/7}{source link}.
\item Philip Garrity, Alicia Danforth, Brian Anderson, Jason M. Thompson (2025). \textit{Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care Patients}. Journal of Health Service Psychology. [published; OpenAlex]. \href{https://doi.org/10.1007/s42843-025-00145-3}{doi:10.1007/s42843-025-00145-3}.
\item Li Y, Li H, Wang H, Wang X (2025). \textit{Exploring the therapeutic potential of psychedelics in treating substance use disorders.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-025-03168-w}{doi:10.1038/s41380-025-03168-w}.
\item Højlund M, Kafali HY, Kırmızı B, Fusar-Poli P, Correll CU, Cortese S, Sabé M, Fiedorowicz J, Saraf G, Zein J, Berk M, Husain MI, Rosenblat JD, Rubaiyat R, Corace K, Wong S, Hatcher S, Kaluzienski M, Yatham LN, Cipriani A, Gosling CJ, Carhart-Harris R, Tanuseputro P, Myran DT, Fabiano N, Moher D, Mayo LM, Nicholls SG, White T, Prisco M, Radua J, Vieta E, Ladha KS, Katz J, Veroniki AA, Solmi M (2025). \textit{Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.}. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.euroneuro.2025.09.011}{doi:10.1016/j.euroneuro.2025.09.011}.
\item Modlin NL, Williamson V, Goodwin GM, Malievskaia E, Atli M, Elek Z, Gaillard A, Koelpin D, Cleare A, Agrawal M, Yehuda R, Kirlic N, Rucker J (2025). \textit{Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.}. EClinicalMedicine. [published; PubMed]. \href{https://doi.org/10.1016/j.eclinm.2025.103692}{doi:10.1016/j.eclinm.2025.103692}.
\item Griffiths RR, Jesse R, Richards WA, Johnson MW, Sepeda ND, Bossis AP, Ross S (2025). \textit{Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0044}{doi:10.1089/psymed.2023.0044}.
\item Liszka P, Ogórek A, Olejnik-Chlewicka KM, Puchalski K, Zasiadła M, Patrzykąt KM, Perediatkiewicz J, Urbański W, Łuczak PM, Brodowski J (2025). \textit{Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.99942}{doi:10.7759/cureus.99942}.
\item Bjørn Holmøy, Kristoffer Andreas Aamodt Andersen (2025). \textit{Persistent Altered States: Psychological Treatment of Psychedelic Adverse Effects}. Tidsskrift for Norsk psykologforening. [published; OpenAlex]. \href{https://doi.org/10.52734/hgsn7664}{doi:10.52734/hgsn7664}.
\item University of Texas at Austin (2025). \textit{Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06132178}{source link}.
\item Charles S. Grob, M.D. (2025). \textit{Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05403086}{source link}.
\item Kruger DJ, Mersereau G, Sullivan A, Barron J, Herberholz M, Pouyan N, Aday JS, Boehnke KF (2025). \textit{Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.}. Harm reduction journal. [published; PubMed]. \href{https://doi.org/10.1186/s12954-025-01337-2}{doi:10.1186/s12954-025-01337-2}.
\item Suspène J, Huet S, Berteina-Raboin S, Benyamina A, Baril P, Morisset-Lopez S, Serreau R. (2025). \textit{Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review}. Qeios. [preprint; Europe PMC]. \href{https://doi.org/10.32388/xcfsag}{doi:10.32388/xcfsag}.
\item Beersheva Mental Health Center (2025). \textit{A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07183748}{source link}.
\item Beersheva Mental Health Center (2025). \textit{Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04882839}{source link}.
\item Zeina Beidas, Anya Ragnhildstveit, Adam Blackman, Thomas Anderson, Emily Fewster, Omer Syed, Valentyne Sobolenko, Ismail Kaan Kanca, Magdalena Jaglinska, Tatiana Son (2025). \textit{Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/hmnsw\_v1}{source link}.
\item Martens MAG, Cunha BG, Erritzoe D, Nutt D, Carhart-Harris R, Harmer CJ (2025). \textit{Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial.}. Translational psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41398-025-03693-w}{doi:10.1038/s41398-025-03693-w}.
\item University of Washington (2025). \textit{A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05847686}{source link}.
\item Aisling McGuigan (2025). \textit{Classic psychedelics may treat depressive disorders, but more evidence and legislative changes are required}. Drugs \& Therapy Perspectives. [published; OpenAlex]. \href{https://doi.org/10.1007/s40267-025-01199-5}{doi:10.1007/s40267-025-01199-5}.
\item Marinis J, Clarke ST, Guerin AA, Guastella AJ, Bedi G (2025). \textit{Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review.}. BJPsych open. [published; PubMed]. \href{https://doi.org/10.1192/bjo.2025.10847}{doi:10.1192/bjo.2025.10847}.
\item Joga R, Yerram S, Patnam JD, Choudhary KK, Varpe P, Raghuvanshi RS, Srivastava S (2025). \textit{Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India.}. Health policy (Amsterdam, Netherlands). [published; PubMed]. \href{https://doi.org/10.1016/j.healthpol.2025.105392}{doi:10.1016/j.healthpol.2025.105392}.
\item André Leão Dantas, Lara Moreira Jalles Milani, Saulo Gabriel Moreira Falci, João Américo da Silveira, Cristina Pereira Isolan, Lia Dietrich (2025). \textit{Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications}. Caderno Pedagógico. [published; OpenAlex]. \href{https://doi.org/10.54033/cadpedv22n12-345}{doi:10.54033/cadpedv22n12-345}.
\item d'Andrea G, Chiappini S, Ciavoni L, Tucci R, Martino F, Semeraro FM, Di Battista D, Mosca A, Miuli A, Di Carlo F, Russo M, Di Petta G, Fornaro M, Pettorruso M, Sensi SL, Martinotti G (2025). \textit{Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.}. Translational psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41398-025-03654-3}{doi:10.1038/s41398-025-03654-3}.
\item Anna Rose Childress, Ph.D. (2025). \textit{A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06786325}{source link}.
\item Richardson C, Chan C, Macgregor E, Hare C, Hannon B, Black S, Schneider E, Buchman D, Wang S, Rac V, Abrahamyan L, Huszti E, Nissim R, Li M, Zimmermann C, Hapke E, Rosenbaum D, Hales S (2025). \textit{Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial.}. Pilot and feasibility studies. [published; PubMed]. \href{https://doi.org/10.1186/s40814-025-01706-5}{doi:10.1186/s40814-025-01706-5}.
\item James J Gattuso, Bilgenur Bezcioglu, Carey Wilson, Kato Havaux, Anthony J. Hannan, Thibault Renoir (2025). \textit{Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp025i.0044}{doi:10.61373/pp025i.0044}.
\item Keighley EE, Abo Hamza E, Bedewy DA, Nalla S, Moustafa AA (2025). \textit{A Systematic Review and Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Use Disorder.}. Healthcare (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/healthcare13212668}{doi:10.3390/healthcare13212668}.
\item special to C EN Mara Johnson-Groh (2025). \textit{Is there more to magic mushrooms than psilocybin?}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-10322-feature2}{doi:10.1021/cen-10322-feature2}.
\item Suspene J, Huet S, Berteina-Raboin S, Benyamina A, Baril P, Morisset-Lopez S, Serreau R. (2025). \textit{Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacity: A Scoping Review}. Preprints.org. [preprint; Europe PMC]. \href{https://doi.org/10.20944/preprints202510.1355.v1}{doi:10.20944/preprints202510.1355.v1}.
\item University of Washington (2025). \textit{A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06644170}{source link}.
\item Razidlo J, Cataldo N, Wenthur CJ (2025). \textit{Psilocybin Enhances Cued Fear Extinction and Extinction Recall in Stress-Naïve, Acutely Stressed, and Chronically Stressed Mice.}. ACS pharmacology \& translational science. [published; PubMed]. \href{https://doi.org/10.1021/acsptsci.5c00462}{doi:10.1021/acsptsci.5c00462}.
\item Centre Hospitalier St Anne (2025). \textit{Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07210112}{source link}.
\item Mackenzie Hancock, Nicole Getz, Shambhu Prasad Adhikari (2025). \textit{Psilocybin-Assisted Therapy for Trauma-Related Disorders: A Scoping Review of a Depression-Dominated Evidence Base with Implications for Intimate Partner Violence-Related PTSD}. Open Science Framework. [published; OpenAlex]. \href{https://doi.org/10.17605/osf.io/ar2s4}{doi:10.17605/osf.io/ar2s4}.
\item M Loganathan, A Saravanakumar, P. Parthiban, G Anandharaj, S Gobika, D Dharshana, Mohamed Safir Ali (2025). \textit{Neurobiological and Therapeutic Potential of Psilocybin in Psychiatric Disorders}. Journal of Pharma Insights and Research.. [published; OpenAlex]. \href{https://doi.org/10.69613/thv1dn30}{doi:10.69613/thv1dn30}.
\item Arif Ersegün Kahraman (2025). \textit{Psilocybin as a Treatment for Depression}. University of Debrecen Electronic Archive. [published; OpenAlex]. \href{https://hdl.handle.net/2437/398317}{source link}.
\item Chweikh Mohamad (2025). \textit{Legal and Regulatory Barriers to Medical Psilocybin Use: An International Overview}. OSF Preprints. [preprint; Crossref]. \href{https://doi.org/10.31219/osf.io/dy5cu\_v1}{doi:10.31219/osf.io/dy5cu\_v1}.
\item Chisamore N, Kaczmarek ES, Doyle Z, Johnson DE, Weiglein G, Meshkat S, Brudner RM, Blainey MG, Riva-Cambrin J, McIntyre RS, Rosenblat JD (2025). \textit{Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude.}. Canadian journal of psychiatry. Revue canadienne de psychiatrie. [published; PubMed]. \href{https://doi.org/10.1177/07067437251328316}{doi:10.1177/07067437251328316}.
\item Pellegrini L, Fineberg NA, O'Connor S, De Souza AMFLP, Godfrey K, Reed S, Peill J, Healy M, Rohani-Shukla C, Lee H, Carhart-Harris R, Robbins TW, Nutt D, Erritzoe D (2025). \textit{Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study.}. Comprehensive psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.comppsych.2025.152619}{doi:10.1016/j.comppsych.2025.152619}.
\item Sabé M, Seragnoli F, Penzenstadler L, Thorens G (2025). \textit{[Role of psychedelics in psychiatry: a true therapeutic revolution or a trend?].}. La Revue du praticien. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/41575100/}{source link}.
\item Anneliese McConnell, Wei He, Harry McConnell, Sandro Sprendei, Paul F. Sowman (2025). \textit{3642 Down the rabbit hole: case reports of a hallucinogen-induced disorder of neuroperception}. Poster Abstracts. [published; OpenAlex]. \href{https://doi.org/10.1136/bmjno-2025-anzan.170}{doi:10.1136/bmjno-2025-anzan.170}.
\item Pinelopi Vlotinou, Konstantinos Christodoulou, Anna Tsiakiri, Foteini Christidi, Aspasia Serdari (2025). \textit{Ethical challenges in the therapeutic application of classical psychedelics for pediatric health conditions: A comprehensive review}. Brazilian Journal of Science. [published; OpenAlex]. \href{https://doi.org/10.14295/bjs.v4i10.785}{doi:10.14295/bjs.v4i10.785}.
\item Egger, Klemens, Meling, Daniel, Polat, Firuze, Seifritz, Erich, Avram, Mihai, Scheidegger, Milan (2025). \textit{Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat}. Universität Zürich, ZORA. [published; OpenAlex]. \href{https://doi.org/10.5167/uzh-280470}{doi:10.5167/uzh-280470}.
\item Caporuscio C, Poppe C, Gieselmann A, Repantis D (2025). \textit{Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review.}. Psychological medicine. [published; PubMed]. \href{https://doi.org/10.1017/s0033291725101761}{doi:10.1017/s0033291725101761}.
\item Healing Advocacy Fund (2025). \textit{Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07189988}{source link}.
\item Matthew Halma, R. Levy, Joseph Varón (2025). \textit{With great power comes great responsibility: Promise and caution in the new psychedelic renaissance}. Brain Disorders. [published; OpenAlex]. \href{https://doi.org/10.1016/j.dscb.2025.100286}{doi:10.1016/j.dscb.2025.100286}.
\item Knock E, Siefried KJ, Bedi G, Albert S, Day RO, Ezard N, Ross M, Liknaitzky P, Brett J (2025). \textit{Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study.}. Addiction (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1111/add.70187}{doi:10.1111/add.70187}.
\item Benjamin R. Lewis (22279166), John Hendrick (22279169), Kevin Byrne (1610821), Madeleine Odette (22279172), Chaorong Wu (8444343), Eric L. Garland (4666660) (2025). \textit{S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial}. Figshare. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pmed.1004519.s001}{doi:10.1371/journal.pmed.1004519.s001}.
\item Calin A, Burlec AF, Mircea C, Macovei I, Hancianu M, Corciova A (2025). \textit{Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US.}. Journal of clinical medicine. [published; PubMed]. \href{https://doi.org/10.3390/jcm14186613}{doi:10.3390/jcm14186613}.
\item Johns Hopkins University (2025). \textit{PRoMiSS: Psilocybin and the Role of Music in Set and Setting}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07180108}{source link}.
\item Lopez, Alissa A, Salloum, Ihsan, Lopez-Alvarenga, Juan C (2025). \textit{Efficacy of Psychedelics Therapy Across Psychiatric Disorders: An Umbrella Review of Meta-Analyses}. ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley). [published; OpenAlex]. \href{https://scholarworks.utrgv.edu/colloquium/2025/talks/1}{source link}.
\item King's College London (2025). \textit{Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07164755}{source link}.
\item Khyber Medical University Peshawar (2025). \textit{Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06746441}{source link}.
\item Anna Blazhkova, Magdalena Czaja, Hanna Sitka, Sven Solisch, Anna Susłow, Ewa Szczęsna (2025). \textit{PSYCHEDELICS IN PSYCHIATRY - OVERVIEW OF PSILOCYBIN RESEARCH}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.3(47).2025.3650}{doi:10.31435/ijitss.3(47).2025.3650}.
\item Palitsky R, Maples-Keller JL, Peacock C, Dunlop BW, Mletzko T, Grant GH, Raison CL, Chao S, Shub I, Mendelbaum-Kweller M, Smolyar L, Kaplan DM, Rothbaum BO, Zarrabi AJ (2025). \textit{A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers.}. Psychotherapy (Chicago, Ill.). [published; PubMed]. \href{https://doi.org/10.1037/pst0000551}{doi:10.1037/pst0000551}.
\item Keller MR, McKinney MG, Sen AK, Guagliardo FG, Hellwarth EB, Islam KN, Kaplan NA, Gibbons WJ, Kemmerly GE, Meers C, Wang X, Jones JA (2025). \textit{Psilocybin biosynthesis enhancement through gene source optimization.}. Metabolic engineering. [published; PubMed]. \href{https://doi.org/10.1016/j.ymben.2025.04.003}{doi:10.1016/j.ymben.2025.04.003}.
\item Estric C, Duron T, Kabani S, Lopez-Castroman J (2025). \textit{Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251338214}{doi:10.1177/02698811251338214}.
\item Miller EA, Capone C, Eaton E, Swift RM, Haass-Koffler CL (2025). \textit{Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action.}. CNS drugs. [published; PubMed]. \href{https://doi.org/10.1007/s40263-025-01199-z}{doi:10.1007/s40263-025-01199-z}.
\item Swieczkowski D, Kwaśny A, Ciurkowska P, Pruc M, Szarpak L, Cubała WJ (2025). \textit{Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811251353250}{doi:10.1177/02698811251353250}.
\item David Nutt, David Erritzøe, Anne Katrin Schlag, David Luke, Deborah C. Mash, Hiroyuki Uchida, Jacob S. Aday, James Rucker, Liliana Galindo, Mark Sweeney, Matthew X. Lowe, Oliver Davis, Plinio Ferreira, Rayyan Zafar, Robin Carhart-Harris, Tadeusz Hawrot, Joanna C. Neill (2025). \textit{A lexicon for psychedelic research and treatment}. Drug Science Policy and Law. [published; OpenAlex]. \href{https://doi.org/10.1177/20503245251380511}{doi:10.1177/20503245251380511}.
\item Samir A Nader (2025). \textit{Psychedelic minimalism: the case against music in psychedelic therapy settings}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2025.1652568}{doi:10.3389/fpsyt.2025.1652568}.
\item Elise C. Tarbi, Skye A. Miner, Kabir Nigam, Zachary Sager, Justin J. Sanders, Michael Ljuslin, Benjamin Guérin, Kimberly Roddy, James A. Tulsky, Manish Agrawal, Yvan Beaussant (2025). \textit{“To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/28314425251370303}{doi:10.1177/28314425251370303}.
\item Zeifman R, Danias G, Agin-Liebes G, Pagni B, Kettner H, Bhat V, Ross S, Erritzoe D, Carhart-Harris R (2025). \textit{Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-Compassion.}. Research square. [published; PubMed]. \href{https://doi.org/10.21203/rs.3.rs-7420529/v1}{doi:10.21203/rs.3.rs-7420529/v1}.
\item Bilenker D, Avena NM (2025). \textit{Psychedelics and the Serotonin Hypothesis of Eating Disorders.}. Brain sciences. [published; PubMed]. \href{https://doi.org/10.3390/brainsci15080893}{doi:10.3390/brainsci15080893}.
\item COMPASS Pathways (2025). \textit{A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05733546}{source link}.
\item Singleton SP, Sevchik BL, Lahey A, Cuijpers P, Harrer M, Jones MT, Nayak SM, Strain EC, Vandekar SN, Dworkin RH, Scott JC, Satterthwaite TD. (2025). \textit{Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2025.08.13.25333530}{doi:10.1101/2025.08.13.25333530}.
\item Repple J, Bayas M, Möser C, Kobayashi NF, Reif A (2025). \textit{Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action.}. Biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.biopsych.2025.02.903}{doi:10.1016/j.biopsych.2025.02.903}.
\item Silczuk A, Madejek RJ, Koweszko T, Mularczyk-Tomczewska P, Adamska E, Gujski M, Szulc A (2025). \textit{Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment.}. Medical science monitor: international medical journal of experimental and clinical research. [published; PubMed]. \href{https://doi.org/10.12659/msm.948302}{doi:10.12659/msm.948302}.
\item Harsha S. Krishna (2025). \textit{Intersecting Psychedelic Pharmacology and Gut-Brain Axis Signaling in Neurodegenerative Disorders}. JUNIOR RESEARCHERS. [published; OpenAlex]. \href{https://doi.org/10.52340/jr.2025.03.03.09}{doi:10.52340/jr.2025.03.03.09}.
\item Fernández-Borkel T, Borkel LF, Rojas-Hernández J, Hernández-Álvarez E, Quintana-Hernández DJ, Ponti LG, Henríquez-Hernández LA (2025). \textit{The Causal Role of Consciousness in Psychedelic Therapy for Treatment-Resistant Depression: Hypothesis and Proposal.}. ACS pharmacology \& translational science. [published; PubMed]. \href{https://doi.org/10.1021/acsptsci.5c00445}{doi:10.1021/acsptsci.5c00445}.
\item Meacham MC, Mian MN, Wang RC, Coker AR, Anderson BT, Montoy JCC (2025). \textit{Latent Classes of Lifetime Use of Seven Hallucinogens in the United States.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2025.2537040}{doi:10.1080/02791072.2025.2537040}.
\item S Meikle, O Carter, P Liknaitzky, L Johansen, R Iyer, N Strauss, M Williams, D Castle, S Rossell (2025). \textit{229. PSILOCYBIN WITH PSYCHOTHERAPEUTIC SUPPORT FOR TREATMENT-RESISTANT DEPRESSION: A PILOT CLINICAL TRIAL}. The international journal of neuropsychopharmacology. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC12359778}{source link}.
\item Hashimoto K (2025). \textit{Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics?}. European archives of psychiatry and clinical neuroscience. [published; PubMed]. \href{https://doi.org/10.1007/s00406-024-01770-7}{doi:10.1007/s00406-024-01770-7}.
\item Swieczkowski D, Kwaśny A, Sadko K, Pruc M, Gaca Z, Szarpak L, Cubała WJ (2025). \textit{Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2025.116559}{doi:10.1016/j.psychres.2025.116559}.
\item Berkovitch L, Fauvel B, Preller KH, Gaillard R (2025). \textit{Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans.}. Neuroscience and biobehavioral reviews. [published; PubMed]. \href{https://doi.org/10.1016/j.neubiorev.2025.106239}{doi:10.1016/j.neubiorev.2025.106239}.
\item Bayes A (2025). \textit{Australia's psychedelic experiment: reflections from a psychiatrist clinical researcher.}. Australasian psychiatry: bulletin of Royal Australian and New Zealand College of Psychiatrists. [published; PubMed]. \href{https://doi.org/10.1177/10398562251347890}{doi:10.1177/10398562251347890}.
\item Adebo M, Bonnet M, Laouej O, Defaix C, McGowan JC, Butlen-Ducuing F, David DJ, Poupon E, Tritschler L, Gardier AM (2025). \textit{Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms.}. Fundamental \& clinical pharmacology. [published; PubMed]. \href{https://doi.org/10.1111/fcp.70038}{doi:10.1111/fcp.70038}.
\item Fernandes-Nascimento MH, Viana-Ferreira K, Negrão AB (2025). \textit{Overview and Specificity of Psilocybin Use in the Treatment of Mental Disorders:.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2024.0031}{doi:10.1089/psymed.2024.0031}.
\item Hiroe Tani (2025). \textit{577. CLINICAL EVIDENCE AND APPLICATIONS OF PSYCHEDELICS FOR MENTAL ILLNESSES}. The International Journal of Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1093/ijnp/pyaf052.377}{doi:10.1093/ijnp/pyaf052.377}.
\item Cheung K, Brodie M, Chang SL, Deschamps P, Fallu JS, Farzin H, Hébert J, Stephan JF, Dorval M, Joly Y, P3A Study Group (2025). \textit{Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians' Concerns.}. The Journal of law, medicine \& ethics: a journal of the American Society of Law, Medicine \& Ethics. [published; PubMed]. \href{https://doi.org/10.1017/jme.2025.10109}{doi:10.1017/jme.2025.10109}.
\item Heidi Allen, B. Stott (2025). \textit{Preparing Social Work for Psychedelic-Assisted Therapy}. Social Work. [published; OpenAlex]. \href{https://doi.org/10.1093/sw/swaf031}{doi:10.1093/sw/swaf031}.
\item Modlin NL, Jessica L MK, Sarang M, Siebenaler L, Maggio C, Pick S, Williamson V, Cleare A, Rucker J (2025). \textit{Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms.}. Psychiatry and clinical psychopharmacology. [published; PubMed]. \href{https://doi.org/10.5152/pcp.2025.24934}{doi:10.5152/pcp.2025.24934}.
\item Bevione F, Lacidogna MC, Lavalle R, Abbate Daga G, Preti A (2025). \textit{Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials.}. Eating and weight disorders: EWD. [published; PubMed]. \href{https://doi.org/10.1007/s40519-025-01771-y}{doi:10.1007/s40519-025-01771-y}.
\item King's College London (2025). \textit{Modulation of Serotonin Pathways Using Psilocybin in Adults With and Without Autism Spectrum Disorder (ASD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05651126}{source link}.
\item Luquiens A, Belahda D, Graux C, Igounenc N, Serrand C, Rochefort P, Mura T, Sergent F (2025). \textit{Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial.}. Addiction (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1111/add.70152}{doi:10.1111/add.70152}.
\item Rodan SC, Meez N, Lloyd-Hurwitz S, Bedoya-Pérez MA, Suraev A, Sommer N, Greenstien K, Maguire S, McGregor IS (2025). \textit{Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.}. Journal of eating disorders. [published; PubMed]. \href{https://doi.org/10.1186/s40337-025-01328-5}{doi:10.1186/s40337-025-01328-5}.
\item Emory University (2025). \textit{The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05506982}{source link}.
\item Cohen ZZ, Blest-Hopley G (2025). \textit{Females in Psychedelic Research: A Perspective for Advancing Research and Practice.}. ACS pharmacology \& translational science. [published; PubMed]. \href{https://doi.org/10.1021/acsptsci.5c00255}{doi:10.1021/acsptsci.5c00255}.
\item Rajwani K, Almonte MT, Feroz F, Hokanson J, Jacobs E, Savulescu J, Singh I, Yaden DB, Earp BD. (2025). \textit{Clinical Psychedelic Therapy Research Involving Adolescents: Protocol for a Scoping Review of Intervention Studies}. Wellcome Open Res. [preprint; Europe PMC]. \href{https://doi.org/10.12688/wellcomeopenres.24181.1}{doi:10.12688/wellcomeopenres.24181.1}.
\item Tolle HM, Luppi AI, Lawn T, Roseman L, Nutt D, Carhart-Harris RL, Mediano PAM. (2025). \textit{Accurate and Interpretable Prediction of Antidepressant Treatment Response from Receptor-informed Neuroimaging}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.07.02.662710}{doi:10.1101/2025.07.02.662710}.
\item Atiq MA, Baker MR, Voort JLV, Vargas MV, Choi DS (2025). \textit{Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-024-06599-5}{doi:10.1007/s00213-024-06599-5}.
\item Swieczkowski D, Kwaśny A, Pruc M, Gaca Z, Szarpak L, Cubała WJ (2025). \textit{Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis.}. Pharmacopsychiatry. [published; PubMed]. \href{https://doi.org/10.1055/a-2529-7029}{doi:10.1055/a-2529-7029}.
\item Chen MJQ, Chen-Li D, Chisamore N, Husain MI, Di Vincenzo JD, Mansur RB, Phan L, Johnson D, McIntyre RS, Rosenblat JD (2025). \textit{Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2025.116532}{doi:10.1016/j.psychres.2025.116532}.
\item Cummins BR, Billac GB, Nichols DE, Nichols CD (2025). \textit{5-HT receptors: Pharmacology and functional selectivity.}. Pharmacological reviews. [published; PubMed]. \href{https://doi.org/10.1016/j.pharmr.2025.100059}{doi:10.1016/j.pharmr.2025.100059}.
\item Hieronymus F, López E, Werin Sjögren H, Lundberg J (2025). \textit{Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis.}. JAMA network open. [published; PubMed]. \href{https://doi.org/10.1001/jamanetworkopen.2025.24119}{doi:10.1001/jamanetworkopen.2025.24119}.
\item Mathieu Fradet (2025). \textit{Increasing the Evaluation and Reporting Rigor of Psychotherapy Interventions in Treatments Involving Psychedelics}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives4030021}{doi:10.3390/psychoactives4030021}.
\item Carvalho LC, Encantado J, Kettner H, Timmermann C, Veiga D, Teixeira PJ (2025). \textit{A Scoping Review of Research in Naturalistic Studies with Psychedelics.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2025.2520221}{doi:10.1080/02791072.2025.2520221}.
\item Czopek A, Jończyk J, Fryc M, Kluzik D, Zagórska A (2025). \textit{Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.5c00152}{doi:10.1021/acschemneuro.5c00152}.
\item Agrawal M, Roddy K, Jenkins B, Leeks C, Emanuel E (2025). \textit{Long-term benefits of single-dose psilocybin in depressed patients with cancer.}. Cancer. [published; PubMed]. \href{https://doi.org/10.1002/cncr.35889}{doi:10.1002/cncr.35889}.
\item Erkizia-Santamaría I, Horrillo I, Martínez-Álvarez N, Pérez-Martínez D, Rivero G, Erdozain AM, Meana JJ, Ortega JE (2025). \textit{Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress.}. Translational psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41398-025-03421-4}{doi:10.1038/s41398-025-03421-4}.
\item Jensen AA, Cecchi CR, Hibicke M, Bach AH, Kaadt E, Märcher-Rørsted E, Nichols CD, Elfving B, Kristensen JL (2025). \textit{The Selective Serotonin 5-HT Receptor Agonist ()-3-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)piperidine (LPH-5) Induces Persistent and Robust Antidepressant-Like Effects in Rodents.}. ACS pharmacology \& translational science. [published; PubMed]. \href{https://doi.org/10.1021/acsptsci.5c00208}{doi:10.1021/acsptsci.5c00208}.
\item MycoMedica Life Sciences PBC (2025). \textit{A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Participants}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06643637}{source link}.
\item Stephen Ross (2025). \textit{Stephen Ross: Psychedelic-assisted therapies for difficult-to-treat psychiatric and medical disorders}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp025k.0017}{doi:10.61373/pp025k.0017}.
\item Matthew Hicks (2025). \textit{Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06372197}{source link}.
\item National University of Natural Medicine (2025). \textit{Optimizing Microdosing and Meditation}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06560658}{source link}.
\item Becker AM, Humbert-Droz M, Mueller L, Jelušić A, Tolev A, Straumann I, Avedisian I, Erne L, Thomann J, Luethi D, Grünblatt E, Meyer Zu Schwabedissen H, Liechti ME (2025). \textit{Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial.}. Clinical pharmacology and therapeutics. [published; PubMed]. \href{https://doi.org/10.1002/cpt.3618}{doi:10.1002/cpt.3618}.
\item Umbacia MA, Leon MX, Quintero JM, Castro LM, Paez V, Dodd S, Bustos RH (2025). \textit{Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being.}. Expert opinion on emerging drugs. [published; PubMed]. \href{https://doi.org/10.1080/14728214.2025.2488786}{doi:10.1080/14728214.2025.2488786}.
\item Meshkat S, Malik G, Zeifman RJ, Swainson J, Balachandra K, Reichelt AC, Zhang Y, Burback L, Winkler O, Greenshaw A, Vermetten E, Mayo LM, Tanguay R, Jetly R, Bhat V (2025). \textit{Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review.}. Neuroscience and biobehavioral reviews. [published; PubMed]. \href{https://doi.org/10.1016/j.neubiorev.2025.106163}{doi:10.1016/j.neubiorev.2025.106163}.
\item Mathew A, Dongre R, Kim SH, Turner J, Mathew A, Cherryholmes E, Mehrinfar M, Kamprath S (2025). \textit{The Clinical Applications of Psilocybin Therapies and Post-COVID Syndrome: A Comprehensive Narrative Review.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.86659}{doi:10.7759/cureus.86659}.
\item Fitzgerald PB, Webb SL, Denning NC, Dowie T, Schweickle MM, Modak A, Chan G, Knight J, Waldron M, Gainsford K, Hawkes H, Zammit S, Sutanto NC, Fitzgibbon BM, Bailey NW. (2025). \textit{Understanding the Psychological Effects of Psilocybin and 3,4-Methylenedioxymethamphetamine in a Non-Clinical Population}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2025.05.28.25328532}{doi:10.1101/2025.05.28.25328532}.
\item Palmer C, Ferber AT, Greenwald BD (2025). \textit{The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review.}. Brain sciences. [published; PubMed]. \href{https://doi.org/10.3390/brainsci15060572}{doi:10.3390/brainsci15060572}.
\item Schäfer T, Sherwood A, Kirkland T, Krüger T, Worbs J, Kniemeyer O, Gressler M, Hoffmeister D (2025). \textit{In Vitro Psilocybin Synthesis by Co-Immobilized Enzymes.}. Chemistry (Weinheim an der Bergstrasse, Germany). [published; PubMed]. \href{https://doi.org/10.1002/chem.202501037}{doi:10.1002/chem.202501037}.
\item Ritika Jagdeep Shah, Ashish Sarangi (2025). \textit{Evaluating the Effectiveness of Psychedelic-Assisted Therapy in Treating Alcohol Use Disorders: A Review}. Alcoholism Treatment Quarterly. [published; OpenAlex]. \href{https://doi.org/10.1080/07347324.2025.2500345}{doi:10.1080/07347324.2025.2500345}.
\item Liebnau J, Betzler F, Kerber A (2025). \textit{Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811241312866}{doi:10.1177/02698811241312866}.
\item Cardone P, Núñez P, Alnagger NLN, Martial C, van der Lande GJM, Sandell R, Carhart-Harris R, Gosseries O (2025). \textit{Psilocybin for disorders of consciousness: A case-report study.}. Clinical neurophysiology: official journal of the International Federation of Clinical Neurophysiology. [published; PubMed]. \href{https://doi.org/10.1016/j.clinph.2025.02.264}{doi:10.1016/j.clinph.2025.02.264}.
\item Falchi-Carvalho M, Palhano-Fontes F, Wießner I, Barros H, Bolcont R, Laborde S, Ruschi B Silva S, Montanini D, C Barbosa D, Teixeira E, Florence-Vilela R, Almeida R, K A de Macedo R, Arichelle F, J Pantrigo É, V Costa-Macedo J, da Cruz Nunes JA, de Araújo Costa Neto LA, Nunes Ferreira LF, Dantas Corrêa L, da Costa Bezerra RB, Arcoverde E, Galvão-Coelho N, B Araujo D (2025). \textit{Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/s41386-025-02091-6}{doi:10.1038/s41386-025-02091-6}.
\item Weintraub MJ, Miklowitz DJ, Jeffrey JK (2025). \textit{Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder.}. Journal of psychiatric practice. [published; PubMed]. \href{https://doi.org/10.1097/pra.0000000000000853}{doi:10.1097/pra.0000000000000853}.
\item Sevander Saara Susan, Rissanen Marja-Liisa Susan (2025). \textit{The benefits and harm of psychedelics in the treatment of patients with mental health and substance abuse disorders: an integrative literature review}. Health, environment and sustainable development: interdisciplinary approach. [published; Crossref]. \href{https://doi.org/10.59476/hesdia.v0i1.700}{doi:10.59476/hesdia.v0i1.700}.
\item Penzenstadler L, Baudois S, Lingenberg A, Catalano Chiuvé S, Tomkova E, Fleury V (2025). \textit{[Treatment with psychedelics: potential benefits in Parkinson's disease].}. Revue medicale suisse. [published; PubMed]. \href{https://doi.org/10.53738/revmed.2025.21.915.47180}{doi:10.53738/revmed.2025.21.915.47180}.
\item Kevin Boehnke (2025). \textit{A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With Fibromyalgia}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05128162}{source link}.
\item Beesley VL, Kennedy TJ, Maccallum F, Ross M, Harvey R, Rossell SL, Sarris J, Perkins D, Neale RE, Bennett-Levy J, Johnson S, Beebe H, Roset N, Strobel J, Parker S (2025). \textit{Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement.}. BMJ open. [published; PubMed]. \href{https://doi.org/10.1136/bmjopen-2024-095992}{doi:10.1136/bmjopen-2024-095992}.
\item Ardini M, Angelucci F, Rea F, Paluzzi L, Gabriele F, Palerma M, Di Leandro L, Ippoliti R, Pitari G (2025). \textit{Functional and structural characterization of the human indolethylamine N-methyltransferase through fluorometric, thermal and computational docking analyses.}. Biology direct. [published; PubMed]. \href{https://doi.org/10.1186/s13062-025-00632-z}{doi:10.1186/s13062-025-00632-z}.
\item Mary E. Kittur, L. Martínez, Brett D. M. Jones, Daniel M. Blumberger, Benoit H. Mulsant, Joshua D. Rosenblat, Ishrat Husain (2025). \textit{188. Mapping Psilocybin Therapy: A Systematic Review of Therapeutic Frameworks, Adaptations, and Standardization Across Contemporary Clinical Trials}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2025.02.425}{doi:10.1016/j.biopsych.2025.02.425}.
\item Erica Kaczmarek, Nelson B. Rodrigues, Noah Chisamore, Zoe Doyle, Roger S. McIntyre, Rodrigo B. Mansur, Joshua D. Rosenblat (2025). \textit{187. Changes in Symptoms of Anhedonia With Psilocybin-Assisted Psychotherapy: A Secondary Analysis of a Randomized Clinical Trial for Treatment-Resistant Depression}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2025.02.424}{doi:10.1016/j.biopsych.2025.02.424}.
\item University of Otago (2025). \textit{Psilocybin-assisted Interpersonal Therapy for Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05581797}{source link}.
\item Omidian H, Omidian A (2025). \textit{The Emergence of Psilocybin in Psychiatry and Neuroscience.}. Pharmaceuticals (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/ph18040555}{doi:10.3390/ph18040555}.
\item Jennifer Jones (2025). \textit{Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimization}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2025.1565852}{doi:10.3389/fpsyt.2025.1565852}.
\item Emmanuelle A. D. Schindler, Christopher Gottschalk, Deepak Cyril D’Souza (2025). \textit{Psilocybin’s Effects on Headache Frequency are Not Related to Acute Psychedelic Effects or Measures of Mental Health: Secondary Analysis of Clinical Trials in Migraine and Cluster Headache (P7-12.001)}. Neurology. [published; OpenAlex]. \href{https://doi.org/10.1212/wnl.0000000000210945}{doi:10.1212/wnl.0000000000210945}.
\item Nathalie M. Rieser, Raoul Bitar, Simon Halm, Christina Rossgoderer, Ladina P Gubser, Maeva Thévenaz, Yara Kreis, Robin von Rotz, Carlos Nordt, Monika Visentini, Flora Moujaes, Etna Engeli, Andres Ort, Erich Seifritz, Franz Xaver Vollenweider, Marcus Herdener, Katrin H. Preller (2025). \textit{Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial}. Universität Zürich, ZORA. [published; OpenAlex]. \href{https://doi.org/10.5167/uzh-284304}{doi:10.5167/uzh-284304}.
\item Ioana A. Cristea, G Tomei, Jazmín Freddi, A. Bonessio (2025). \textit{Selective outcome reporting and non-reporting in trials of psychedelic drugs for mental disorders}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2025.393}{doi:10.1192/j.eurpsy.2025.393}.
\item Matsukubo J, Dickson S, Xiao J, Friesen EL, Solmi M, Fiedorowicz JG, Fischer B, Myran DT (2025). \textit{Psilocybin Dispensaries and Online Health Claims in Canada.}. JAMA network open. [published; PubMed]. \href{https://doi.org/10.1001/jamanetworkopen.2025.2853}{doi:10.1001/jamanetworkopen.2025.2853}.
\item Mimms C, Sotelo K, Khaliq AS (2025). \textit{Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.82532}{doi:10.7759/cureus.82532}.
\item Unity Health Toronto (2025). \textit{Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06731335}{source link}.
\item McMaster University (2025). \textit{An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06225232}{source link}.
\item Centre Hospitalier Universitaire de Nīmes (2025). \textit{Psilocybin in Alcohol Use Disorder With Comorbid Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06235411}{source link}.
\item Meyer TD, Ibrahim M, Vale LN, Soares JC (2025). \textit{Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2024.12.044}{doi:10.1016/j.jad.2024.12.044}.
\item University Hospital, Basel, Switzerland (2025). \textit{Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05523401}{source link}.
\item Aicher HD, Müller F, Gasser P (2025). \textit{Further education in psychedelic-assisted therapy - experiences from Switzerland.}. BMC medical education. [published; PubMed]. \href{https://doi.org/10.1186/s12909-025-06871-y}{doi:10.1186/s12909-025-06871-y}.
\item Craig, Danny R, Blalock, Eric M. (2025). \textit{Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain?}. UKnowledge (University of Kentucky). [published; OpenAlex]. \href{https://uknowledge.uky.edu/jpns/vol2/iss1/1}{source link}.
\item Sabé M, Sulstarova A, Glangetas A, De Pieri M, Mallet L, Curtis L, Richard-Lepouriel H, Penzenstadler L, Seragnoli F, Thorens G, Zullino D, Preller K, Böge K, Leucht S, Correll CU, Solmi M, Kaiser S, Kirschner M (2025). \textit{Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-024-02800-5}{doi:10.1038/s41380-024-02800-5}.
\item Chen Junqi, Wang Ziteng, Yong Ching Yee, Goh Evelyn Mei Ling, Moy Hooi Yan, Chan Eric Chun Yong (2025). \textit{Elucidating the Phase I metabolism of psilocin in vitro}. Archives of Toxicology. [published; Crossref]. \href{https://doi.org/10.1007/s00204-024-03952-7}{doi:10.1007/s00204-024-03952-7}.
\item Haft SL, Downey AE, Raymond-Flesch M, Fernandes-Osterhold G, Bradley ER, O'Donovan A, Woolley J (2025). \textit{A systematic review of participant diversity in psychedelic-assisted psychotherapy trials.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2025.116359}{doi:10.1016/j.psychres.2025.116359}.
\item Belitzky E, Ravani Carvalho LV, Taylor M, Ortiz CN, Baum L, Fiellin DA, Lustberg MB (2025). \textit{Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy.}. Cancer medicine. [published; PubMed]. \href{https://doi.org/10.1002/cam4.70586}{doi:10.1002/cam4.70586}.
\item Gold ND, Pagni BA, Petridis PD, Bogenschutz MP (2025). \textit{Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2024.0030}{doi:10.1089/psymed.2024.0030}.
\item Modlin NL, McPhee T, Zazon N, Sarang M, Hignett R, Pick S, Cleare A, Williamson V, Rucker J (2025). \textit{Participants' Experience of Psychedelic Integration Groups and Processes: A Qualitative Thematic Analysis.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2024.0027}{doi:10.1089/psymed.2024.0027}.
\item Petrovitch D, Hosford S, Littlefield AK, Austin-Robillard H. (2025). \textit{Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/26tz7\_v1}{doi:10.31234/osf.io/26tz7\_v1}.
\item Dan Petrovitch, Samuel Hosford, Andrew K. Littlefield, Heather Austin-Robillard (2025). \textit{Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/26tz7\_v1}{source link}.
\item Michel Bourin (2025). \textit{Psychedelics are Bringing a new wind to the Pharmacopoeia}. Neuroscience and Neurological Surgery. [published; OpenAlex]. \href{https://doi.org/10.31579/2578-8868/360}{doi:10.31579/2578-8868/360}.
\item Brouwer A, Brown JK, Erowid E, Erowid F, Thyssen S, Raison CL, Carhart-Harris RL (2025). \textit{A qualitative analysis of the psychedelic mushroom come-up and come-down.}. Npj mental health research. [published; PubMed]. \href{https://doi.org/10.1038/s44184-024-00095-6}{doi:10.1038/s44184-024-00095-6}.
\item Lucido MJ, Dunlop BW (2025). \textit{Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges.}. Brain sciences. [published; PubMed]. \href{https://doi.org/10.3390/brainsci15020161}{doi:10.3390/brainsci15020161}.
\item Hogea L, Tabugan DC, Costea I, Albai O, Nussbaum L, Cojocaru A, Corsaro L, Anghel T (2025). \textit{The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials.}. Medicina (Kaunas, Lithuania). [published; PubMed]. \href{https://doi.org/10.3390/medicina61020278}{doi:10.3390/medicina61020278}.
\item Bender DA, Nayak SM, Siegel JS, Hellerstein DJ, Ercal BC, Lenze EJ (2025). \textit{Psychological Support Approaches in Psychedelic Therapy: Results From a Survey of Psychedelic Practitioners.}. The Journal of clinical psychiatry. [published; PubMed]. \href{https://doi.org/10.4088/jcp.24m15521}{doi:10.4088/jcp.24m15521}.
\item de Miranda AS, C B Toscano E, Venna VR, Graeff FG, Teixeira AL (2025). \textit{Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches.}. Expert opinion on drug discovery. [published; PubMed]. \href{https://doi.org/10.1080/17460441.2025.2460674}{doi:10.1080/17460441.2025.2460674}.
\item Matthew Weirick Johnson (2025). \textit{Clinical Trial Comparing Psilocybin to Nicotine Patch for Tobacco Addiction}. Drug and Alcohol Dependence. [published; OpenAlex]. \href{https://doi.org/10.1016/j.drugalcdep.2024.112187}{doi:10.1016/j.drugalcdep.2024.112187}.
\item Freitas RR, Gotsis ES, Gallo AT, Fitzgibbon BM, Bailey NW, Fitzgerald PB (2025). \textit{The safety of psilocybin-assisted psychotherapy: A systematic review.}. The Australian and New Zealand journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1177/00048674241289024}{doi:10.1177/00048674241289024}.
\item Geller J, Whitney E (2025). \textit{Therapeutic Potential of MDMA- and Psychedelic-Assisted Psychotherapy for Adolescent Depression and Trauma.}. Current psychiatry reports. [published; PubMed]. \href{https://doi.org/10.1007/s11920-024-01577-2}{doi:10.1007/s11920-024-01577-2}.
\item Swieczkowski D, Kwaśny A, Pruc M, Gaca Z, Szarpak L, Cubała WJ (2025). \textit{Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2024.116337}{doi:10.1016/j.psychres.2024.116337}.
\item Piper T, Small F, Brown S, Kelleher M, Mitcheson L, Rucker J, Young AH, Marsden J (2025). \textit{Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.}. Addiction (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1111/add.16762}{doi:10.1111/add.16762}.
\item Central Institute of Mental Health, Mannheim (2025). \textit{A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04670081}{source link}.
\item Melani A, Bonaso M, Biso L, Zucchini B, Conversano C, Scarselli M (2025). \textit{Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications.}. Pharmaceuticals (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/ph18010130}{doi:10.3390/ph18010130}.
\item Low ZXB, Ng WS, Lim ESY, Goh BH, Kumari Y (2025). \textit{The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2024.111139}{doi:10.1016/j.pnpbp.2024.111139}.
\item Erkizia-Santamaría I, Horrillo I, Meana JJ, Ortega JE (2025). \textit{Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2025.111249}{doi:10.1016/j.pnpbp.2025.111249}.
\item Constantino JL, van Dalfsen JH, Massetti S, Kamphuis J, Schoevers RA (2025). \textit{Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2025.111251}{doi:10.1016/j.pnpbp.2025.111251}.
\item Socoró Garrigosa M, Sanz Perl Y, Kringelbach ML, Carhart-Harris R, Vohryzek J, Deco G. (2025). \textit{Perturbing whole-brain models of brain hierarchy: an application for depression following pharmacological treatment}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.01.01.631011}{doi:10.1101/2025.01.01.631011}.
\item Kelly TJ, Liu QS (2025). \textit{Exploring the therapeutic potential of psychedelics: Fear extinction mechanisms and amygdala modulation.}. Psychedelics. [published; PubMed]. \href{https://doi.org/10.61373/pp024b.0019}{doi:10.61373/pp024b.0019}.
\item Papp N, Gonda X (2025). \textit{[Psychedelics and pyschodelic-associated psychotherapies - Who is PAP for after all?].}. Psychiatria Hungarica: A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/42412648/}{source link}.
\item Machado Henrique Tofoli Vieira, Seixas Geovana Mendes de, Silva Luis Gustavo Alves, Brito Mariana Duarte Garcia, Castro Giovanna Miziara (2025). \textit{Alternative therapy for neurological and psychiatric disorders using psilocybin}. São Paulo Medical Journal. [published; Crossref]. \href{https://doi.org/10.5327/1516-3180.cpn.1123}{doi:10.5327/1516-3180.cpn.1123}.
\item Barnett BS, Vest MF, Delatte MS, King Iv F, Mauney EE, Coulson AJ, Nayak SM, Hendricks PS, Greer GR, Murnane KS (2025). \textit{Practical considerations in the establishment of psychedelic research programs.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-024-06722-6}{doi:10.1007/s00213-024-06722-6}.
\item Kirlić N, Lennard-Jones M, Atli M, Malievskaia E, Modlin NL, Peck SK, Gaillard A, Goodwin GM, Koelpin D (2025). \textit{Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20230884}{doi:10.1176/appi.ajp.20230884}.
\item Fonzo GA, Wolfgang AS, Barksdale BR, Krystal JH, Carpenter LL, Kraguljac NV, Grzenda A, McDonald WM, Widge AS, Rodriguez CI, Nemeroff CB (2025). \textit{Psilocybin: From Psychiatric Pariah to Perceived Panacea.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20230682}{doi:10.1176/appi.ajp.20230682}.
\item Ramaekers JG, Reckweg JT, Mason NL (2025). \textit{Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20230890}{doi:10.1176/appi.ajp.20230890}.
\item Pagni BA, Zeifman RJ, Mennenga SE, Carrithers BM, Goldway N, Bhatt S, O'Donnell KC, Ross S, Bogenschutz MP (2025). \textit{Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20230887}{doi:10.1176/appi.ajp.20230887}.
\item Manzano-Nunez R, Gomez DA, Toledo-Mendoza C, Perez-Otero M, Matilla IL, Prats C, Perez-Lopez E, Pardo H, Díaz-Pellicer P, De La Torre-Fornell R, Aldea AM (2025). \textit{Exploring Psychedelics Pharmacology: A Scoping Review Charting the Course of Psilocybin Pharmacokinetics.}. Clinical neuropharmacology. [published; PubMed]. \href{https://doi.org/10.1097/wnf.0000000000000617}{doi:10.1097/wnf.0000000000000617}.
\item Lewis BR, Hendrick J, Byrne K, Odette M, Wu C, Garland EL (2025). \textit{Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial.}. medRxiv: the preprint server for health sciences. [published; PubMed]. \href{https://doi.org/10.1101/2024.12.31.24319806}{doi:10.1101/2024.12.31.24319806}.
\item Bires J (2025). \textit{Existing evidence for the use of psychedelics in patients with cancer and other serious illness: A narrative review.}. Journal of psychosocial oncology. [published; PubMed]. \href{https://doi.org/10.1080/07347332.2025.2482917}{doi:10.1080/07347332.2025.2482917}.
\item Totomanova I, Haijen ECHM, Hurks PPM, Ramaekers JG, Kuypers KPC (2025). \textit{Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry?}. International review of neurobiology. [published; PubMed]. \href{https://doi.org/10.1016/bs.irn.2025.03.002}{doi:10.1016/bs.irn.2025.03.002}.
\item Wingert AM, Agnorelli C, Peill J, Reed S, Nutt DJ, Erritzoe D (2025). \textit{Serotonergic psychedelics for depression: A comprehensive overview.}. International review of neurobiology. [published; PubMed]. \href{https://doi.org/10.1016/bs.irn.2025.04.009}{doi:10.1016/bs.irn.2025.04.009}.
\item DuPont CM, Johnson MW (2025). \textit{Psychedelics and substance use disorder treatment.}. International review of neurobiology. [published; PubMed]. \href{https://doi.org/10.1016/bs.irn.2025.03.005}{doi:10.1016/bs.irn.2025.03.005}.
\item Bostoen T, Tap S, Breeksema J, Schoevers R (2025). \textit{Post-traumatic stress disorder in psychedelic research.}. International review of neurobiology. [published; PubMed]. \href{https://doi.org/10.1016/bs.irn.2025.02.004}{doi:10.1016/bs.irn.2025.02.004}.
\item Vogt SB, Liechti ME (2025). \textit{Clinical pharmacology.}. International review of neurobiology. [published; PubMed]. \href{https://doi.org/10.1016/bs.irn.2025.02.003}{doi:10.1016/bs.irn.2025.02.003}.
\item Zamaria JA, Fernandes-Osterhold G, Shedler J, Yehuda R (2025). \textit{Psychedelics assisting therapy, or therapy assisting psychedelics? The importance of psychotherapy in psychedelic-assisted therapy.}. Frontiers in psychology. [published; PubMed]. \href{https://doi.org/10.3389/fpsyg.2025.1505894}{doi:10.3389/fpsyg.2025.1505894}.
\item Silva F, Butlen-Ducuing F, Guizzaro L, Balabanov P (2025). \textit{A review of psychedelics trials completed in depression, informed by European regulatory perspectives.}. Neuroscience applied. [published; PubMed]. \href{https://doi.org/10.1016/j.nsa.2025.105516}{doi:10.1016/j.nsa.2025.105516}.
\item Roseby W, Kettner H, Roseman L, Spriggs MJ, Lyons T, Peill J, Giribaldi B, Erritzoe D, Nutt DJ, Carhart-Harris RL (2025). \textit{Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies.}. Frontiers in psychology. [published; PubMed]. \href{https://doi.org/10.3389/fpsyg.2025.1580663}{doi:10.3389/fpsyg.2025.1580663}.
\item Małgorzata W, Kopczyk R, Gerlach A, Rymaszewska J (2025). \textit{Therapeutic and legal aspects of psilocybin in cancer-related depression.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2025.1591864}{doi:10.3389/fpsyt.2025.1591864}.
\item Thaoboonruang N, Lohitnavy M, Lohitnavy O (2025). \textit{Pharmacokinetics of Psilocybin, a Tryptamine Alkaloid in Magic Mushroom (): A Systematic Review.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2024.2399128}{doi:10.1080/02791072.2024.2399128}.
\item Ludbrook G, Bryson N, Taylor B, Hocevar-Trnka J, Johnson MW, Hirman J, Morrish G, Alexander R, Pollack M (2025). \textit{Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study.}. Journal of clinical psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1097/jcp.0000000000002047}{doi:10.1097/jcp.0000000000002047}.
\item Ross ML, Iyer R, Williams ML, Boughey M, O'Callaghan C, Hiscock R, Dwyer J (2025). \textit{Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial.}. General hospital psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.genhosppsych.2025.08.001}{doi:10.1016/j.genhosppsych.2025.08.001}.
\item Cheung K, Propes C, Graziosi M, Patch K, Yaden DB (2025). \textit{Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis.}. AJOB empirical bioethics. [published; PubMed]. \href{https://doi.org/10.1080/23294515.2025.2526339}{doi:10.1080/23294515.2025.2526339}.
\item Meikle S, Carter O, Liknaitzky P, Johansen L, Iyer R, Strauss N, Williams M, Castle D, Rossell SL (2025). \textit{Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/20451253251377187}{doi:10.1177/20451253251377187}.
\item Wong S, Jones BDM, Thiyagarajah MT, Sabbah SG, Thompson C, Solmi M, Umer M, Zrenner C, Voineskos D, Rosenblat JD, Mulsant BH, Blumberger DM, Husain MI (2025). \textit{Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/20451253251384513}{doi:10.1177/20451253251384513}.
\item Havlik JL, Isaac S, Raman P, Tran N, Hidalgo K, Suppes T (2025). \textit{Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders.}. Journal of clinical psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1097/jcp.0000000000002095}{doi:10.1097/jcp.0000000000002095}.
\item Beaussant Y, Tarbi E, Nigam K, Miner S, Sager Z, Sanders J, Ljuslin M, Guérin B, Sholevar R, Roddy K, Tulsky JA, Agrawal M (2025). \textit{Set and setting in psilocybin-assisted therapy: A qualitative study of patients with cancer and depression.}. General hospital psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.genhosppsych.2025.10.010}{doi:10.1016/j.genhosppsych.2025.10.010}.
\item McHerron D, Barber M, Ham R, Liknaitzky P, Carter A, Gardner J (2025). \textit{The ethical use of therapeutic touch in psychedelic-assisted therapy: a qualitative study of researcher perspectives and experiences.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/20451253251377191}{doi:10.1177/20451253251377191}.
\item Afsharnia S, Liang V, Lunsky Y, Orsini AP, Tint A, Lin HY (2025). \textit{Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey.}. PLOS mental health. [published; PubMed]. \href{https://doi.org/10.1371/journal.pmen.0000514}{doi:10.1371/journal.pmen.0000514}.
\item Zafar RR, Kleine P, Kurtin D, Wall M, Erritzoe D (2025). \textit{High hopes? Precision psychedelic addiction medicine.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2025.1681795}{doi:10.3389/fpsyt.2025.1681795}.
\item Khalaud Naseeb Alhajry, Zahra Mohammed Sukairi, Hamidah Abdullah Lajami, Safiah Anber Bin Ali Ibrahim, Nawal Obaid Alanazi, Eman Ali Alsafwani, Ashwag Saad Hnif Albishi, Nada Naser Alomi, Zahrh Ahmed Ali Al-Hamadah, Anwar Mehdaf Akash Alrowaly (2024). \textit{Psychedelic-Assisted Therapy: The Emerging Role of the Psychiatric-Mental Health Nurse}. Saudi Journal of Medicine and Public Health. [published; OpenAlex]. \href{https://doi.org/10.64483/20251153}{doi:10.64483/20251153}.
\item Mohammad Ali, Urbah Viqar (2024). \textit{Treatment-Resistant Depression: A Comprehensive Insight of Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Psychedelic-Assisted Psychotherapy}. Annals of Punjab Medical College. [published; OpenAlex]. \href{https://doi.org/10.29054/apmc/2024.1658}{doi:10.29054/apmc/2024.1658}.
\item Muniz, John Marco D.F. (2024). \textit{Comparative Efficacy of Hallucinogens in Treating Mood Disorders Through a Meta-Analysis of Symptom Reduction, Dosage, and Duration}. Journal of International Crisis and Risk Communication Research. [published; OpenAlex]. \href{https://stars.library.ucf.edu/hut2024/268}{source link}.
\item Spangemacher M, Mertens LJ, Färber LV, Jungaberle A, Jungaberle H, Gründer G (2024). \textit{Psilocybin as a Disease-Modifying Drug-A Salutogenic Approach in Psychiatry.}. Deutsches Arzteblatt international. [published; PubMed]. \href{https://doi.org/10.3238/arztebl.m2024.0224}{doi:10.3238/arztebl.m2024.0224}.
\item Lodetti G, de Bitencourt RM, Rico EP (2024). \textit{Classic psychedelics and the treatment for alcoholism.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2024.111129}{doi:10.1016/j.pnpbp.2024.111129}.
\item Barnett JH, Todd KT, Benetatos J, Rabichow BE, Gibson KA, Olney KC, Fryer JD. (2024). \textit{Psilocybin causes sex, time, and dose dependent alterations in brain signaling pathways}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.12.16.628764}{doi:10.1101/2024.12.16.628764}.
\item Christina M. Andrews, Wayne Hall, Keith Humphreys, John Marsden (2024). \textit{Disentangling debate about therapeutic and recreational use of psychedelics}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.16744}{doi:10.1111/add.16744}.
\item Wahba M, Hayes C, Kletter M, McAllister-Williams RH (2024). \textit{Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience.}. BJPsych open. [published; PubMed]. \href{https://doi.org/10.1192/bjo.2024.768}{doi:10.1192/bjo.2024.768}.
\item Back AL, Freeman-Young TK, Morgan L, Sethi T, Baker KK, Myers S, McGregor BA, Harvey K, Tai M, Kollefrath A, Thomas BJ, Sorta D, Kaelen M, Kelmendi B, Gooley TA (2024). \textit{Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.}. JAMA network open. [published; PubMed]. \href{https://doi.org/10.1001/jamanetworkopen.2024.49026}{doi:10.1001/jamanetworkopen.2024.49026}.
\item Juan Scuro (2024). \textit{God hasn’t died, it has merely been encapsulated - Psilocybin and ayahuasca in the psychedelic renaissance: Intersections between religion, indigenous cosmologies, spirituality, and science}. Social Compass. [published; OpenAlex]. \href{https://doi.org/10.1177/00377686241301923}{doi:10.1177/00377686241301923}.
\item Li G, Facchini PJ (2024). \textit{New frontiers in the biosynthesis of psychoactive specialized metabolites.}. Current opinion in plant biology. [published; PubMed]. \href{https://doi.org/10.1016/j.pbi.2024.102626}{doi:10.1016/j.pbi.2024.102626}.
\item Marwood L, Croal M, Mistry S, Simmons H, Tsai J, Young MB, Goodwin GM (2024). \textit{The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression.}. Journal of psychiatric research. [published; PubMed]. \href{https://doi.org/10.1016/j.jpsychires.2024.10.009}{doi:10.1016/j.jpsychires.2024.10.009}.
\item Ehrenkranz R, Agrawal M, Penberthy JK, Yaden DB (2024). \textit{Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.}. International review of psychiatry (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1080/09540261.2024.2357668}{doi:10.1080/09540261.2024.2357668}.
\item Back A, Myers S, Guy J, Perez J, Lazar Thorn L, McGregor B (2024). \textit{Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0069}{doi:10.1089/psymed.2023.0069}.
\item Adams DR, Allen H, Nicol GE, Cabassa LJ (2024). \textit{Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science.}. Translational behavioral medicine. [published; PubMed]. \href{https://doi.org/10.1093/tbm/ibae053}{doi:10.1093/tbm/ibae053}.
\item Yale University (2024). \textit{Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03356483}{source link}.
\item TRYP Therapeutics (2024). \textit{A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05035927}{source link}.
\item Kargbo RB (2024). \textit{Expanding the Therapeutic Horizons of Psilocybin in Mental Health.}. ACS medicinal chemistry letters. [published; PubMed]. \href{https://doi.org/10.1021/acsmedchemlett.4c00488}{doi:10.1021/acsmedchemlett.4c00488}.
\item Stéphanie Knatz Peck, Hannah M. Fisher, Jessie Kim, Samantha Shao, Julie Trim, Walter H. Kaye (2024). \textit{Psychedelic treatment for anorexia nervosa: A first-hand view of how psilocybin treatment did and did not help}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp024e.0034}{doi:10.61373/pp024e.0034}.
\item Aday JS, McAfee J, Conroy DA, Hosanagar A, Tarnal V, Weston C, Scott K, Horowitz D, Harte SE, Pouyan N, Glynos NG, Baker AK, Guss J, Davis AK, Burgess HJ, Mashour GA, Clauw DJ, Boehnke KF. (2024). \textit{Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/j8zb5}{doi:10.31234/osf.io/j8zb5}.
\item Jacob S. Aday, Jenna McAfee, Deirdre A. Conroy, Avinash Hosanagar, Vijay Tarnal, Cody Weston, Katharine Scott, Dana Horowitz, Steven E. Harte, Niloufar Pouyan (2024). \textit{Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/j8zb5\_v1}{source link}.
\item Kim A, Halton B, Shah A, Seecof OM, Ross S (2024). \textit{Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application-a review.}. Annals of palliative medicine. [published; PubMed]. \href{https://doi.org/10.21037/apm-24-35}{doi:10.21037/apm-24-35}.
\item Reid MJ, Kettner H, Blanken TF, Weiss B, Carhart-Harris R (2024). \textit{Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action.}. Current psychiatry reports. [published; PubMed]. \href{https://doi.org/10.1007/s11920-024-01539-8}{doi:10.1007/s11920-024-01539-8}.
\item Petridis PD, Grinband J, Agin-Liebes G, Kinslow CJ, Zeifman RJ, Bogenschutz MP, Griffiths RR, Ross S (2024). \textit{Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer.}. Nature. Mental health. [published; PubMed]. \href{https://doi.org/10.1038/s44220-024-00331-0}{doi:10.1038/s44220-024-00331-0}.
\item Luoma JB, Wilson-Poe A, Pertl K, Hoffman K, Bazinet A, Stauffer C, McCarty D, Korthuis P. (2024). \textit{Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/dwhcu\_v1}{doi:10.31234/osf.io/dwhcu\_v1}.
\item Wahba M, Hayes C, Kletter M, McAllister-Williams RH (2024). \textit{Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: Case report and thematic analysis of one participant's experience}. BJPsych Open. [published; OpenAlex]. \href{https://openalex.org/W7139416359}{source link}.
\item Jason Luoma, Adie Wilson-Poe, Kellie Pertl, Kim Hoffman, Alissa Bazinet, Christopher Stauffer, Dennis McCarty, Philip Korthuis (2024). \textit{Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/dwhcu\_v1}{source link}.
\item Filament Health Corp. (2024). \textit{A Registered Clinical Trial of PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06666010}{source link}.
\item Pamela Kryskow, Paul Stamets, Joseph La Torre, Kathy Sattler, Vivian W. L. Tsang, Monnica T. Williams (2024). \textit{“The mushroom was more alive and vibrant”: Patient reports of synthetic versus organic forms of psilocybin}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2024.00379}{doi:10.1556/2054.2024.00379}.
\item Imperial College London (2024). \textit{Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03429075}{source link}.
\item Perez Rosal SR, La Torre JT, Birnkammer S, Chernoloz O, Williams MT, Faber SC (2024). \textit{Expert recommendations for Germany's integration of psychedelic-assisted therapy.}. BMC medical education. [published; PubMed]. \href{https://doi.org/10.1186/s12909-024-06141-3}{doi:10.1186/s12909-024-06141-3}.
\item James Rucker, Matthew Butler, Sadie Hambleton, Catherine Bird, Mathieu Seynaeve, Sanjay Cheema, Kete Campbell-Coker, Carolina Maggio, Fiona Dunbar, Giorgio Lambru, Manjit Matharu (2024). \textit{Plain Language Summary Publication: Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: Results from an open-label phase Ib ascending dose study}. Headache The Journal of Head and Face Pain. [published; OpenAlex]. \href{https://doi.org/10.1111/head.14846}{doi:10.1111/head.14846}.
\item MycoMedica Life Sciences PBC (2024). \textit{A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06326606}{source link}.
\item Daniel Spinosa, Stacy M. Fischer, Richard J. Zeifman, Carolyn Lefkowits, Petros Petridis, Stephen Ross (2024). \textit{PR012/\#955 Psilocybin assisted psychotherapy for patients with ovarian caner: a subset analysis of a randomized, double-blind, placebo-controlled, phase II clinical trial}. International Journal of Gynecological Cancer. [published; OpenAlex]. \href{https://doi.org/10.1136/ijgc-2024-igcs.54}{doi:10.1136/ijgc-2024-igcs.54}.
\item Conn K, Milton LK, Huang K, Munguba H, Ruuska J, Lemus MB, Greaves E, Homman-Ludiye J, Oldfield BJ, Foldi CJ (2024). \textit{Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms.}. Molecular psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41380-024-02575-9}{doi:10.1038/s41380-024-02575-9}.
\item Najib J (2024). \textit{The role of psilocybin in depressive disorders.}. Current medical research and opinion. [published; PubMed]. \href{https://doi.org/10.1080/03007995.2024.2396536}{doi:10.1080/03007995.2024.2396536}.
\item Sarris J, Halman A, Urokohara A, Lehrner M, Perkins D (2024). \textit{Artificial intelligence and psychedelic medicine.}. Annals of the New York Academy of Sciences. [published; PubMed]. \href{https://doi.org/10.1111/nyas.15229}{doi:10.1111/nyas.15229}.
\item Erritzoe D, Barba T, Greenway KT, Murphy R, Martell J, Giribaldi B, Timmermann C, Murphy-Beiner A, Jones MB, Nutt D, Weiss B, Carhart-Harris R (2024). \textit{Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.}. EClinicalMedicine. [published; PubMed]. \href{https://doi.org/10.1016/j.eclinm.2024.102799}{doi:10.1016/j.eclinm.2024.102799}.
\item Fisher EL, Smith R, Conn K, Corcoran AW, Milton LK, Hohwy J, Foldi CJ (2024). \textit{Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats.}. Translational psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41398-024-03103-7}{doi:10.1038/s41398-024-03103-7}.
\item Western University, Canada (2024). \textit{The Effects of Psilocybin on Shared Experience in Film Processing}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06529939}{source link}.
\item Armstrong SB, Davis AK (2024). \textit{Psychedelic research at a crossroads.}. Science (New York, N.Y.). [published; PubMed]. \href{https://doi.org/10.1126/science.adt1024}{doi:10.1126/science.adt1024}.
\item Danielle B Rodrigues (2024). \textit{Use of Psilocybin in the Treatment of Mental Disorders: Systematic Review of Clinal Trials}. Journal of Complementary Medicine \& Alternative Healthcare. [published; OpenAlex]. \href{https://doi.org/10.19080/jcmah.2024.13.555852}{doi:10.19080/jcmah.2024.13.555852}.
\item Kargbo RB (2024). \textit{Current Trends in Psychedelic Science: Integrating Modified Lysergic Acid Derivatives and Psilocybin in Modern Medicine.}. ACS medicinal chemistry letters. [published; PubMed]. \href{https://doi.org/10.1021/acsmedchemlett.4c00414}{doi:10.1021/acsmedchemlett.4c00414}.
\item Cynthia Duan, Navid Farkhondehpay, Viana Safa, Emma Yuan (2024). \textit{Usage of Psilocybin to Treat Huntington's Disease: A Research Protocol}. Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal. [published; OpenAlex]. \href{https://doi.org/10.26685/urncst.644}{doi:10.26685/urncst.644}.
\item Köhne S, Hillemacher T, Glahn A, Bach P (2024). \textit{Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder.}. Expert opinion on emerging drugs. [published; PubMed]. \href{https://doi.org/10.1080/14728214.2024.2342951}{doi:10.1080/14728214.2024.2342951}.
\item Smith CL, Sackett N, Stark BC, Dinh V, Romesburg EW, Roll J (2024). \textit{Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0074}{doi:10.1089/psymed.2023.0074}.
\item Klučková T, Nikolič M, Tylš F, Viktorin V, Vejmola Č, Viktorinová M, Bravermanová A, Androvičová R, Andrashko V, Korčák J, Zach P, Hájková K, Kuchař M, Balíková M, Brunovský M, Horáček J, Páleníček T. (2024). \textit{The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience or setting}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2024.08.26.24311611}{doi:10.1101/2024.08.26.24311611}.
\item Jensen ME, Stenbæk DS, Messell CD, Poulsen ED, Varga TV, Fisher PM, Nielsen MKK, Johansen SS, Volkow ND, Knudsen GM, Fink-Jensen A. (2024). \textit{­­­­Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-4947184/v1}{doi:10.21203/rs.3.rs-4947184/v1}.
\item Hsu TW, Tsai CK, Kao YC, Thompson T, Carvalho AF, Yang FC, Tseng PT, Hsu CW, Yu CL, Tu YK, Liang CS (2024). \textit{Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.}. BMJ (Clinical research ed.). [published; PubMed]. \href{https://doi.org/10.1136/bmj-2023-078607}{doi:10.1136/bmj-2023-078607}.
\item Alnagger NL, Cardone P, Martial C, Sanz Perl Y, Mindlin I, Sitt JD, Roseman L, Carhart-Harris R, Nutt D, Mallaroni P, Mason NL, Ramaekers JG, Bonhomme V, Laureys S, Deco G, Gosseries O, Nunez P, Annen J. (2024). \textit{A virtual clinical trial of psychedelics to treat patients with disorders of consciousness}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.08.16.608251}{doi:10.1101/2024.08.16.608251}.
\item Salvetti G, Saccenti D, Moro AS, Lamanna J, Ferro M (2024). \textit{Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials.}. Brain sciences. [published; PubMed]. \href{https://doi.org/10.3390/brainsci14080829}{doi:10.3390/brainsci14080829}.
\item Clairvoyant Therapeutics (2024). \textit{A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05646303}{source link}.
\item Brugmann University Hospital (2024). \textit{Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy \& (Neuro)Cognitive Mechanisms}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06160232}{source link}.
\item Gustavo Deco, Yonatan Sanz Perl, Samuel Johnson, Niamh Bourke, Robin Carhart-Harris, Morten L. Kringelbach (2024). \textit{Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression}. Nature Mental Health. [published; OpenAlex]. \href{https://doi.org/10.1038/s44220-024-00298-y}{doi:10.1038/s44220-024-00298-y}.
\item Mehtani NJ, Johnson MO, Hendricks PS, Mitchell J, Anderson BT (2024). \textit{Psilocybin-assisted therapy and HIV-related shame.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-024-68908-4}{doi:10.1038/s41598-024-68908-4}.
\item Kaminski D, Reinert JP (2024). \textit{The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review.}. The Annals of pharmacotherapy. [published; PubMed]. \href{https://doi.org/10.1177/10600280231205645}{doi:10.1177/10600280231205645}.
\item Aday JS, Horton D, Fernandes-Osterhold G, O'Donovan A, Bradley ER, Rosen RC, Woolley JD (2024). \textit{Psychedelic-assisted psychotherapy: where is the psychotherapy research?}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-024-06620-x}{doi:10.1007/s00213-024-06620-x}.
\item Chisamore N, Johnson D, Chen MJQ, Offman H, Chen-Li D, Kaczmarek ES, Doyle Z, McIntyre RS, Rosenblat JD (2024). \textit{Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.}. Journal of psychiatric research. [published; PubMed]. \href{https://doi.org/10.1016/j.jpsychires.2024.05.051}{doi:10.1016/j.jpsychires.2024.05.051}.
\item Appiani FJ, Caroff SN (2024). \textit{The cyclical revival of psychedelics in psychiatric treatment.}. Current medical research and opinion. [published; PubMed]. \href{https://doi.org/10.1080/03007995.2024.2368725}{doi:10.1080/03007995.2024.2368725}.
\item Korthuis PT, Hoffman K, Wilson-Poe AR, Luoma JB, Bazinet A, Pertl K, Morgan DL, Cook RR, Bielavitz S, Myers R, Wolf RC, McCarty D, Stauffer CS (2024). \textit{Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811241257839}{doi:10.1177/02698811241257839}.
\item Siegel JS, Subramanian S, Perry D, Kay BP, Gordon EM, Laumann TO, Reneau TR, Metcalf NV, Chacko RV, Gratton C, Horan C, Krimmel SR, Shimony JS, Schweiger JA, Wong DF, Bender DA, Scheidter KM, Whiting FI, Padawer-Curry JA, Shinohara RT, Chen Y, Moser J, Yacoub E, Nelson SM, Vizioli L, Fair DA, Lenze EJ, Carhart-Harris R, Raison CL, Raichle ME, Snyder AZ, Nicol GE, Dosenbach NUF (2024). \textit{Psilocybin desynchronizes the human brain.}. Nature. [published; PubMed]. \href{https://doi.org/10.1038/s41586-024-07624-5}{doi:10.1038/s41586-024-07624-5}.
\item de la Salle S, Kettner H, Thibault Lévesque J, Garel N, Dames S, Patchett-Marble R, Rej S, Gloeckler S, Erritzoe D, Carhart-Harris R, Greenway KT (2024). \textit{Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-024-66817-0}{doi:10.1038/s41598-024-66817-0}.
\item Kristoffer Andreas Aamodt Andersen, Bjørn Holmøy, Lowan H. Stewart (2024). \textit{Assessment of psychedelic--induced states: Norwegian translation and adaptation of the revised Mystical Experience Questionnaire (MEQ-30)}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2024.00346}{doi:10.1556/2054.2024.00346}.
\item DeBattista C, Schatzberg AF (2024). \textit{The Black Book of Psychotropic Dosing and Monitoring.}. Psychopharmacology bulletin. [published; PubMed]. \href{https://doi.org/10.64719/pb.4493}{doi:10.64719/pb.4493}.
\item Hussein El Bourji, Aziz Farhat, Zahi Hamdan, Ritvij Satodiya, Rashmi Shukla, Samer El Hayek (2024). \textit{Psilocybin in the Management of Substance Use Disorders: A Summary ofCurrent Evidence}. Current Psychopharmacologye. [published; OpenAlex]. \href{https://doi.org/10.2174/0122115560288779240628043307}{doi:10.2174/0122115560288779240628043307}.
\item Peck SK, Shao S, Gruen T, Yang K, Babakanian A, Trim J, Finn DM, Kaye WH (2024). \textit{Psilocybin Therapy for Females With Anorexia Nervosa: A Phase 1, Open-Label Feasibility Study.}. Focus (American Psychiatric Publishing). [published; PubMed]. \href{https://doi.org/10.1176/appi.focus.24022013}{doi:10.1176/appi.focus.24022013}.
\item Stoliker D, Novelli L, Vollenweider FX, Egan GF, Preller KH, Razi A (2024). \textit{Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin.}. Biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.biopsych.2024.01.002}{doi:10.1016/j.biopsych.2024.01.002}.
\item Xenakis SN, Shannon SM (2024). \textit{What is needed for the roll-out of psychedelic treatments?}. Current opinion in psychiatry. [published; PubMed]. \href{https://doi.org/10.1097/yco.0000000000000946}{doi:10.1097/yco.0000000000000946}.
\item Downey AE, Gorrell S (2024). \textit{Innovative and Emerging Treatments for Anorexia Nervosa.}. Focus (American Psychiatric Publishing). [published; PubMed]. \href{https://doi.org/10.1176/appi.focus.20230041}{doi:10.1176/appi.focus.20230041}.
\item Brownstien M, Lazar M, Botvinnik A, Shevakh C, Blakolmer K, Lerer L, Lifschytz T, Lerer B (2024). \textit{Striking Long Term Beneficial Effects of Single Dose Psilocybin and Psychedelic Mushroom Extract in the SAPAP3 Rodent Model of OCD-Like Excessive Self-Grooming.}. bioRxiv: the preprint server for biology. [published; PubMed]. \href{https://doi.org/10.1101/2024.06.25.600634}{doi:10.1101/2024.06.25.600634}.
\item Parker C, Wood BM (2024). \textit{At the Forefront: Social Workers' Role in Psilocybin Treatment for Depression and Substance Misuse.}. Social work. [published; PubMed]. \href{https://doi.org/10.1093/sw/swae019}{doi:10.1093/sw/swae019}.
\item Bryson N, Alexander R, Asnis-Alibozek A, Ehlers MD (2024). \textit{RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-,-diisopropyltryptamine.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.4c00058}{doi:10.1021/acschemneuro.4c00058}.
\item Torrado Pacheco A, Moghaddam B (2024). \textit{Licit use of illicit drugs for treating depression: the pill and the process.}. The Journal of clinical investigation. [published; PubMed]. \href{https://doi.org/10.1172/jci180217}{doi:10.1172/jci180217}.
\item Linda M. Richmond (2024). \textit{Psychedelics’ Use as Medicine Hits Significant Roadblock}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.07.7.54}{doi:10.1176/appi.pn.2024.07.7.54}.
\item Petrovitch D, Mitchell SM, Van Allen J, Littlefield AK. (2024). \textit{Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/adnpg}{doi:10.31234/osf.io/adnpg}.
\item University of Sydney (2024). \textit{A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06444243}{source link}.
\item Dan Petrovitch, Sean M. Mitchell, Jason Van Allen, Andrew K. Littlefield (2024). \textit{Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/adnpg\_v1}{source link}.
\item Lasch A, Schweikert T, Dora E, Kolb T, Schurig HL, Walther A (2024). \textit{[Psilocybin-Assisted Treatment of Depression, Anxiety and Substance use Disorders: Neurobiological Basis and Clinical Application].}. Fortschritte der Neurologie-Psychiatrie. [published; PubMed]. \href{https://doi.org/10.1055/a-2046-5202}{doi:10.1055/a-2046-5202}.
\item Szigeti B, Weiss B, Rosas FE, Erritzoe D, Nutt D, Carhart-Harris R (2024). \textit{Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.}. Psychological medicine. [published; PubMed]. \href{https://doi.org/10.1017/s0033291723003653}{doi:10.1017/s0033291723003653}.
\item Downey AE, Bradley ER, Lerche AS, O'Donovan A, Krystal AD, Woolley J (2024). \textit{A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0051}{doi:10.1089/psymed.2023.0051}.
\item DiRenzo D, Barrett FS, Perin J, Darrah E, Christopher-Stine L, Griffiths RR (2024). \textit{Impact of Psilocybin on Peripheral Cytokine Production.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0039}{doi:10.1089/psymed.2023.0039}.
\item Wang SM, Kim S, Choi WS, Lim HK, Woo YS, Pae CU, Bahk WM (2024). \textit{Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials.}. Clinical psychopharmacology and neuroscience: the official scientific journal of the Korean College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.9758/cpn.23.1134}{doi:10.9758/cpn.23.1134}.
\item Hoyer D. (2024). \textit{On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.}. Authorea Preprints. [preprint; Europe PMC]. \href{https://doi.org/10.22541/au.171648613.31141136/v1}{doi:10.22541/au.171648613.31141136/v1}.
\item Bhagavan C, Glue P, Evans W, Reynolds L, Turner T, King C, Russell BR, Morunga E, Mills JL, Layton G, Menkes DB (2024). \textit{Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.}. Trials. [published; PubMed]. \href{https://doi.org/10.1186/s13063-024-08174-x}{doi:10.1186/s13063-024-08174-x}.
\item Fisher EL, Smith R, Corcoran AW, Milton LK, Conn K, Hohwy J, Foldi CJ. (2024). \textit{Psilocybin increases optimistic engagement over time: computational modelling of behavior in rats}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.05.16.594614}{doi:10.1101/2024.05.16.594614}.
\item Shunichiro Ikeda, Toshihiko Kinoshita (2024). \textit{Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogens}. Psychiatry and Clinical Neurosciences Reports. [published; OpenAlex]. \href{https://doi.org/10.1002/pcn5.196}{doi:10.1002/pcn5.196}.
\item M Ro Rsted E, Jensen AA, Smits G, Frydenvang K, Kristensen JL (2024). \textit{Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT Receptor Agonists.}. Journal of medicinal chemistry. [published; PubMed]. \href{https://doi.org/10.1021/acs.jmedchem.4c00082}{doi:10.1021/acs.jmedchem.4c00082}.
\item University of Calgary (2024). \textit{Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05995769}{source link}.
\item Brancaccio Hanna (2024). \textit{Efficacy of Psilocybin in the Treatment of Substance and Alcohol Use Disorders}. Research Posters. [published; Crossref]. \href{https://doi.org/10.31986/issn.2689-0690\_rdw.stratford\_research\_day.149\_2024}{doi:10.31986/issn.2689-0690\_rdw.stratford\_research\_day.149\_2024}.
\item Nicholas A Kerna, Kevin D. Pruitt, N.D. Victor Carsrud, Kyle Kadivi, Dabeluchi C. Ngwu, Hilary M. Holets, John V. Flores, Ijeoma Nnake, Cornelius I. Azi, Joseph Anderson, Fatimah A. Olunlade, Uzoamaka Nwokorie (2024). \textit{From Venerable Cultural Practices to Modern Psychological Solutions: Enter Entheogens into Mainstream Medicine}. European Journal of Arts Humanities and Social Sciences. [published; OpenAlex]. \href{https://doi.org/10.59324/ejahss.2024.1(3).10}{doi:10.59324/ejahss.2024.1(3).10}.
\item Szigeti B, Heifets BD (2024). \textit{Expectancy Effects in Psychedelic Trials.}. Biological psychiatry. Cognitive neuroscience and neuroimaging. [published; PubMed]. \href{https://doi.org/10.1016/j.bpsc.2024.02.004}{doi:10.1016/j.bpsc.2024.02.004}.
\item Erritzoe D, Barba T, Spriggs MJ, Rosas FE, Nutt DJ, Carhart-Harris R (2024). \textit{Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811241237870}{doi:10.1177/02698811241237870}.
\item Metaxa AM, Clarke M (2024). \textit{Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.}. BMJ (Clinical research ed.). [published; PubMed]. \href{https://doi.org/10.1136/bmj-2023-078084}{doi:10.1136/bmj-2023-078084}.
\item Thomann Jan, Kolaczynska Karolina E., Stoeckmann Oliver V., Rudin Deborah, Vizeli Patrick, Hoener Marius C., Pryce Christopher R., Vollenweider Franz X., Liechti Matthias E., Duthaler Urs (2024). \textit{In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin}. Frontiers in Pharmacology. [published; Crossref]. \href{https://doi.org/10.3389/fphar.2024.1391689}{doi:10.3389/fphar.2024.1391689}.
\item Whelan TP, Daly E, Puts NA, Smith P, Allison C, Baron-Cohen S, Malievskaia E, Murphy DGM, McAlonan GM (2024). \textit{The 'PSILAUT' protocol: an experimental medicine study of autistic differences in the function of brain serotonin targets of psilocybin.}. BMC psychiatry. [published; PubMed]. \href{https://doi.org/10.1186/s12888-024-05768-2}{doi:10.1186/s12888-024-05768-2}.
\item Downey AE, Chaphekar AV, Woolley J, Raymond-Flesch M (2024). \textit{Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians.}. Journal of eating disorders. [published; PubMed]. \href{https://doi.org/10.1186/s40337-024-01005-z}{doi:10.1186/s40337-024-01005-z}.
\item Terri D’Arrigo (2024). \textit{MedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and More}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.05.5.1}{doi:10.1176/appi.pn.2024.05.5.1}.
\item Jensen AA, Cecchi CR, Hibicke M, Bach AH, Kaadt E, Märcher-Rørsted E, Nichols CD, Elfving B, Kristensen JL. (2024). \textit{The selective 5-HT2A receptor agonist LPH-5 induces persistent and robust antidepressant-like effects in rodents}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.04.19.590212}{doi:10.1101/2024.04.19.590212}.
\item Section for Affective Disorders; Northern Stockholm Psychiatry (2024). \textit{The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04630964}{source link}.
\item Sloshower J, Zeifman RJ, Guss J, Krause R, Safi-Aghdam H, Pathania S, Pittman B, D'Souza DC (2024). \textit{Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-024-58318-x}{doi:10.1038/s41598-024-58318-x}.
\item Valerie A. Canady (2024). \textit{Psychedelic therapists, pharma collaborate on clinical trial}. Mental Health Weekly. [published; OpenAlex]. \href{https://doi.org/10.1002/mhw.34009}{doi:10.1002/mhw.34009}.
\item Erika Dyck (2024). \textit{Who will staff the psychedelic resurgence?}. Open Access Government. [published; OpenAlex]. \href{https://doi.org/10.56367/oag-042-10690}{doi:10.56367/oag-042-10690}.
\item López E, Yngwe H, Beckman M, Tiger M, Hieronymus F, Lundberg J (2024). \textit{[Psychedelic psychiatry].}. Lakartidningen. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/38572715/}{source link}.
\item J. S. Seo (2024). \textit{Current situation regarding psychedelics and magic mushroom in Korea}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2024.1695}{doi:10.1192/j.eurpsy.2024.1695}.
\item Kim P. C. Kuypers (2024). \textit{Microdosing psychedelics in the treatment of ADHD and comorbid disorders}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2024.44}{doi:10.1192/j.eurpsy.2024.44}.
\item Rucker JJ (2024). \textit{Evidence versus expectancy: the development of psilocybin therapy.}. BJPsych bulletin. [published; PubMed]. \href{https://doi.org/10.1192/bjb.2023.28}{doi:10.1192/bjb.2023.28}.
\item Beaussant Y, Tarbi E, Nigam K, Miner S, Sager Z, Sanders JJ, Ljuslin M, Guérin B, Thambi P, Tulsky JA, Agrawal M (2024). \textit{Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis.}. Cancer. [published; PubMed]. \href{https://doi.org/10.1002/cncr.35024}{doi:10.1002/cncr.35024}.
\item Agrawal M, Richards W, Beaussant Y, Shnayder S, Ameli R, Roddy K, Stevens N, Richards B, Schor N, Honstein H, Jenkins B, Bates M, Thambi P (2024). \textit{Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder.}. Cancer. [published; PubMed]. \href{https://doi.org/10.1002/cncr.35010}{doi:10.1002/cncr.35010}.
\item Yerubandi A, Thomas JE, Bhuiya NMMA, Harrington C, Villa Zapata L, Caballero J (2024). \textit{Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis.}. JAMA network open. [published; PubMed]. \href{https://doi.org/10.1001/jamanetworkopen.2024.5960}{doi:10.1001/jamanetworkopen.2024.5960}.
\item Wilkes R, Roberts DM, Liknaitzky P, Brett J (2024). \textit{The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.}. Clinical toxicology (Philadelphia, Pa.). [published; PubMed]. \href{https://doi.org/10.1080/15563650.2024.2346612}{doi:10.1080/15563650.2024.2346612}.
\item Terri D’Arrigo (2024). \textit{MedCheck; Psilocybin, Roluperidone, Latozinemab, Lacosamide}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.04.4.1}{doi:10.1176/appi.pn.2024.04.4.1}.
\item Adrian Preda (2024). \textit{Psychedelic Renaissance: Evidence and Culture}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.04.4.39}{doi:10.1176/appi.pn.2024.04.4.39}.
\item Hoener S, Wolfgang A, Nissan D, Howe E (2024). \textit{Ethical considerations for psychedelic-assisted therapy in military clinical settings.}. Journal of medical ethics. [published; PubMed]. \href{https://doi.org/10.1136/jme-2023-108943}{doi:10.1136/jme-2023-108943}.
\item Ben Seal (2024). \textit{Psychedelic drugs and the law: What’s next?}. Knowable Magazine. [published; OpenAlex]. \href{https://doi.org/10.1146/knowable-031424-2}{doi:10.1146/knowable-031424-2}.
\item Aaronson ST, Kozak Z (2024). \textit{New evidence for flexible psilocybin dosing in patients with treatment-resistant depression.}. Med (New York, N.Y.). [published; PubMed]. \href{https://doi.org/10.1016/j.medj.2024.01.014}{doi:10.1016/j.medj.2024.01.014}.
\item Rosenblat JD, Meshkat S, Doyle Z, Kaczmarek E, Brudner RM, Kratiuk K, Mansur RB, Schulz-Quach C, Sethi R, Abate A, Ali S, Bawks J, Blainey MG, Brietzke E, Cronin V, Danilewitz J, Dhawan S, Di Fonzo A, Di Fonzo M, Drzadzewski P, Dunlop W, Fiszter H, Gomes FA, Grewal S, Leon-Carlyle M, McCallum M, Mofidi N, Offman H, Riva-Cambrin J, Schmidt J, Smolkin M, Quinn JM, Zumrova A, Marlborough M, McIntyre RS (2024). \textit{Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.}. Med (New York, N.Y.). [published; PubMed]. \href{https://doi.org/10.1016/j.medj.2024.01.005}{doi:10.1016/j.medj.2024.01.005}.
\item Brandon Weiss, Leor Roseman, Bruna Giribaldi, David Nutt, Robin Carhart-Harris, David Erritzøe (2024). \textit{Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder}. International Journal of Mental Health and Addiction. [published; OpenAlex]. \href{https://doi.org/10.1007/s11469-024-01253-9}{doi:10.1007/s11469-024-01253-9}.
\item Falchi-Carvalho M, Wießner I, Silva SRB, O Maia L, Barros H, Laborde S, Arichelle F, Tullman S, Silva-Costa N, Assunção A, Almeida R, Pantrigo ÉJ, Bolcont R, Costa-Macedo JV, Arcoverde E, Galvão-Coelho N, Araujo DB, Palhano-Fontes F (2024). \textit{Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial.}. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.euroneuro.2023.12.006}{doi:10.1016/j.euroneuro.2023.12.006}.
\item Barnett BS, Arakelian M, Beebe D, Ontko J, Riegal C, Siu WO, Weleff J, Pope HG (2024). \textit{American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A7-Year Follow-Up Survey.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0036}{doi:10.1089/psymed.2023.0036}.
\item Brouwer A, Brown JK, Erowid E, Erowid F, Thyssen S, Raison CL, Carhart-Harris RL. (2024). \textit{The Temporal Trajectory of the Psychedelic Mushroom Experience Mimics the Narrative Arc of the Hero’s Journey}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-3941205/v1}{doi:10.21203/rs.3.rs-3941205/v1}.
\item Pagni BA, Petridis PD, Podrebarac SK, Grinband J, Claus ED, Bogenschutz MP (2024). \textit{Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-024-52967-8}{doi:10.1038/s41598-024-52967-8}.
\item Barba T, Kettner H, Radu C, Peill JM, Roseman L, Nutt DJ, Erritzoe D, Carhart-Harris R, Giribaldi B (2024). \textit{Psychedelics and sexual functioning: a mixed-methods study.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-023-49817-4}{doi:10.1038/s41598-023-49817-4}.
\item Breeksema JJ, Niemeijer A, Krediet E, Karsten T, Kamphuis J, Vermetten E, van den Brink W, Schoevers R (2024). \textit{Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-024-53188-9}{doi:10.1038/s41598-024-53188-9}.
\item Borissova A, Rucker JJ (2024). \textit{The development of psilocybin therapy for treatment-resistant depression: an update.}. BJPsych bulletin. [published; PubMed]. \href{https://doi.org/10.1192/bjb.2023.25}{doi:10.1192/bjb.2023.25}.
\item Videira NB, Nair V, Paquet V, Calhoun D (2024). \textit{The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits.}. Journal of applied toxicology: JAT. [published; PubMed]. \href{https://doi.org/10.1002/jat.4533}{doi:10.1002/jat.4533}.
\item Phil Wolfson, Gita Vaid (2024). \textit{Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective-a new and evolving approach}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2024.1209419}{doi:10.3389/fpsyt.2024.1209419}.
\item Houman Farzin (2024). \textit{Psilocybin-assisted psychotherapy for cancer patients}. International Journal of Whole Person Care. [published; OpenAlex]. \href{https://doi.org/10.26443/ijwpc.v11i1.390}{doi:10.26443/ijwpc.v11i1.390}.
\item Marc J. Weintraub, David J. Miklowitz (2024). \textit{How should psychotherapy proceed when adjoined with psychedelics?}. World Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1002/wps.21170}{doi:10.1002/wps.21170}.
\item Duan W, Cao D, Wang S, Cheng J (2024). \textit{Serotonin 2A Receptor (5-HTR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants.}. Chemical reviews. [published; PubMed]. \href{https://doi.org/10.1021/acs.chemrev.3c00375}{doi:10.1021/acs.chemrev.3c00375}.
\item Johns Hopkins University (2024). \textit{Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05562973}{source link}.
\item Vanderijst L, Hever F, Buot A, Dauré C, Benoit J, Hanak C, Veeser J, Morgiève M, Campanella S, Kornreich C, Mallet L, Leys C, Noël X. (2024). \textit{Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-3829237/v1}{doi:10.21203/rs.3.rs-3829237/v1}.
\item Michael D. Alpert, Kelley C. O’Donnell, Casey A. Paleos, Evan Sola, Christopher S. Stauffer, Anne Catherine Wagner, Christopher R. Nicholas, Michael C. Mithoefer (2024). \textit{Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary}. American Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.ajp.20230665}{doi:10.1176/appi.ajp.20230665}.
\item Prosenjit Ghosh, Avinash Desousa (2024). \textit{Psychedelics: The New Kid on the Block}. Annals of Indian Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.4103/aip.aip\_195\_23}{doi:10.4103/aip.aip\_195\_23}.
\item Koning E, Brietzke E (2024). \textit{Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence.}. Trends in psychiatry and psychotherapy. [published; PubMed]. \href{https://doi.org/10.47626/2237-6089-2022-0597}{doi:10.47626/2237-6089-2022-0597}.
\item Weiss B, Ginige I, Shannon L, Giribaldi B, Murphy-Beiner A, Murphy R, Baker-Jones M, Martell J, Nutt DJ, Carhart-Harris RL, Erritzoe D (2024). \textit{Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.}. Psychological medicine. [published; PubMed]. \href{https://doi.org/10.1017/s0033291723001514}{doi:10.1017/s0033291723001514}.
\item Jacobs E, Murphy-Beiner A, Rouiller I, Nutt D, Spriggs MJ (2024). \textit{When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research.}. Neuroethics. [published; PubMed]. \href{https://doi.org/10.1007/s12152-023-09536-z}{doi:10.1007/s12152-023-09536-z}.
\item Wolinsky D, Barrett FS, Vandrey R (2024). \textit{The psychedelic effects of cannabis: A review of the literature.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231209194}{doi:10.1177/02698811231209194}.
\item Hovmand OR, Poulsen ED, Arnfred S (2024). \textit{Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231200019}{doi:10.1177/02698811231200019}.
\item Borkel LF, Rojas-Hernández J, Henríquez-Hernández LA, Santana Del Pino Á, Quintana-Hernández DJ (2024). \textit{Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study.}. Expert review of clinical pharmacology. [published; PubMed]. \href{https://doi.org/10.1080/17512433.2023.2295997}{doi:10.1080/17512433.2023.2295997}.
\item Madsen MK, Petersen AS, Stenbaek DS, Sørensen IM, Schiønning H, Fjeld T, Nykjaer CH, Larsen SMU, Grzywacz M, Mathiesen T, Klausen IL, Overgaard-Hansen O, Brendstrup-Brix K, Linnet K, Johansen SS, Fisher PM, Jensen RH, Knudsen GM (2024). \textit{CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity.}. Headache. [published; PubMed]. \href{https://doi.org/10.1111/head.14656}{doi:10.1111/head.14656}.
\item Bouchet L, Sager Z, Yrondi A, Nigam KB, Anderson BT, Ross S, Petridis PD, Beaussant Y (2024). \textit{Older adults in psychedelic-assisted therapy trials: A systematic review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231215420}{doi:10.1177/02698811231215420}.
\item Zaretsky TG, Jagodnik KM, Barsic R, Antonio JH, Bonanno PA, MacLeod C, Pierce C, Carney H, Morrison MT, Saylor C, Danias G, Lepow L, Yehuda R (2024). \textit{The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.}. Current neuropharmacology. [published; PubMed]. \href{https://doi.org/10.2174/1570159x22666231027111147}{doi:10.2174/1570159x22666231027111147}.
\item E-Wen McCulloch D, Liechti ME, Kuypers KP, Nutt D, Lundberg J, Stenbæk DS, Goodwin GM, Gründer G, Butlen-Ducuing F, Haberkamp M, Thirstrup S, Knudsen GM (2024). \textit{Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects.}. Neuroscience applied. [published; PubMed]. \href{https://doi.org/10.1016/j.nsa.2024.103938}{doi:10.1016/j.nsa.2024.103938}.
\item Fang S, Yang X, Zhang W (2024). \textit{Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2024.1359088}{doi:10.3389/fpsyt.2024.1359088}.
\item Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS (2024). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.}. American journal of therapeutics. [published; PubMed]. \href{https://doi.org/10.1097/mjt.0000000000001727}{doi:10.1097/mjt.0000000000001727}.
\item Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS (2024). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.}. American journal of therapeutics. [published; PubMed]. \href{https://doi.org/10.1097/mjt.0000000000001724}{doi:10.1097/mjt.0000000000001724}.
\item Levin AW, Lancelotta R, Sepeda ND, Gukasyan N, Nayak S, Wagener TL, Barrett FS, Griffiths RR, Davis AK (2024). \textit{The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder.}. PloS one. [published; PubMed]. \href{https://doi.org/10.1371/journal.pone.0300501}{doi:10.1371/journal.pone.0300501}.
\item Thomas KL, Jesse R, Mehtani NJ, Mitchell JM, Anderson BT (2024). \textit{Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2023.2201244}{doi:10.1080/02791072.2023.2201244}.
\item Norring SA, Spigarelli MG (2024). \textit{The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov.}. Drug design, development and therapy. [published; PubMed]. \href{https://doi.org/10.2147/dddt.s443177}{doi:10.2147/dddt.s443177}.
\item Szafoni S, Gręblowski P, Grabowska K, Więckiewicz G (2024). \textit{Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2024.1406888}{doi:10.3389/fpsyt.2024.1406888}.
\item Jones GM, Ricard JA, Nock MK (2024). \textit{Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2024.1169686}{doi:10.3389/fpsyt.2024.1169686}.
\item Do A, Michaud V, Stephan JF, Moreau M, Benoît É, Bérubé FA, Bibaud-De Serres A, Taillefer A, Vincent P (2024). \textit{Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2024.1394962}{doi:10.3389/fpsyt.2024.1394962}.
\item Chen MH, Cheng SL, Kao YC, Tseng PT, Hsu CW, Yu CL, Yang FC, Thompson T, Hsu TW, Liang CS (2024). \textit{The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2024.1439347}{doi:10.3389/fpsyt.2024.1439347}.
\item Min H, Park SY, Park J, Na S, Lee HS, Kim T, Ham J, Park YT (2024). \textit{A narrative exploration of psilocybin's potential in mental health.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2024.1429373}{doi:10.3389/fpsyt.2024.1429373}.
\item Rucker J, Butler M, Hambleton S, Bird C, Seynaeve M, Cheema S, Campbell-Coker K, Maggio C, Dunbar F, Lambru G, Matharu M (2024). \textit{Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study.}. Headache. [published; PubMed]. \href{https://doi.org/10.1111/head.14837}{doi:10.1111/head.14837}.
\item Brett J, Knock E, Watson K, Albert S, Siefried KJ, Guss J (2024). \textit{Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2024.1490907}{doi:10.3389/fpsyt.2024.1490907}.
\item Verheijen Marcha C.T. (2023). \textit{Psilocybin Therapy for Depression: A Review of Current Molecular Knowledge}. Journal of the Netherlands Society of Toxicology. [published; Crossref]. \href{https://doi.org/10.61833/jnst.2024.0002}{doi:10.61833/jnst.2024.0002}.
\item Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS. (2023). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and Overview}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/byms6}{doi:10.31234/osf.io/byms6}.
\item Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS. (2023). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/a8xwk}{doi:10.31234/osf.io/a8xwk}.
\item Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D. Beutler, Kirsten Cherian, Viviana D. Evans, Chelsey Fasano, Owen S. Muir (2023). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and Overview}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/byms6\_v1}{source link}.
\item Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D. Beutler, Kirsten Cherian, Viviana D. Evans, Chelsey Fasano, Owen S. Muir (2023). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/a8xwk\_v1}{source link}.
\item Jingxuan Chen (2023). \textit{Application of psilocybin in mental health disorders}. Theoretical and Natural Science. [published; OpenAlex]. \href{https://doi.org/10.54254/2753-8818/21/20230859}{doi:10.54254/2753-8818/21/20230859}.
\item Reinwald JR, Schmitz CN, Skorodumov I, Kuchar M, Weber-Fahr W, Spanagel R, Meinhardt MW (2023). \textit{Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats.}. Translational psychiatry. [published; PubMed]. \href{https://doi.org/10.1038/s41398-023-02690-1}{doi:10.1038/s41398-023-02690-1}.
\item Conn K, Milton L, Huang K, Munguba H, Ruuska J, Lemus M, Greaves E, Homman-Ludiye J, Oldfield B, Foldi C. (2023). \textit{Psilocybin prevents activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2023.12.12.571374}{doi:10.1101/2023.12.12.571374}.
\item Ivana Turek (2023). \textit{Psychotropics: A scientific, regulatory, and public view on the medicinal uses of cannabinoids and psilocybin}. Medical Writing. [published; OpenAlex]. \href{https://doi.org/10.56012/tsen2260}{doi:10.56012/tsen2260}.
\item Dyck E, Marchildon GP (2023). \textit{A history and future of psychedelics: The case of the Canadian military.}. Journal of military, veteran and family health. [published; PubMed]. \href{https://doi.org/10.3138/jmvfh-2023-0010}{doi:10.3138/jmvfh-2023-0010}.
\item Gramling R, Bennett E, Curtis K, Richards W, Rizzo DM, Arnoldy F, Hegg L, Porter J, Honstein H, Pratt S, Tarbi E, Reblin M, Thambi P, Agrawal M (2023). \textit{Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study.}. Journal of palliative medicine. [published; PubMed]. \href{https://doi.org/10.1089/jpm.2023.0189}{doi:10.1089/jpm.2023.0189}.
\item Śladowska K, Kawalec P, Brzostek T, Pilc A (2023). \textit{Potential use of psilocybin drugs in the treatment of depression.}. Expert opinion on emerging drugs. [published; PubMed]. \href{https://doi.org/10.1080/14728214.2023.2264180}{doi:10.1080/14728214.2023.2264180}.
\item Wsół A (2023). \textit{Cardiovascular safety of psychedelic medicine: current status and future directions.}. Pharmacological reports: PR. [published; PubMed]. \href{https://doi.org/10.1007/s43440-023-00539-4}{doi:10.1007/s43440-023-00539-4}.
\item Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST (2023). \textit{Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.}. Drug discovery today. [published; PubMed]. \href{https://doi.org/10.1016/j.drudis.2023.103818}{doi:10.1016/j.drudis.2023.103818}.
\item Carter S, Packard G, Coghlan C, George JR, Brown AJ, Ching THW, Julian J, Maples-Keller JL (2023). \textit{Perceptions of psychedelic-assisted therapy among Black Americans.}. Journal of mood and anxiety disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.xjmad.2023.100023}{doi:10.1016/j.xjmad.2023.100023}.
\item Weintraub MJ, Jeffrey JK, Grob CS, Ichinose MC, Bergman RL, Cooper ZD, Miklowitz DJ (2023). \textit{Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0018}{doi:10.1089/psymed.2023.0018}.
\item Brennan W, Kelman AR, Belser AB (2023). \textit{A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0007}{doi:10.1089/psymed.2023.0007}.
\item Tahlia R. Harrison (2023). \textit{Altered stakes: Identifying gaps in the informed consent process for psychedelic-assisted therapy trials}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2023.00267}{doi:10.1556/2054.2023.00267}.
\item Danelle Jones (2023). \textit{Psychedelic Integration: Psychotherapy for non-ordinary states of consciousness}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2023.00306}{doi:10.1556/2054.2023.00306}.
\item Downey AE, Boyd M, Chaphekar AV, Woolley J, Raymond-Flesch M (2023). \textit{"But the reality is it's happening": A qualitative study of eating disorder providers about psilocybin-assisted psychotherapy.}. The International journal of eating disorders. [published; PubMed]. \href{https://doi.org/10.1002/eat.24041}{doi:10.1002/eat.24041}.
\item Haikazian S, Chen-Li DCJ, Johnson DE, Fancy F, Levinta A, Husain MI, Mansur RB, McIntyre RS, Rosenblat JD (2023). \textit{Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2023.115531}{doi:10.1016/j.psychres.2023.115531}.
\item Kargbo RB (2023). \textit{Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential.}. ACS medicinal chemistry letters. [published; PubMed]. \href{https://doi.org/10.1021/acsmedchemlett.3c00390}{doi:10.1021/acsmedchemlett.3c00390}.
\item Robert H. Dworkin, Michael McDermott, Sandeep M. Nayak, Eric C. Strain (2023). \textit{Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?}. Clinical Pharmacology \& Therapeutics. [published; OpenAlex]. \href{https://doi.org/10.1002/cpt.3050}{doi:10.1002/cpt.3050}.
\item Donegan CJ, Daldegan-Bueno D, Sumner R, Menkes D, Evans W, Hoeh N, Sundram F, Reynolds L, Ponton R, Cavadino A, Smith T, Roop P, Allen N, Abeysinghe B, Svirskis D, Forsyth A, Bansal M, Muthukumaraswamy S (2023). \textit{An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1).}. Pilot and feasibility studies. [published; PubMed]. \href{https://doi.org/10.1186/s40814-023-01399-8}{doi:10.1186/s40814-023-01399-8}.
\item Amanda E. Downey (2023). \textit{6.3 Psilocybin Therapy for the Treatment of Young Adults With Anorexia Nervosa: State of the Research}. Journal of the American Academy of Child \& Adolescent Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jaac.2023.07.666}{doi:10.1016/j.jaac.2023.07.666}.
\item Gold ND, Mallard AJ, Hermann JC, Zeifman RJ, Pagni BA, Bogenschutz MP, Ross S (2023). \textit{Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis.}. Journal of palliative medicine. [published; PubMed]. \href{https://doi.org/10.1089/jpm.2022.0604}{doi:10.1089/jpm.2022.0604}.
\item Wolfgang AS, Hoge CW (2023). \textit{Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations.}. Current psychiatry reports. [published; PubMed]. \href{https://doi.org/10.1007/s11920-023-01446-4}{doi:10.1007/s11920-023-01446-4}.
\item Goel A, Rai Y, Sivadas S, Diep C, Clarke H, Shanthanna H, Ladha KS (2023). \textit{Use of Psychedelics for Pain: A Scoping Review.}. Anesthesiology. [published; PubMed]. \href{https://doi.org/10.1097/aln.0000000000004673}{doi:10.1097/aln.0000000000004673}.
\item Schuitmaker Nicole (2023). \textit{Psilocybin-Assisted Therapy: A scoping review of participants’ and facilitators’ experiences in qualitative studies}. Research, Society and Development. [published; Crossref]. \href{https://doi.org/10.33448/rsd-v12i9.43308}{doi:10.33448/rsd-v12i9.43308}.
\item Mitch Earleywine, Maha N. Mian, Joseph A. De Leo (2023). \textit{Expectancies for Subjective and Antidepressant Effects in Psilocybin Users}. Journal of Humanistic Psychology. [published; OpenAlex]. \href{https://doi.org/10.1177/00221678231194798}{doi:10.1177/00221678231194798}.
\item University of Zurich (2023). \textit{Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04141501}{source link}.
\item Guy M. Goodwin (2023). \textit{The psychedelic experience and treatment-resistant depression}. World Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1002/wps.21140}{doi:10.1002/wps.21140}.
\item Heal DJ, Smith SL, Belouin SJ, Henningfield JE (2023). \textit{Psychedelics: Threshold of a Therapeutic Revolution.}. Neuropharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.neuropharm.2023.109610}{doi:10.1016/j.neuropharm.2023.109610}.
\item Lobe Sciences Ltd. (2023). \textit{Phase 1, Open-Label, One-Treatment, Single-Dose, One-Period, Pharmacokinetic Study of Psilocin 4 mg as Its Mucic Acid Salt (L-130) Form, in Healthy Subjects Under Fasted Conditions}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06035900}{source link}.
\item Lawrence Canale, Dhvanit Raval, Preet Chatha, Katie Penn, Claudia Weber, Catherine Stout, Jeremy Weleff (2023). \textit{Classic Psychedelics for the Treatment of Depressive Disorders: An Update for Psychiatrists in Training}. American Journal of Psychiatry Residents Journal. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.ajp-rj.2023.190103}{doi:10.1176/appi.ajp-rj.2023.190103}.
\item Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, Kakar R, Hassman M, Trivedi RP, Robison R, Gukasyan N, Nayak SM, Hu X, O'Donnell KC, Kelmendi B, Sloshower J, Penn AD, Bradley E, Kelly DF, Mletzko T, Nicholas CR, Hutson PR, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis MC, Nelson-Douthit C, Wilson S, Brown C, Linton W, Ross S, Griffiths RR (2023). \textit{Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.}. JAMA. [published; PubMed]. \href{https://doi.org/10.1001/jama.2023.14530}{doi:10.1001/jama.2023.14530}.
\item Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, O'Keane V, Peck SK, Simmons H, Sisa C, Stansfield SC, Tsai J, Williams S, Malievskaia E (2023). \textit{Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/s41386-023-01648-7}{doi:10.1038/s41386-023-01648-7}.
\item Schindler EAD (2023). \textit{The Potential of Psychedelics for the Treatment of Episodic Migraine.}. Current pain and headache reports. [published; PubMed]. \href{https://doi.org/10.1007/s11916-023-01145-y}{doi:10.1007/s11916-023-01145-y}.
\item Sharma P, Nguyen QA, Matthews SJ, Carpenter E, Mathews DB, Patten CA, Hammond CJ (2023). \textit{Psilocybin history, action and reaction: A narrative clinical review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231190858}{doi:10.1177/02698811231190858}.
\item Herrmann Z, Levin AW, Cole SP, Slabaugh S, Barnett B, Penn A, Jain R, Raison C, Rajanna B, Jain S (2023). \textit{Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0030}{doi:10.1089/psymed.2023.0030}.
\item Nick Zagorski (2023). \textit{Australia Legalizes Psychedelics for Use in Depression, PTSD Therapy}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.09.9.20}{doi:10.1176/appi.pn.2023.09.9.20}.
\item Usona Institute (2023). \textit{A Phase 1, Two-Part Study in Healthy Volunteers to Evaluate The Effect of Psilocybin on Cardiac Repolarization and The Effect of Food on Psilocybin Pharmacokinetics}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05478278}{source link}.
\item Thase ME (2023). \textit{Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy.}. The Journal of clinical psychiatry. [published; PubMed]. \href{https://doi.org/10.4088/jcp.mulmdd3048sho}{doi:10.4088/jcp.mulmdd3048sho}.
\item Anna Jaremek, Joanna Kępa, Norbert Kandefer, Michał Wyszkowski, Aleksandra Grabarczyk, Anna Pawlak, Sylwia Grad, Małgorzata Gregorek, Paweł Gregorek (2023). \textit{Psilocybin's Emerging Role in Combating Depressive Disorder}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2023.40.01.011}{doi:10.12775/jehs.2023.40.01.011}.
\item Ibrahim IB, Videbech P, Straszek SPV (2023). \textit{[Not Available].}. Ugeskrift for laeger. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/37615227/}{source link}.
\item Zia FZ, Baumann MH, Belouin SJ, Dworkin RH, Ghauri MH, Hendricks PS, Henningfield JE, Lanier RK, Ross S, Berger A (2023). \textit{Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.}. Neuropharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.neuropharm.2023.109528}{doi:10.1016/j.neuropharm.2023.109528}.
\item Jing X, Hoeh NR, Menkes DB (2023). \textit{Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.}. Palliative \& supportive care. [published; PubMed]. \href{https://doi.org/10.1017/s147895152300069x}{doi:10.1017/s147895152300069x}.
\item Terri D’Arrigo (2023). \textit{Med Check: FDA, Anti-Amyloid Beta Vaccine, Clinical Trials of Psychedelics, and Lumryz}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.08.8.3}{doi:10.1176/appi.pn.2023.08.8.3}.
\item Brain and Cognition Discovery Foundation (2023). \textit{The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05029466}{source link}.
\item William Brennan, Alex Kelman, Alexander B. Belser (2023). \textit{A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.1089/psymed.2023.00071}{doi:10.1089/psymed.2023.00071}.
\item Brennan B, Kelman A, Belser AB. (2023). \textit{A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/2ab59}{doi:10.31234/osf.io/2ab59}.
\item Nicolas Garel, Julien Thibault Lévesque, Dasha A. Sandra, Justin Lessard-Wajcer, Elizaveta Solomonova, Michael Lifshitz, Stéphane Richard-Devantoy, Kyle T. Greenway (2023). \textit{Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings}. Frontiers in Human Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.3389/fnhum.2023.1200393}{doi:10.3389/fnhum.2023.1200393}.
\item Jorge Valdiviezo-Oña, Lizbeth Toscano-Molina, Juan Fernando Chávez, Jonathan Elias Herrera Criollo, Clara Paz (2023). \textit{Outcomes of usage of psychedelics by people reporting an eating disorder in clinical and non-clinical settings: a scoping review}. Advances in Mental Health. [published; OpenAlex]. \href{https://doi.org/10.1080/18387357.2023.2235030}{doi:10.1080/18387357.2023.2235030}.
\item Chernoff T, Kliger B, Venturini DH (2023). \textit{[Psychedelic Experiences: Phenomenology, Therapeutic Potentials and Explanatory Models].}. Vertex (Buenos Aires, Argentina). [published; PubMed]. \href{https://doi.org/10.53680/vertex.v34i160.463}{doi:10.53680/vertex.v34i160.463}.
\item Grace Wade (2023). \textit{Psychedelic drug psilocybin shows promise treating anorexia in early trials}. The New Scientist. [published; OpenAlex]. \href{https://doi.org/10.1016/s0262-4079(23)01394-5}{doi:10.1016/s0262-4079(23)01394-5}.
\item Feduccia A, Agin-Liebes G, Price CM, Grinsell N, Paradise S, Rabin DM (2023). \textit{The need for establishing best practices and gold standards in psychedelic medicine.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2023.03.083}{doi:10.1016/j.jad.2023.03.083}.
\item Weiss B, Erritzoe D, Giribaldi B, Nutt DJ, Carhart-Harris RL (2023). \textit{A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231167848}{doi:10.1177/02698811231167848}.
\item Hovmand OR, Poulsen ED, Arnfred S, Storebø OJ (2023). \textit{Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231180276}{doi:10.1177/02698811231180276}.
\item Valerie A. Canady (2023). \textit{FDA issues first draft guidance on psychedelic research}. Mental Health Weekly. [published; OpenAlex]. \href{https://doi.org/10.1002/mhw.33697}{doi:10.1002/mhw.33697}.
\item Halucenex Life Sciences Inc. (2023). \textit{Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05243329}{source link}.
\item Terri D’Arrigo (2023). \textit{Experts Offer Tips on Talking With Patients About Psychedelics}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.07.7.51}{doi:10.1176/appi.pn.2023.07.7.51}.
\item Wulff AB, Nichols CD, Thompson SM (2023). \textit{Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders.}. Neuropharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.neuropharm.2023.109504}{doi:10.1016/j.neuropharm.2023.109504}.
\item Tooba Noor, Areej Shakil, Aimen Waqar Khan, Syeda Mahrukh Fatima Zaidi, Hussain Sohail Rangwala, Burhanuddin Sohail Rangwala (2023). \textit{Psilocybin therapy: A novel approach to treating depression}. International Journal of Surgery Global Health. [published; OpenAlex]. \href{https://doi.org/10.1097/gh9.0000000000000175}{doi:10.1097/gh9.0000000000000175}.
\item Strauss D, Ghosh S, Murray Z, Gryzenhout M (2023). \textit{Global species diversity and distribution of the psychedelic fungal genus.}. Heliyon. [published; PubMed]. \href{https://doi.org/10.1016/j.heliyon.2023.e16338}{doi:10.1016/j.heliyon.2023.e16338}.
\item Gold ND, Podrebarac SK, White LA, Marini C, Simon NM, Mittelman MS, Ross S, Bogenschutz MP, Petridis PD (2023). \textit{Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2022.0011}{doi:10.1089/psymed.2022.0011}.
\item Whelan TP, Daly E, Puts NA, Malievskaia E, Murphy DG, McAlonan GM. (2023). \textit{Bridging the translational neuroscience gap: Development of the ‘shiftability’ paradigm and an exemplar protocol to capture psilocybin-elicited ‘shift’ in neurobiological mechanisms in autism}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2023.05.25.23290521}{doi:10.1101/2023.05.25.23290521}.
\item University of Wisconsin, Madison (2023). \textit{Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04842045}{source link}.
\item Raithatha SA, Hagel JM, Matinkhoo K, Yu L, Press D, Cook SG, Sharma G, D D, Jensen G, Lee JB, Cai C, Gallant J, Bains JS, Tucker JE, Facchini PJ. (2023). \textit{Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disorders}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2023.05.16.540994}{doi:10.1101/2023.05.16.540994}.
\item University of Wisconsin, Madison (2023). \textit{A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral Psilocybin}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05467761}{source link}.
\item Davis AK, Levin AW, Nagib PB, Armstrong SB, Lancelotta RL (2023). \textit{Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD.}. BMJ open. [published; PubMed]. \href{https://doi.org/10.1136/bmjopen-2022-068884}{doi:10.1136/bmjopen-2022-068884}.
\item Goodwin GM, Croal M, Marwood L, Malievskaia E (2023). \textit{Unblinding and demand characteristics in the treatment of depression.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2023.02.030}{doi:10.1016/j.jad.2023.02.030}.
\item Schneier FR, Feusner J, Wheaton MG, Gomez GJ, Cornejo G, Naraindas AM, Hellerstein DJ (2023). \textit{Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.}. Journal of psychiatric research. [published; PubMed]. \href{https://doi.org/10.1016/j.jpsychires.2023.03.031}{doi:10.1016/j.jpsychires.2023.03.031}.
\item Bennett JN, Blough MD, Mitchell I, Galloway L, Bains R. (2023). \textit{A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2023.04.12.23288325}{doi:10.1101/2023.04.12.23288325}.
\item Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Lennard-Jones MR, Licht RW, Marwood L, Mistry S, Páleníček T, Redjep O, Repantis D, Schoevers RA, Septimus B, Simmons HJ, Soares JC, Somers M, Stansfield SC, Stuart JR, Tadley HH, Thiara NK, Tsai J, Wahba M, Williams S, Winzer RI, Young AH, Young MB, Zisook S, Malievskaia E (2023). \textit{Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2023.01.108}{doi:10.1016/j.jad.2023.01.108}.
\item David Nutt (2023). \textit{Psychedelic Medicine: From Brain Science to Clinical Trials}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2023.02.022}{doi:10.1016/j.biopsych.2023.02.022}.
\item Lyes M, Yang KH, Castellanos J, Furnish T (2023). \textit{Microdosing psilocybin for chronic pain: a case series.}. Pain. [published; PubMed]. \href{https://doi.org/10.1097/j.pain.0000000000002778}{doi:10.1097/j.pain.0000000000002778}.
\item Holze F, Becker AM, Kolaczynska KE, Duthaler U, Liechti ME (2023). \textit{Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants.}. Clinical pharmacology and therapeutics. [published; PubMed]. \href{https://doi.org/10.1002/cpt.2821}{doi:10.1002/cpt.2821}.
\item Kelly DF, Heinzerling K, Sharma A, Gowrinathan S, Sergi K, Mallari RJ (2023). \textit{Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology.}. Neurosurgery. [published; PubMed]. \href{https://doi.org/10.1227/neu.0000000000002275}{doi:10.1227/neu.0000000000002275}.
\item Domanegg K, Sommer WH, Meinhardt MW (2023). \textit{Psychedelic Targeting of Metabotropic Glutamate Receptor 2 and Its Implications for the Treatment of Alcoholism.}. Cells. [published; PubMed]. \href{https://doi.org/10.3390/cells12060963}{doi:10.3390/cells12060963}.
\item Turkia M. (2023). \textit{Understanding psychedelic 'mystical experience'-A case example}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/dh92g}{doi:10.31234/osf.io/dh92g}.
\item Turkia M. (2023). \textit{Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin-A retrospective case study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/t6k9b}{doi:10.31234/osf.io/t6k9b}.
\item Mika Turkia (2023). \textit{Understanding psychedelic 'mystical experience'-A case example}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/dh92g\_v1}{source link}.
\item Mika Turkia (2023). \textit{Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin-A retrospective case study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/t6k9b\_v1}{source link}.
\item Steven W. Cotten, Frederick G. Strathmann, Frederick S. Barrett, Laura Labay, James Mullally, Alexander M. Sherwood, Frank Wiegand (2023). \textit{Psychedelics for Medicinal Use: How Will This Alter the Collective Laboratory Consciousness?}. Clinical Chemistry. [published; OpenAlex]. \href{https://doi.org/10.1093/clinchem/hvad016}{doi:10.1093/clinchem/hvad016}.
\item Jha MK, Mathew SJ (2023). \textit{Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.20230025}{doi:10.1176/appi.ajp.20230025}.
\item Hibicke M, Kramer HM, Nichols CD (2023). \textit{A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to Depression.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2022.0012}{doi:10.1089/psymed.2022.0012}.
\item Aday JS, Skiles Z, Eaton N, Fredenburg L, Pleet M, Mantia J, Bradley ER, Fernandes-Osterhold G, Woolley JD (2023). \textit{Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2022.0004}{doi:10.1089/psymed.2022.0004}.
\item Ashish Sarangi, Omotola Akinkunmi (2023). \textit{Psychedelics for the Neuropsychiatric Symptoms of Alzheimer's disease}. American Journal of Geriatric Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jagp.2022.12.201}{doi:10.1016/j.jagp.2022.12.201}.
\item Shnayder S, Ameli R, Sinaii N, Berger A, Agrawal M (2023). \textit{Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2022.11.046}{doi:10.1016/j.jad.2022.11.046}.
\item Jeffery Heilman (2023). \textit{The History, Legalization and Potentials of Psilocybin-Assisted Psychotherapy}. Journal of Scientific Exploration. [published; OpenAlex]. \href{https://doi.org/10.31275/20222633}{doi:10.31275/20222633}.
\item Gonda X, Dome P, Neill JC, Tarazi FI (2023). \textit{Novel antidepressant drugs: Beyond monoamine targets.}. CNS spectrums. [published; PubMed]. \href{https://doi.org/10.1017/s1092852921000791}{doi:10.1017/s1092852921000791}.
\item Ko K, Kopra EI, Cleare AJ, Rucker JJ (2023). \textit{Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2022.09.168}{doi:10.1016/j.jad.2022.09.168}.
\item von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, Jäncke L, Preller KH, Vollenweider FX (2023). \textit{Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.}. EClinicalMedicine. [published; PubMed]. \href{https://doi.org/10.1016/j.eclinm.2022.101809}{doi:10.1016/j.eclinm.2022.101809}.
\item von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, Jäncke L, Preller KH, Vollenweider FX (2023). \textit{Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'.}. EClinicalMedicine. [published; PubMed]. \href{https://doi.org/10.1016/j.eclinm.2023.101841}{doi:10.1016/j.eclinm.2023.101841}.
\item Washington University School of Medicine (2023). \textit{SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05601648}{source link}.
\item Stokłosa I, Więckiewicz G, Stokłosa M, Piegza M, Pudlo R, Gorczyca P (2023). \textit{Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective.}. International journal of environmental research and public health. [published; PubMed]. \href{https://doi.org/10.3390/ijerph20031870}{doi:10.3390/ijerph20031870}.
\item Benjamin R. Lewis, Kevin Byrne, John Hendrick, Eric L. Garland, Paul Thielking, Anna C. Beck (2023). \textit{Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2022.00222}{doi:10.1556/2054.2022.00222}.
\item Keith Heinzerling (2023). \textit{Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04410913}{source link}.
\item Gukasyan N (2023). \textit{On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression.}. Med (New York, N.Y.). [published; PubMed]. \href{https://doi.org/10.1016/j.medj.2022.12.003}{doi:10.1016/j.medj.2022.12.003}.
\item Kaden Venugopal, Nefissa Bedri (2023). \textit{The Therapeutic Potential of Psilocybin in Alcohol Use Disorder Recovery: A Literature Review}. Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal. [published; OpenAlex]. \href{https://doi.org/10.26685/urncst.420}{doi:10.26685/urncst.420}.
\item Guy M. Goodwin, Megan Croal, J. Chai-Rees, Lindsey Marwood, S. Mistry, Anna Nowakowska, H. Clifton Simmons, Jeng-Yu Tsai (2023). \textit{Withdrawal of antidepressants does not impact the efficacy of COMP360 psilocybin therapy: results from a phase IIb randomised controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2023.103487}{doi:10.1016/j.nsa.2023.103487}.
\item Peter Hess (2023). \textit{Going on Trial: Serotonin drug; psilocybin phase 2; placebo response data}. The Transmitter. [published; OpenAlex]. \href{https://doi.org/10.53053/etcr6498}{doi:10.53053/etcr6498}.
\item Peter Hess (2023). \textit{Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses}. The Transmitter. [published; OpenAlex]. \href{https://doi.org/10.53053/nbdr8957}{doi:10.53053/nbdr8957}.
\item John R. Rossiter (2023). \textit{Psychedelic Drug Therapy for Mental Disorders?}. Open Journal of Medical Psychology. [published; OpenAlex]. \href{https://doi.org/10.4236/ojmp.2023.123010}{doi:10.4236/ojmp.2023.123010}.
\item Hodge AT, Sukpraprut-Braaten S, Narlesky M, Strayhan RC (2023). \textit{The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2022.2044096}{doi:10.1080/02791072.2022.2044096}.
\item Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenway KT, Garel N, Beaulieu S, Kennedy SH, Lam RW, Milev R, Ravindran AV, Tourjman V, Ameringen MV, Yatham LN, Taylor V (2023). \textit{The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.}. Canadian journal of psychiatry. Revue canadienne de psychiatrie. [published; PubMed]. \href{https://doi.org/10.1177/07067437221111371}{doi:10.1177/07067437221111371}.
\item Johnston CB, Mangini M, Grob C, Anderson B (2023). \textit{The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.}. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.jagp.2022.08.007}{doi:10.1016/j.jagp.2022.08.007}.
\item Kious B, Schwartz Z, Lewis B (2023). \textit{Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811221133461}{doi:10.1177/02698811221133461}.
\item Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J (2023). \textit{Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811221131997}{doi:10.1177/02698811221131997}.
\item Henningfield JE, Ashworth J, Heal DJ, Smith SL (2023). \textit{Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811221140004}{doi:10.1177/02698811221140004}.
\item Feulner L, Sermchaiwong T, Rodland N, Galarneau D (2023). \textit{Efficacy and Safety of Psychedelics in Treating Anxiety Disorders.}. Ochsner journal. [published; PubMed]. \href{https://doi.org/10.31486/toj.23.0076}{doi:10.31486/toj.23.0076}.
\item Edelsohn GA, Sisti D (2023). \textit{Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment.}. Perspectives in biology and medicine. [published; PubMed]. \href{https://doi.org/10.1353/pbm.2023.0007}{doi:10.1353/pbm.2023.0007}.
\item van der Meer PB, Fuentes JJ, Kaptein AA, Schoones JW, de Waal MM, Goudriaan AE, Kramers K, Schellekens A, Somers M, Bossong MG, Batalla A (2023). \textit{Therapeutic effect of psilocybin in addiction: A systematic review.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2023.1134454}{doi:10.3389/fpsyt.2023.1134454}.
\item Brett J, Knock E, Korthuis PT, Liknaitzky P, Murnane KS, Nicholas CR, Patterson JC, Stauffer CS (2023). \textit{Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2023.1123424}{doi:10.3389/fpsyt.2023.1123424}.
\item IsHak WW, Garcia P, Pearl R, Dang J, William C, Totlani J, Danovitch I (2023). \textit{The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials.}. Innovations in clinical neuroscience. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/37387703/}{source link}.
\item Khan I, Jaura TA, Tukruna A, Arif A, Tebha SS, Nasir S, Mukherjee D, Masroor N, Yosufi A (2023). \textit{Use of Selective Alternative Therapies for Treatment of OCD.}. Neuropsychiatric disease and treatment. [published; PubMed]. \href{https://doi.org/10.2147/ndt.s403997}{doi:10.2147/ndt.s403997}.
\item Liu J, Wang Y, Xia K, Wu J, Zheng D, Cai A, Yan H, Su R (2023). \textit{Acute psilocybin increased cortical activities in rats.}. Frontiers in neuroscience. [published; PubMed]. \href{https://doi.org/10.3389/fnins.2023.1168911}{doi:10.3389/fnins.2023.1168911}.
\item De La Haye W, Walcott G, Eaton J, Beckford J, Greene J (2023). \textit{Psychedelic Assisted Psychotherapy preparing your target using psychohistoriography: a Jamaican perspective.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2023.1136990}{doi:10.3389/fpsyt.2023.1136990}.
\item Schindler EAD, Hendricks PS (2023). \textit{Adapting psychedelic medicine for headache and chronic pain disorders.}. Expert review of neurotherapeutics. [published; PubMed]. \href{https://doi.org/10.1080/14737175.2023.2246655}{doi:10.1080/14737175.2023.2246655}.
\item Kozak Z, Johnson MW, Aaronson ST (2023). \textit{Assessing potential of psilocybin for depressive disorders.}. Expert opinion on investigational drugs. [published; PubMed]. \href{https://doi.org/10.1080/13543784.2023.2273493}{doi:10.1080/13543784.2023.2273493}.
\item Herrmann Z, Earleywine M, De Leo J, Slabaugh S, Kenny T, Rush AJ (2023). \textit{Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2022.2125467}{doi:10.1080/02791072.2022.2125467}.
\item Kruger DJ, Glynos NG, Fields CW, Herberholz M, Boehnke KF (2023). \textit{An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2022.2142709}{doi:10.1080/02791072.2022.2142709}.
\item Heinzerling KG, Sergi K, Linton M, Rich R, Youssef B, Bentancourt I, Bramen J, Siddarth P, Schwartzberg L, Kelly DF (2023). \textit{Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2023.1215972}{doi:10.3389/fpsyt.2023.1215972}.
\item Acero VP, Cribas ES, Browne KD, Rivellini O, Burrell JC, O'Donnell JC, Das S, Cullen DK (2023). \textit{Bedside to bench: the outlook for psychedelic research.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2023.1240295}{doi:10.3389/fphar.2023.1240295}.
\item Ko K, Carter B, Cleare AJ, Rucker JJ (2023). \textit{Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis.}. Neuropsychiatric disease and treatment. [published; PubMed]. \href{https://doi.org/10.2147/ndt.s426193}{doi:10.2147/ndt.s426193}.
\item Kvam TM, Uthaug MV, Andersen KAA, Refsum BB, Tunstad PA, Stewart LH, Jacobsen HB, Grønnerød C (2023). \textit{Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2023.1287196}{doi:10.3389/fpsyt.2023.1287196}.
\item Freidel N, Kreuder L, Rabinovitch BS, Chen FY, Huang RST, Lewis EC (2023). \textit{Psychedelics, epilepsy, and seizures: a review.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2023.1326815}{doi:10.3389/fphar.2023.1326815}.
\item Munafò A, Arillotta D, Mannaioni G, Schifano F, Bernardini R, Cantarella G (2022). \textit{Psilocybin for Depression: From Credibility to Feasibility, What's Missing?}. Pharmaceuticals (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/ph16010068}{doi:10.3390/ph16010068}.
\item Hartogsohn I, Petranker R (2022). \textit{Set and setting in microdosing: an oft-overlooked principle.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-022-06249-8}{doi:10.1007/s00213-022-06249-8}.
\item O'Donnell KC, Mennenga SE, Owens LT, Podrebarac SK, Baron T, Rotrosen J, Ross S, Forcehimes AA, Bogenschutz MP (2022). \textit{Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.}. Contemporary clinical trials. [published; PubMed]. \href{https://doi.org/10.1016/j.cct.2022.106976}{doi:10.1016/j.cct.2022.106976}.
\item Gukasyan N, Schreyer CC, Griffiths RR, Guarda AS (2022). \textit{Psychedelic-Assisted Therapy for People with Eating Disorders.}. Current psychiatry reports. [published; PubMed]. \href{https://doi.org/10.1007/s11920-022-01394-5}{doi:10.1007/s11920-022-01394-5}.
\item Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E (2022). \textit{Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.}. The New England journal of medicine. [published; PubMed]. \href{https://doi.org/10.1056/nejmoa2206443}{doi:10.1056/nejmoa2206443}.
\item Hamna Raheel, Unaiza Naeem, Asim Shaikh, Omer Ahmed Shaikh (2022). \textit{The psychedelic renaissance: can psilocybin possibly combat depression?}. International Journal of Surgery Global Health. [published; OpenAlex]. \href{https://doi.org/10.1097/gh9.0000000000000089}{doi:10.1097/gh9.0000000000000089}.
\item Raut SB, Marathe PA, van Eijk L, Eri R, Ravindran M, Benedek DM, Ursano RJ, Canales JJ, Johnson LR (2022). \textit{Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation.}. Pharmacology \& therapeutics. [published; PubMed]. \href{https://doi.org/10.1016/j.pharmthera.2022.108195}{doi:10.1016/j.pharmthera.2022.108195}.
\item Watts R, Kettner H, Geerts D, Gandy S, Kartner L, Mertens L, Timmermann C, Nour MM, Kaelen M, Nutt D, Carhart-Harris R, Roseman L (2022). \textit{The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-022-06187-5}{doi:10.1007/s00213-022-06187-5}.
\item Irizarry R, Winczura A, Dimassi O, Dhillon N, Minhas A, Larice J (2022). \textit{Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.31796}{doi:10.7759/cureus.31796}.
\item Jensen ME, Stenbæk DS, Juul TS, Fisher PM, Ekstrøm CT, Knudsen GM, Fink-Jensen A (2022). \textit{Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial).}. BMJ open. [published; PubMed]. \href{https://doi.org/10.1136/bmjopen-2022-066019}{doi:10.1136/bmjopen-2022-066019}.
\item Beckley Psytech Limited (2022). \textit{An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04905121}{source link}.
\item Dworkin RH, Anderson BT, Andrews N, Edwards RR, Grob CS, Ross S, Satterthwaite TD, Strain EC (2022). \textit{If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics.}. The journal of pain. [published; PubMed]. \href{https://doi.org/10.1016/j.jpain.2022.05.003}{doi:10.1016/j.jpain.2022.05.003}.
\item Prouzeau D, Conejero I, Voyvodic PL, Becamel C, Abbar M, Lopez-Castroman J (2022). \textit{Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.}. Current psychiatry reports. [published; PubMed]. \href{https://doi.org/10.1007/s11920-022-01361-0}{doi:10.1007/s11920-022-01361-0}.
\item Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L (2022). \textit{Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.}. JAMA psychiatry. [published; PubMed]. \href{https://doi.org/10.1001/jamapsychiatry.2022.2096}{doi:10.1001/jamapsychiatry.2022.2096}.
\item Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA (2022). \textit{Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811221116926}{doi:10.1177/02698811221116926}.
\item Butler M, Jelen L, Rucker J (2022). \textit{Expectancy in placebo-controlled trials of psychedelics: if so, so what?}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-022-06221-6}{doi:10.1007/s00213-022-06221-6}.
\item Dougherty RF, Clarke P, Alti M, Kuc J, Schlosser D, Dunlop BW, Hellerstein DJ, Aaronson ST, Zisook S, Young AH, Carhart-Harris R, Goodwin G, Ryslik GA. (2022). \textit{Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/kh3cx}{doi:10.31234/osf.io/kh3cx}.
\item Robert F. Dougherty, Patrick Clarke, Merve Alti, Joanna Kuc, Danielle Schlosser, Boadie W. Dunlop, David J. Hellerstein, Scott T. Aaronson, Sidney Zisook, Allan H Young (2022). \textit{Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/kh3cx\_v1}{source link}.
\item Michael Eisenstein (2022). \textit{The psychedelic escape from depression}. Nature. [published; OpenAlex]. \href{https://doi.org/10.1038/d41586-022-02872-9}{doi:10.1038/d41586-022-02872-9}.
\item da Costa SC, Oesterle T, Rummans TA, Richelson E, Gold M (2022). \textit{Psychedelic drugs for psychiatric disorders.}. Journal of the neurological sciences. [published; PubMed]. \href{https://doi.org/10.1016/j.jns.2022.120332}{doi:10.1016/j.jns.2022.120332}.
\item Stoliker D, Novelli L, Vollenweider FX, Egan GF, Preller KH, Razi A. (2022). \textit{Effective connectivity of emotion and cognition under psilocybin}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2022.09.06.22279626}{doi:10.1101/2022.09.06.22279626}.
\item O'Leary K (2022). \textit{Psilocybin therapy reduces heavy drinking.}. Nature medicine. [published; PubMed]. \href{https://doi.org/10.1038/d41591-022-00093-1}{doi:10.1038/d41591-022-00093-1}.
\item Barba T, Buehler S, Kettner H, Radu C, Cunha BG, Nutt DJ, Erritzoe D, Roseman L, Carhart-Harris R (2022). \textit{Effects of psilocybin versus escitalopram on rumination and thought suppression in depression.}. BJPsych open. [published; PubMed]. \href{https://doi.org/10.1192/bjo.2022.565}{doi:10.1192/bjo.2022.565}.
\item special to C EN Attabey Rodríguez Benítez (2022). \textit{Psychedelics’ binding depends on receptor mutations}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-10031-scicon6}{doi:10.1021/cen-10031-scicon6}.
\item Brian S. Barnett, Jeremy Weleff (2022). \textit{Psychedelics in the Treatment of Substance Use Disorders}. Psychiatric Annals. [published; OpenAlex]. \href{https://doi.org/10.3928/00485713-20220804-01}{doi:10.3928/00485713-20220804-01}.
\item Johannesdottir A, Sigurdsson E (2022). \textit{[The use of psilocybin for treatment-resistant depression].}. Laeknabladid. [published; PubMed]. \href{https://doi.org/10.17992/lbl.2022.09.706}{doi:10.17992/lbl.2022.09.706}.
\item Kurtz JS, Patel NA, Gendreau JL, Yang C, Brown N, Bui N, Picton B, Harris M, Hatter M, Beyer R, Sahyouni R, Diaz-Aguilar LD, Castellanos J, Schuster N, Abraham ME (2022). \textit{The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.29167}{doi:10.7759/cureus.29167}.
\item Neşe Devenot, Trey Conner, Richard Doyle (2022). \textit{Dark Side of the Shroom: Erasing Indigenous and Counterculture Wisdoms with Psychedelic Capitalism, and the Open Source Alternative}. Anthropology of Consciousness. [published; OpenAlex]. \href{https://doi.org/10.1111/anoc.12154}{doi:10.1111/anoc.12154}.
\item Brian Peacock (2022). \textit{A-118 Psychedelic Interventions for Neuropsychological Conditions}. Archives of Clinical Neuropsychology. [published; OpenAlex]. \href{https://doi.org/10.1093/arclin/acac060.118}{doi:10.1093/arclin/acac060.118}.
\item Henner RL, Keshavan MS, Hill KP (2022). \textit{Review of potential psychedelic treatments for PTSD.}. Journal of the neurological sciences. [published; PubMed]. \href{https://doi.org/10.1016/j.jns.2022.120302}{doi:10.1016/j.jns.2022.120302}.
\item Gitte Moos Knudsen (2022). \textit{Prophylactic Effects of Psilocybin on Chronic Cluster Headache: an Open-label Clinical Trial and Neuroimaging Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04280055}{source link}.
\item Terri D’Arrigo (2022). \textit{Med Check: Psilocybin for OCD, Nuplazid Vote, and More}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2022.08.8.2}{doi:10.1176/appi.pn.2022.08.8.2}.
\item James A. Kaduk, Alexander M. Sherwood, Robert B. Kargbo, Kristi W. Kaylo, Poncho Meisenheimer, Nicholas V. Cozzi (2022). \textit{Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples}. Acta Crystallographica Section A Foundations and Advances. [published; OpenAlex]. \href{https://doi.org/10.1107/s2053273322097261}{doi:10.1107/s2053273322097261}.
\item University of California, San Diego (2022). \textit{Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04661514}{source link}.
\item Madsen MK, Petersen AS, Stenbæk DS, Sørensen IM, Schiønning H, Fjeld T, Nykjær CH, Ulv Larsen SM, Grzywacz M, Mathiesen T, Klausen IL, Overgaard-Hansen O, Brendstrup-Brix K, Linnet K, Johansen SS, Fisher PM, Jensen RH, Knudsen GM. (2022). \textit{Psilocybin-induced reduction in chronic cluster headache attack frequency correlates with changes in hypothalamic functional connectivity}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2022.07.10.22277414}{doi:10.1101/2022.07.10.22277414}.
\item Bosch OG, Halm S, Seifritz E (2022). \textit{Psychedelics in the treatment of unipolar and bipolar depression.}. International journal of bipolar disorders. [published; PubMed]. \href{https://doi.org/10.1186/s40345-022-00265-5}{doi:10.1186/s40345-022-00265-5}.
\item Kozlowska U, Nichols C, Wiatr K, Figiel M (2022). \textit{From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders.}. Journal of neurochemistry. [published; PubMed]. \href{https://doi.org/10.1111/jnc.15509}{doi:10.1111/jnc.15509}.
\item Köck P, Froelich K, Walter M, Lang U, Dürsteler KM (2022). \textit{A systematic literature review of clinical trials and therapeutic applications of ibogaine.}. Journal of substance abuse treatment. [published; PubMed]. \href{https://doi.org/10.1016/j.jsat.2021.108717}{doi:10.1016/j.jsat.2021.108717}.
\item Sakurai H, Yonezawa K, Tani H, Mimura M, Bauer M, Uchida H (2022). \textit{Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry.}. Pharmacopsychiatry. [published; PubMed]. \href{https://doi.org/10.1055/a-1714-9097}{doi:10.1055/a-1714-9097}.
\item Zhai W, Li L, Zhao J, Xiang P, Liu M, Shi Y, Dang Y (2022). \textit{Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MS.}. Drug testing and analysis. [published; PubMed]. \href{https://doi.org/10.1002/dta.3255}{doi:10.1002/dta.3255}.
\item Wake Network, Inc. (2022). \textit{Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04989972}{source link}.
\item Kevin F. Boehnke, Alan K. Davis, Jenna McAfee (2022). \textit{Applying Lessons From Cannabis to the Psychedelic Highway}. JAMA Health Forum. [published; OpenAlex]. \href{https://doi.org/10.1001/jamahealthforum.2022.1618}{doi:10.1001/jamahealthforum.2022.1618}.
\item Hibicke M, Nichols CD (2022). \textit{Validation of the forced swim test in Drosophila, and its use to demonstrate psilocybin has long-lasting antidepressant-like effects in flies.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-022-14165-2}{doi:10.1038/s41598-022-14165-2}.
\item Annie M. McCartney, H. T. McGovern, Alexander De Foe (2022). \textit{Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2022.00211}{doi:10.1556/2054.2022.00211}.
\item Anthony Principe (2022). \textit{Neuropharmacological analysis of the anti-addictive and therapeutic effects of psilocybin}. SURG Journal. [published; OpenAlex]. \href{https://doi.org/10.21083/surg.v14i1.6870}{doi:10.21083/surg.v14i1.6870}.
\item Bender D, Hellerstein DJ (2022). \textit{Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-021-06049-6}{doi:10.1007/s00213-021-06049-6}.
\item Müller F, Kraus E, Holze F, Becker A, Ley L, Schmid Y, Vizeli P, Liechti ME, Borgwardt S (2022). \textit{Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-022-06066-z}{doi:10.1007/s00213-022-06066-z}.
\item van Amsterdam J, van den Brink W (2022). \textit{The therapeutic potential of psilocybin: a systematic review.}. Expert opinion on drug safety. [published; PubMed]. \href{https://doi.org/10.1080/14740338.2022.2047929}{doi:10.1080/14740338.2022.2047929}.
\item McClure-Begley TD, Roth BL (2022). \textit{The promises and perils of psychedelic pharmacology for psychiatry.}. Nature reviews. Drug discovery. [published; PubMed]. \href{https://doi.org/10.1038/s41573-022-00421-7}{doi:10.1038/s41573-022-00421-7}.
\item Rossi GN, Hallak JEC, Bouso Saiz JC, Dos Santos RG (2022). \textit{Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.}. Expert opinion on drug safety. [published; PubMed]. \href{https://doi.org/10.1080/14740338.2022.2066650}{doi:10.1080/14740338.2022.2066650}.
\item Inouye A, Wolfgang A (2022). \textit{3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.26402}{doi:10.7759/cureus.26402}.
\item Manish Agrawal, Paul Thambi, Sarah Shnayder (2022). \textit{The safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder.}. Journal of Clinical Oncology. [published; OpenAlex]. \href{https://doi.org/10.1200/jco.2022.40.16\_suppl.12097}{doi:10.1200/jco.2022.40.16\_suppl.12097}.
\item National Institute of Mental Health, Czech Republic (2022). \textit{Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05383313}{source link}.
\item Andrew Hodge, Suporn Sukpraprut-Braaten, Robert Strayhan (2022). \textit{The Efficacy of Psilocybin in the Treatment of Depression andAnxiety: A Meta-Analysis}. Current Psychiatry Research and Reviews. [published; OpenAlex]. \href{https://doi.org/10.2174/2666082218666220513142002}{doi:10.2174/2666082218666220513142002}.
\item Sotille R, Singh H, Weisman A, Vida T (2022). \textit{Unraveling the Mysteries of Mental Illness With Psilocybin.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.25414}{doi:10.7759/cureus.25414}.
\item University of Zurich (2022). \textit{Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy in Major Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03715127}{source link}.
\item Scott Aaronson, Tammy Miller, Samuel Rudow, MacKenzie Forbes, Trisha Suppes (2022). \textit{P388. Open Label Psilocybin Administration in Severely Treatment Resistant Depression}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2022.02.624}{doi:10.1016/j.biopsych.2022.02.624}.
\item Hackl B, Todt H, Kubista H, Hilber K, Koenig X (2022). \textit{Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity.}. The international journal of neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1093/ijnp/pyab085}{doi:10.1093/ijnp/pyab085}.
\item Jones G, Ricard JA, Lipson J, Nock MK (2022). \textit{Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample.}. Scientific reports. [published; PubMed]. \href{https://doi.org/10.1038/s41598-022-08085-4}{doi:10.1038/s41598-022-08085-4}.
\item Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R (2022). \textit{Increased global integration in the brain after psilocybin therapy for depression.}. Nature medicine. [published; PubMed]. \href{https://doi.org/10.1038/s41591-022-01744-z}{doi:10.1038/s41591-022-01744-z}.
\item Michael Avissar, Adrian Jacques H. Ambrose (2022). \textit{Demystifying Psychedelic Treatments in Psychiatry: Is Ego Dissolution the Solution?}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2022.04.4.35}{doi:10.1176/appi.pn.2022.04.4.35}.
\item Pearson C, Siegel J, Gold JA (2022). \textit{Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.}. Journal of the neurological sciences. [published; PubMed]. \href{https://doi.org/10.1016/j.jns.2021.120096}{doi:10.1016/j.jns.2021.120096}.
\item Kargbo RB, Sherwood AM, Meisenheimer P, Lenoch K, Abebe S (2022). \textit{Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD).}. ACS omega. [published; PubMed]. \href{https://doi.org/10.1021/acsomega.1c06708}{doi:10.1021/acsomega.1c06708}.
\item Hase A, Erdmann M, Limbach V, Hasler G (2022). \textit{Analysis of recreational psychedelic substance use experiences classified by substance.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-022-06062-3}{doi:10.1007/s00213-022-06062-3}.
\item Ziff S, Stern B, Lewis G, Majeed M, Gorantla VR (2022). \textit{Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review.}. Cureus. [published; PubMed]. \href{https://doi.org/10.7759/cureus.21944}{doi:10.7759/cureus.21944}.
\item Jurriaan F. M. Strous (2022). \textit{Psilocybine vergeleken met escitalopram bij depressie}. Pure Amsterdam UMC. [published; OpenAlex]. \href{https://pure.amsterdamumc.nl/en/publications/b99a8d48-a871-49d6-978c-969dd09a6dae}{source link}.
\item Strous JFM (2022). \textit{[Psilocybin compared with escitalopram for depression].}. Nederlands tijdschrift voor geneeskunde. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/35138714/}{source link}.
\item Valerie A. Canady (2022). \textit{Pennsylvania bill seeks clinical research on psychedelics}. Mental Health Weekly. [published; OpenAlex]. \href{https://doi.org/10.1002/mhw.33077}{doi:10.1002/mhw.33077}.
\item G. Goodwin, Scott T. Aaronson, Boadie W. Dunlop, D. Feifel, David J. Hellerstein, L. Marwood, S. Mistry, Metten Somers, S.C. Stansfield, J. Tsai, S. Williams, Allan H. Young, Sidney Zisook, E. Malievskaia (2022). \textit{The efficacy of COMP360 psilocybin therapy in treatment-resistant depression: exploratory results from a phase IIb randomised controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2022.100213}{doi:10.1016/j.nsa.2022.100213}.
\item G.M. Goodwin, Scott T. Aaronson, Boadie W. Dunlop, David Feifel, David J. Hellerstein, N. Hewitt, L. Marwood, S. Mistry, Metten Somers, S.C. Stansfield, J. Tsai, S. Williams, Antony Young, Sidney Zisook, E. Malievskaia (2022). \textit{The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2022.100511}{doi:10.1016/j.nsa.2022.100511}.
\item John Bailey, Joanna Kempner (2022). \textit{Standards Without Labs: Drug Development in the Psychedelic Underground}. Citizen Science Theory and Practice. [published; OpenAlex]. \href{https://doi.org/10.5334/cstp.527}{doi:10.5334/cstp.527}.
\item F. N. Smith, Joanna C. Neill, Verity Wainwright (2022). \textit{An Interpretative Phenomenological Analysis of the use of psilocybin by veterans with symptoms of trauma}. Drug Science Policy and Law. [published; OpenAlex]. \href{https://doi.org/10.1177/20503245221124117}{doi:10.1177/20503245221124117}.
\item Leger RF, Unterwald EM (2022). \textit{Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811211044688}{doi:10.1177/02698811211044688}.
\item Li NX, Hu YR, Chen WN, Zhang B (2022). \textit{Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2021.09.041}{doi:10.1016/j.jad.2021.09.041}.
\item Barnett BS, Parker SE, Weleff J (2022). \textit{United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.}. The International journal on drug policy. [published; PubMed]. \href{https://doi.org/10.1016/j.drugpo.2021.103473}{doi:10.1016/j.drugpo.2021.103473}.
\item Agin-Liebes G, Davis AK (2022). \textit{Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach.}. Current topics in behavioral neurosciences. [published; PubMed]. \href{https://doi.org/10.1007/7854\_2021\_282}{doi:10.1007/7854\_2021\_282}.
\item Sarris J, Pinzon Rubiano D, Day K, Galvão-Coelho NL, Perkins D (2022). \textit{Psychedelic medicines for mood disorders: current evidence and clinical considerations.}. Current opinion in psychiatry. [published; PubMed]. \href{https://doi.org/10.1097/yco.0000000000000759}{doi:10.1097/yco.0000000000000759}.
\item Sherwood AM, Kargbo RB, Kaylo KW, Cozzi NV, Meisenheimer P, Kaduk JA (2022). \textit{Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples.}. Acta crystallographica. Section C, Structural chemistry. [published; PubMed]. \href{https://doi.org/10.1107/s2053229621013164}{doi:10.1107/s2053229621013164}.
\item Rucker JJ, Marwood L, Ajantaival RJ, Bird C, Eriksson H, Harrison J, Lennard-Jones M, Mistry S, Saldarini F, Stansfield S, Tai SJ, Williams S, Weston N, Malievskaia E, Young AH (2022). \textit{The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811211064720}{doi:10.1177/02698811211064720}.
\item Strickland JC, Johnson MW (2022). \textit{Human behavioral pharmacology of psychedelics.}. Advances in pharmacology (San Diego, Calif.). [published; PubMed]. \href{https://doi.org/10.1016/bs.apha.2021.10.003}{doi:10.1016/bs.apha.2021.10.003}.
\item Plotnik L, Gibbs G, Graham T (2022). \textit{Psilocybin Conspectus: Status, Production Methods, and Considerations.}. International journal of medicinal mushrooms. [published; PubMed]. \href{https://doi.org/10.1615/intjmedmushrooms.2021041921}{doi:10.1615/intjmedmushrooms.2021041921}.
\item Mertens LJ, Koslowski M, Betzler F, Evens R, Gilles M, Jungaberle A, Jungaberle H, Majić T, Ströhle A, Wolff M, Wellek S, Gründer G (2022). \textit{Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.}. Neuroscience applied. [published; PubMed]. \href{https://doi.org/10.1016/j.nsa.2022.100104}{doi:10.1016/j.nsa.2022.100104}.
\item Raison CL, Jain R, Penn AD, Cole SP, Jain S (2022). \textit{Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2022.831092}{doi:10.3389/fpsyt.2022.831092}.
\item Pots W, Chakhssi F (2022). \textit{Psilocybin-Assisted Compassion Focused Therapy for Depression.}. Frontiers in psychology. [published; PubMed]. \href{https://doi.org/10.3389/fpsyg.2022.812930}{doi:10.3389/fpsyg.2022.812930}.
\item Ledwos N, Rosenblat JD, Blumberger DM, Castle DJ, McIntyre RS, Mulsant BH, Husain MI (2022). \textit{A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.}. Journal of clinical psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1097/jcp.0000000000001608}{doi:10.1097/jcp.0000000000001608}.
\item DellaCrosse M, Pleet M, Morton E, Ashtari A, Sakai K, Woolley J, Michalak E (2022). \textit{"A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use.}. PloS one. [published; PubMed]. \href{https://doi.org/10.1371/journal.pone.0279073}{doi:10.1371/journal.pone.0279073}.
\item Rabinowitz J, Lev-Ran S, Gross R (2022). \textit{The association between naturalistic use of psychedelics and co-occurring substance use disorders.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2022.1066369}{doi:10.3389/fpsyt.2022.1066369}.
\item University Hospital, Basel, Switzerland (2021). \textit{LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03153579}{source link}.
\item Niles H, Fogg C, Kelmendi B, Lazenby M (2021). \textit{Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies.}. BMC palliative care. [published; PubMed]. \href{https://doi.org/10.1186/s12904-021-00889-x}{doi:10.1186/s12904-021-00889-x}.
\item Louk J. M. J. Vanderschuren, Paul Willner, Emily M. Jutkiewicz, Bart Ellenbroek (2021). \textit{Announcement of two special issues: behavioural pharmacology of synaptopathies and psychedelic drugs}. Behavioural Pharmacology. [published; OpenAlex]. \href{https://doi.org/10.1097/fbp.0000000000000662}{doi:10.1097/fbp.0000000000000662}.
\item Horton DM, Morrison B, Schmidt J (2021). \textit{Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy.}. American journal of psychotherapy. [published; PubMed]. \href{https://doi.org/10.1176/appi.psychotherapy.20200055}{doi:10.1176/appi.psychotherapy.20200055}.
\item Yaden DB, Berghella AP, Regier PS, Garcia-Romeu A, Johnson MW, Hendricks PS (2021). \textit{Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs.}. The International journal on drug policy. [published; PubMed]. \href{https://doi.org/10.1016/j.drugpo.2021.103380}{doi:10.1016/j.drugpo.2021.103380}.
\item Rucker J, Jafari H, Mantingh T, Bird C, Modlin NL, Knight G, Reinholdt F, Day C, Carter B, Young A (2021). \textit{Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial.}. BMJ open. [published; PubMed]. \href{https://doi.org/10.1136/bmjopen-2021-056091}{doi:10.1136/bmjopen-2021-056091}.
\item Maryland Oncology Hematology, PA (2021). \textit{The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04593563}{source link}.
\item Ryan Cross﻿ (2021). \textit{Delix to synthesize psychedelic drugs}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-09936-buscon3}{doi:10.1021/cen-09936-buscon3}.
\item Fogg C, Michaels TI, de la Salle S, Jahn ZW, Williams MT (2021). \textit{Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.}. Experimental and clinical psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1037/pha0000490}{doi:10.1037/pha0000490}.
\item Yu CL, Yang FC, Yang SN, Tseng PT, Stubbs B, Yeh TC, Hsu CW, Li DJ, Liang CS (2021). \textit{Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis.}. Psychiatry investigation. [published; PubMed]. \href{https://doi.org/10.30773/pi.2021.0209}{doi:10.30773/pi.2021.0209}.
\item Benjamin R. Lewis, Kevin Byrne (2021). \textit{Is MDD the right target for early-stage psychedelic-assisted therapy trials?}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2021.00180}{doi:10.1556/2054.2021.00180}.
\item Tehseen Noorani, Jonny Martell (2021). \textit{New Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2021.727050}{doi:10.3389/fpsyt.2021.727050}.
\item Muthukumaraswamy SD, Forsyth A, Lumley T (2021). \textit{Blinding and expectancy confounds in psychedelic randomized controlled trials.}. Expert review of clinical pharmacology. [published; PubMed]. \href{https://doi.org/10.1080/17512433.2021.1933434}{doi:10.1080/17512433.2021.1933434}.
\item Ryan Cross﻿ (2021). \textit{Beckley raises funds for psychedelic drugs}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-09930-buscon17}{doi:10.1021/cen-09930-buscon17}.
\item Peixoto C, Santos F, Rego D, Medeiros H. (2021). \textit{Psychedelics and psychiatric disorders: A emerging role}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9470409}{source link}.
\item Fraga A, Esteves-Sousa D, Facucho-Oliveira J, Albuquerque M, Costa M, Dos Santos P, Moura N, Moutinho A. (2021). \textit{Effects of psilocybin-assisted therapy on treatment-resistant depression}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9480034}{source link}.
\item Descalço N, Medeiros A, Santos C, Borges G. (2021). \textit{Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?}. European psychiatry: the journal of the Association of European Psychiatrists. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9476072}{source link}.
\item Wayne Hall, Michael Farrell (2021). \textit{What can we learn from the history of research on psychedelic drugs in the addictions?}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.15560}{doi:10.1111/add.15560}.
\item Psiuk D, Nowak E, Cholewa K, Łopuszańska U, Samardakiewicz M (2021). \textit{The Potential Role of Serotonergic Hallucinogens in Depression Treatment.}. Life (Basel, Switzerland). [published; PubMed]. \href{https://doi.org/10.3390/life11080765}{doi:10.3390/life11080765}.
\item King's College London (2021). \textit{A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04959253}{source link}.
\item Mertens LJ, Preller KH (2021). \textit{Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.}. Pharmacopsychiatry. [published; PubMed]. \href{https://doi.org/10.1055/a-1341-1907}{doi:10.1055/a-1341-1907}.
\item Earleywine M, Ueno LF, Mian MN, Altman BR (2021). \textit{Cannabis-induced oceanic boundlessness.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881121997099}{doi:10.1177/0269881121997099}.
\item McCartney A, McGovern H, De Foe A. (2021). \textit{Psychedelic Assisted Therapy for Major Depressive Disorder: A Review}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/9kuhs}{doi:10.31234/osf.io/9kuhs}.
\item Annie McCartney, Hugh McGovern, Alexander De Foe (2021). \textit{Psychedelic Assisted Therapy for Major Depressive Disorder: A Review}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/9kuhs\_v1}{source link}.
\item McCulloch DE, Knudsen GM, Barrett FS, Doss M, Deco G, Carhart-Harris R, Rosas F, Preller K, Ramaekers J, Mason N, Müller F, Fisher PM. (2021). \textit{Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/64kyg}{doi:10.31234/osf.io/64kyg}.
\item Drummond E-Wen McCulloch, Gitte Moos Knudsen, Frederick Streeter Barrett, Manoj Doss, Gustavo Deco, Robin Carhart-Harris, Fernando Rosas, Katrin Preller, Johannes Ramaekers, Natasha Mason (2021). \textit{Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/64kyg\_v1}{source link}.
\item Chao YS, Horton J. (2021). \textit{Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders}. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON). [published; Europe PMC]. \href{https://europepmc.org/article/MED/36170470}{source link}.
\item Kelly JR, Crockett MT, Alexander L, Haran M, Baker A, Burke L, Brennan C, O'Keane V (2021). \textit{Psychedelic science in post-COVID-19 psychiatry.}. Irish journal of psychological medicine. [published; PubMed]. \href{https://doi.org/10.1017/ipm.2020.94}{doi:10.1017/ipm.2020.94}.
\item Daws R, Timmerman C, Giribaldi B, Sexton J, Wall M, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R. (2021). \textit{Decreased brain modularity after psilocybin therapy for depression.}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-513323/v1}{doi:10.21203/rs.3.rs-513323/v1}.
\item Evan Lewis-Healey, Ruben Eero Laukkonen, Michiel van Elk (2021). \textit{Future Directions for Clinical Psilocybin Research: The Relaxed Symptom Network}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.1037/pne0000290}{doi:10.1037/pne0000290}.
\item Lewis-Healey E, Laukkonen RE, van Elk M. (2021). \textit{Future Directions for Clinical Psilocybin Research: The Relaxed Symptom Network}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/q3ymd}{doi:10.31234/osf.io/q3ymd}.
\item Wayne Hall (2021). \textit{The need for publicly funded research on therapeutic use of psychedelic drugs}. World Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1002/wps.20847}{doi:10.1002/wps.20847}.
\item Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2021). \textit{Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.}. JAMA psychiatry. [published; PubMed]. \href{https://doi.org/10.1001/jamapsychiatry.2020.3285}{doi:10.1001/jamapsychiatry.2020.3285}.
\item Senese Nicolas, Nguyen Thu, Cologna Stephanie, Rasenick Mark (2021). \textit{Effects of the putative antidepressant psilocin on the lipid-raft proteome and lipid-raft signaling}. The FASEB Journal. [published; Crossref]. \href{https://doi.org/10.1096/fasebj.2021.35.s1.03168}{doi:10.1096/fasebj.2021.35.s1.03168}.
\item University of Zurich (2021). \textit{Characterization of Altered Waking States of Consciousness in Healthy Humans}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03853577}{source link}.
\item Henrik Børsting Jacobsen, Audun Stubhaug, Bjørn Holmøy, Tor Morten Kvam, Silje Endresen Rème (2021). \textit{Have Norwegians tried psilocybin, and do they accept it as a medicine?}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2021.00167}{doi:10.1556/2054.2021.00167}.
\item Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021). \textit{Trial of Psilocybin versus Escitalopram for Depression.}. The New England journal of medicine. [published; PubMed]. \href{https://doi.org/10.1056/nejmoa2032994}{doi:10.1056/nejmoa2032994}.
\item Zeifman RJ, Singhal N, Breslow L, Weissman CR (2021). \textit{On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review.}. ACS pharmacology \& translational science. [published; PubMed]. \href{https://doi.org/10.1021/acsptsci.1c00024}{doi:10.1021/acsptsci.1c00024}.
\item Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, Franco Corso S, Bjerre Real C, Guss J, Bossis A, Mennenga SE (2021). \textit{Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.}. ACS pharmacology \& translational science. [published; PubMed]. \href{https://doi.org/10.1021/acsptsci.1c00020}{doi:10.1021/acsptsci.1c00020}.
\item Gard DE, Pleet MM, Bradley ER, Penn A, Gallenstein ML, Riley LS, DellaCrosse M, Garfinkle E, Michalak EE, Woolley JD. (2021). \textit{Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2021.04.02.21254838}{doi:10.1101/2021.04.02.21254838}.
\item Nelson Descalço, Ana Beatriz Medeiros, Cátia Fernandes Santos, Guilherme Borges (2021). \textit{Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2021.1114}{doi:10.1192/j.eurpsy.2021.1114}.
\item A. Fraga, Daniel Esteves-Sousa, João Facucho-Oliveira, Margarida Albuquerque, M. Costa, Paulo Santos, Nuno Moura, A. Moutinho (2021). \textit{Effects of psilocybin-assisted therapy on treatment-resistant depression}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2021.1836}{doi:10.1192/j.eurpsy.2021.1836}.
\item Stanley N. Caroff (2021). \textit{The Return of Psychedelics: Still Time to Prevent Tragedy}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2021.4.8}{doi:10.1176/appi.pn.2021.4.8}.
\item Muthukumaraswamy S, Forsyth A, Lumley T. (2021). \textit{Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/q2hzm}{doi:10.31234/osf.io/q2hzm}.
\item Suresh Muthukumaraswamy, Anna Forsyth, Thomas Lumley (2021). \textit{Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/q2hzm\_v1}{source link}.
\item Avinash Hosanagar, Joseph Cusimano, Rajiv Radhakrishnan (2021). \textit{Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2}. The Journal of Clinical Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.4088/jcp.20ac13787}{doi:10.4088/jcp.20ac13787}.
\item Galvão-Coelho NL, Marx W, Gonzalez M, Sinclair J, de Manincor M, Perkins D, Sarris J (2021). \textit{Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-020-05719-1}{doi:10.1007/s00213-020-05719-1}.
\item Joost J. Breeksema, Martijn H B Koolen, Metten Somers, Robert A. Schoevers (2021). \textit{Behandeling met psilocybine}. Data Archiving and Networked Services (DANS). [published; OpenAlex]. \href{https://research.rug.nl/en/publications/5e83b45d-b208-402a-a435-f0380fad6429}{source link}.
\item Breeksema JJ, Koolen MHB, Somers M, Schoevers RA (2021). \textit{[Treatment with psilocybin: applications for patients with psychiatric disorders].}. Nederlands tijdschrift voor geneeskunde. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/33560605/}{source link}.
\item Inserra A, De Gregorio D, Gobbi G (2021). \textit{Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms.}. Pharmacological reviews. [published; PubMed]. \href{https://doi.org/10.1124/pharmrev.120.000056}{doi:10.1124/pharmrev.120.000056}.
\item Bouso JC, Ona G, Dos Santos RG, Hallak JEC (2021). \textit{Psychedelic Medicines in Major Depression: Progress and Future Challenges.}. Advances in experimental medicine and biology. [published; PubMed]. \href{https://doi.org/10.1007/978-981-33-6044-0\_26}{doi:10.1007/978-981-33-6044-0\_26}.
\item Tai SJ, Nielson EM, Lennard-Jones M, Johanna Ajantaival RL, Winzer R, Richards WA, Reinholdt F, Richards BD, Gasser P, Malievskaia E (2021). \textit{Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.586682}{doi:10.3389/fpsyt.2021.586682}.
\item Castro Santos H, Gama Marques J (2021). \textit{What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review.}. Porto biomedical journal. [published; PubMed]. \href{https://doi.org/10.1097/j.pbj.0000000000000128}{doi:10.1097/j.pbj.0000000000000128}.
\item Dos Santos RG, Bouso JC, Rocha JM, Rossi GN, Hallak JE (2021). \textit{The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges.}. Risk management and healthcare policy. [published; PubMed]. \href{https://doi.org/10.2147/rmhp.s300656}{doi:10.2147/rmhp.s300656}.
\item Rucker JJ, Young AH (2021). \textit{Psilocybin: From Serendipity to Credibility?}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.659044}{doi:10.3389/fpsyt.2021.659044}.
\item Dahmane Elyes, Hutson Paul R., Gobburu Jogarao V. S. (2021). \textit{Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin}. Clinical Pharmacology in Drug Development. [published; Crossref]. \href{https://doi.org/10.1002/cpdd.796}{doi:10.1002/cpdd.796}.
\item Spriggs MJ, Douglass HM, Park RJ, Read T, Danby JL, de Magalhães FJC, Alderton KL, Williams TM, Blemings A, Lafrance A, Nicholls DE, Erritzoe D, Nutt DJ, Carhart-Harris RL (2021). \textit{Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study".}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.735523}{doi:10.3389/fpsyt.2021.735523}.
\item Williams ML, Korevaar D, Harvey R, Fitzgerald PB, Liknaitzky P, O'Carroll S, Puspanathan P, Ross M, Strauss N, Bennett-Levy J (2021). \textit{Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.737738}{doi:10.3389/fpsyt.2021.737738}.
\item Gill H, Gill B, Chen-Li D, El-Halabi S, Rodrigues NB, Cha DS, Lipsitz O, Lee Y, Rosenblat JD, Majeed A, Mansur RB, Nasri F, Ho R, McIntyre RS (2020). \textit{The emerging role of psilocybin and MDMA in the treatment of mental illness.}. Expert review of neurotherapeutics. [published; PubMed]. \href{https://doi.org/10.1080/14737175.2020.1826931}{doi:10.1080/14737175.2020.1826931}.
\item Mason NL, Kuypers KPC, Müller F, Reckweg J, Tse DHY, Toennes SW, Hutten NRPW, Jansen JFA, Stiers P, Feilding A, Ramaekers JG (2020). \textit{Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin.}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/s41386-020-0718-8}{doi:10.1038/s41386-020-0718-8}.
\item Luoma JB, Chwyl C, Bathje G, Davis AK, Lancelotta RL. (2020). \textit{A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/nhbjk}{doi:10.31234/osf.io/nhbjk}.
\item Olivia Gosseries, Charlotte Martial (2020). \textit{The use of psychedelics in the treatment of disorders of consciousness. An interview with Olivia Gosseries by Charlotte Martial.}. Open Repository and Bibliography (University of Liège). [published; OpenAlex]. \href{https://doi.org/10.34700/gv0w-y052}{doi:10.34700/gv0w-y052}.
\item Russ Curtis, Lisen C. Roberts, Elizabeth Graves, Heather Thompson Rainey, D. D. Wynn, Daphne Krantz, Verena Wieloch (2020). \textit{The Role of Psychedelics and Counseling in Mental Health Treatment}. Journal of Mental Health Counseling. [published; OpenAlex]. \href{https://doi.org/10.17744/mehc.42.4.03}{doi:10.17744/mehc.42.4.03}.
\item Cozzi NV, Daley PF (2020). \textit{Synthesis and characterization of high-purity N,N-dimethyltryptamine hemifumarate for human clinical trials.}. Drug testing and analysis. [published; PubMed]. \href{https://doi.org/10.1002/dta.2889}{doi:10.1002/dta.2889}.
\item Nicole Harrington Cirino (2020). \textit{Wait for the Science Before Widespread Use of Psilocybin}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2020.10a32}{doi:10.1176/appi.pn.2020.10a32}.
\item Vitkauskas M, Mathuru AS (2020). \textit{Total Recall: Lateral Habenula and Psychedelics in the Study of Depression and Comorbid Brain Disorders.}. International journal of molecular sciences. [published; PubMed]. \href{https://doi.org/10.3390/ijms21186525}{doi:10.3390/ijms21186525}.
\item Vargas AS, Luís Â, Barroso M, Gallardo E, Pereira L (2020). \textit{Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases-A Systematic Review and Meta-Analysis of Clinical Trials.}. Biomedicines. [published; PubMed]. \href{https://doi.org/10.3390/biomedicines8090331}{doi:10.3390/biomedicines8090331}.
\item James E, Robertshaw TL, Hoskins M, Sessa B (2020). \textit{Psilocybin occasioned mystical-type experiences.}. Human psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1002/hup.2742}{doi:10.1002/hup.2742}.
\item Robin Carhart-Harris (2020). \textit{4 Psychedelics: therapeutic mechanisms}. Journal of Neurology Neurosurgery \& Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1136/jnnp-2020-bnpa.4}{doi:10.1136/jnnp-2020-bnpa.4}.
\item Fricke J, Kargbo R, Regestein L, Lenz C, Peschel G, Rosenbaum MA, Sherwood A, Hoffmeister D (2020). \textit{Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin.}. Chemistry (Weinheim an der Bergstrasse, Germany). [published; PubMed]. \href{https://doi.org/10.1002/chem.202000134}{doi:10.1002/chem.202000134}.
\item Milne N, Thomsen P, Mølgaard Knudsen N, Rubaszka P, Kristensen M, Borodina I (2020). \textit{Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives.}. Metabolic engineering. [published; PubMed]. \href{https://doi.org/10.1016/j.ymben.2019.12.007}{doi:10.1016/j.ymben.2019.12.007}.
\item Meinhardt MW, Güngör C, Skorodumov I, Mertens LJ, Spanagel R (2020). \textit{Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse.}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/s41386-020-0694-z}{doi:10.1038/s41386-020-0694-z}.
\item Luoma JB. (2020). \textit{A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/sgujx}{doi:10.31234/osf.io/sgujx}.
\item Greenway KT, Garel N, Jerome L, Feduccia AA (2020). \textit{Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.}. Expert review of clinical pharmacology. [published; PubMed]. \href{https://doi.org/10.1080/17512433.2020.1772054}{doi:10.1080/17512433.2020.1772054}.
\item Ron Shore (2020). \textit{Psychedelics, Safety and Clinical Trial Design}. QSpace (Queen's University Library). [published; OpenAlex]. \href{http://hdl.handle.net/1974/27835}{source link}.
\item Lea T, Amada N, Jungaberle H, Schecke H, Scherbaum N, Klein M (2020). \textit{Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-020-05477-0}{doi:10.1007/s00213-020-05477-0}.
\item Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, Kalin NH, McDonald WM, the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research (2020). \textit{Psychedelics and Psychedelic-Assisted Psychotherapy.}. The American journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1176/appi.ajp.2019.19010035}{doi:10.1176/appi.ajp.2019.19010035}.
\item University of Wisconsin, Madison (2020). \textit{Pharmacokinetics of Psilocybin in Normal Adult Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT02163707}{source link}.
\item Nick Zagorski (2020). \textit{Psychedelics for Psychiatric Disorders: More Research Needed}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2020.4a14}{doi:10.1176/appi.pn.2020.4a14}.
\item Katie O’Connor (2020). \textit{Can Psychedelics Radically Change SUD Treatment?}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2020.2a12}{doi:10.1176/appi.pn.2020.2a12}.
\item Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD (2020). \textit{Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.9b00493}{doi:10.1021/acschemneuro.9b00493}.
\item Dalton Budhram, Preet Dhaliwal (2020). \textit{Psilocybin Therapy for Depression: A Scoping Review Protocol}. Open MIND. [published; OpenAlex]. \href{https://osf.io/4syt6}{source link}.
\item Lea T, Amada N, Jungaberle H, Schecke H, Klein M (2020). \textit{Microdosing psychedelics: Motivations, subjective effects and harm reduction.}. The International journal on drug policy. [published; PubMed]. \href{https://doi.org/10.1016/j.drugpo.2019.11.008}{doi:10.1016/j.drugpo.2019.11.008}.
\item Foldi CJ, Liknaitzky P, Williams M, Oldfield BJ (2020). \textit{Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models.}. Frontiers in neuroscience. [published; PubMed]. \href{https://doi.org/10.3389/fnins.2020.00043}{doi:10.3389/fnins.2020.00043}.
\item Sofia Gyllvik (2019). \textit{The Therapeutic Potential of Psilocybin and 3,4-Methylenedioxymethamphetamine in the Treatment of Depression and Post-Traumatic Stress Disorder}. Diva portal (Dalarna University Library). [published; OpenAlex]. \href{http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-18729}{source link}.
\item Reham Shaba (2019). \textit{Development of an improved psilocybin synthesis}. Uppsala University Publications (Uppsala University). [published; OpenAlex]. \href{http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-420295}{source link}.
\item Shore R, Ioudovski P, Goldie C, McKeown S, Dumont E, Queen’s University, Kingston On. (2019). \textit{Mapping Psilocybin-Assisted Therapies: A Scoping Review}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2019.12.04.19013896}{doi:10.1101/2019.12.04.19013896}.
\item Laura Mertens, M.B. Wall, L. Roseman, L. Demetriou, D.J. Nutt, R.L. Carhart-Harris (2019). \textit{P.609 Therapeutic mechanisms of psychedelic drugs: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression}. European Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.euroneuro.2019.09.593}{doi:10.1016/j.euroneuro.2019.09.593}.
\item Adams AM, Kaplan NA, Wei Z, Brinton JD, Monnier CS, Enacopol AL, Ramelot TA, Jones JA (2019). \textit{In vivo production of psilocybin in E. coli.}. Metabolic engineering. [published; PubMed]. \href{https://doi.org/10.1016/j.ymben.2019.09.009}{doi:10.1016/j.ymben.2019.09.009}.
\item Fricke J, Sherwood A, Kargbo R, Orry A, Blei F, Naschberger A, Rupp B, Hoffmeister D (2019). \textit{Enzymatic Route toward 6-Methylated Baeocystin and Psilocybin.}. Chembiochem: a European journal of chemical biology. [published; PubMed]. \href{https://doi.org/10.1002/cbic.201900358}{doi:10.1002/cbic.201900358}.
\item Muttoni S, Ardissino M, John C (2019). \textit{Classical psychedelics for the treatment of depression and anxiety: A systematic review.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2019.07.076}{doi:10.1016/j.jad.2019.07.076}.
\item Dos Santos RG, Bouso JC, Hallak JEC (2019). \textit{Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer.}. BMC psychiatry. [published; PubMed]. \href{https://doi.org/10.1186/s12888-019-2288-z}{doi:10.1186/s12888-019-2288-z}.
\item Nick Zagorski (2019). \textit{Johns Hopkins Opens Research Center on Psychedelics}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2019.10a16}{doi:10.1176/appi.pn.2019.10a16}.
\item Megha Satyanarayana (2019). \textit{Modified E. coli pump out psilocybin}. C\&EN Global Enterprise. [published; OpenAlex]. \href{https://doi.org/10.1021/cen-09739-scicon9}{doi:10.1021/cen-09739-scicon9}.
\item Kelley C. O’Donnell, Sarah E. Mennenga, Michael P. Bogenschutz (2019). \textit{Psilocybin for depression: Considerations for clinical trial design}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2019.026}{doi:10.1556/2054.2019.026}.
\item Carhart-Harris RL, Friston KJ (2019). \textit{REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.}. Pharmacological reviews. [published; PubMed]. \href{https://doi.org/10.1124/pr.118.017160}{doi:10.1124/pr.118.017160}.
\item Richard Simoneaux (2019). \textit{The Potential of Psilocybin Administration in Terminal Cancer Patients}. Oncology Times. [published; OpenAlex]. \href{https://doi.org/10.1097/01.cot.0000574916.46844.cf}{doi:10.1097/01.cot.0000574916.46844.cf}.
\item Meghan Hibicke, Alexus N. Landry, Zoe K. Talman, Charles D. Nichols (2019). \textit{Psychedelics Improve the Mental Health of Rats}. The FASEB Journal. [published; OpenAlex]. \href{https://doi.org/10.1096/fasebj.2019.33.1\_supplement.666.1}{doi:10.1096/fasebj.2019.33.1\_supplement.666.1}.
\item Jenna Varley (2019). \textit{Psychedelic-assisted therapy for anxiety and depression in the face of death: A critical review with an anthropological lens}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2019.005}{doi:10.1556/2054.2019.005}.
\item Fricke J, Lenz C, Wick J, Blei F, Hoffmeister D (2019). \textit{Production Options for Psilocybin: Making of the Magic.}. Chemistry (Weinheim an der Bergstrasse, Germany). [published; PubMed]. \href{https://doi.org/10.1002/chem.201802758}{doi:10.1002/chem.201802758}.
\item Nutt D (2019). \textit{Psychedelic drugs-a new era in psychiatry?.}. Dialogues in clinical neuroscience. [published; PubMed]. \href{https://doi.org/10.31887/dcns.2019.21.2/dnutt}{doi:10.31887/dcns.2019.21.2/dnutt}.
\item Doblin RE, Christiansen M, Jerome L, Burge B (2019). \textit{The Past and Future of Psychedelic Science: An Introduction to This Issue.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2019.1606472}{doi:10.1080/02791072.2019.1606472}.
\item Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC (2019). \textit{Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2019.00672}{doi:10.3389/fpsyt.2019.00672}.
\item Rucker JJH, Iliff J, Nutt DJ (2018). \textit{Psychiatry \& the psychedelic drugs. Past, present \& future.}. Neuropharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.neuropharm.2017.12.040}{doi:10.1016/j.neuropharm.2017.12.040}.
\item Nichols DE (2018). \textit{Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD).}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.8b00043}{doi:10.1021/acschemneuro.8b00043}.
\item Aixalà M, Dos Santos RG, Hallak JEC, Bouso JC (2018). \textit{Psychedelics and Personality.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.8b00237}{doi:10.1021/acschemneuro.8b00237}.
\item Wasko MJ, Witt-Enderby PA, Surratt CK (2018). \textit{DARK Classics in Chemical Neuroscience: Ibogaine.}. ACS chemical neuroscience. [published; PubMed]. \href{https://doi.org/10.1021/acschemneuro.8b00294}{doi:10.1021/acschemneuro.8b00294}.
\item Ross S (2018). \textit{Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.}. International review of psychiatry (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1080/09540261.2018.1482261}{doi:10.1080/09540261.2018.1482261}.
\item Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T (2018). \textit{Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2017.09.012}{doi:10.1016/j.pnpbp.2017.09.012}.
\item Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ (2018). \textit{Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-017-4771-x}{doi:10.1007/s00213-017-4771-x}.
\item Link Swanson (2018). \textit{Unlearning to See: Linking the Perceptual and Clinical Effects of Psychedelic Drugs.}. Cognitive Science. [published; OpenAlex]. \href{https://escholarship.org/uc/item/67x0n7rq}{source link}.
\item Thomas Cody Swift (2018). \textit{Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Psychological Distress}. Western CEDAR (Western Washington University). [published; OpenAlex]. \href{https://cedar.wwu.edu/pci/lectures\_events/holistic\_pain\_management/3}{source link}.
\item Bogenschutz MP, Ross S (2018). \textit{Therapeutic Applications of Classic Hallucinogens.}. Current topics in behavioral neurosciences. [published; PubMed]. \href{https://doi.org/10.1007/7854\_2016\_464}{doi:10.1007/7854\_2016\_464}.
\item Canal CE (2018). \textit{Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.}. Handbook of experimental pharmacology. [published; PubMed]. \href{https://doi.org/10.1007/164\_2018\_107}{doi:10.1007/164\_2018\_107}.
\item Bogenschutz MP, Podrebarac SK, Duane JH, Amegadzie SS, Malone TC, Owens LT, Ross S, Mennenga SE (2018). \textit{Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2018.00100}{doi:10.3389/fphar.2018.00100}.
\item Nielson EM, May DG, Forcehimes AA, Bogenschutz MP (2018). \textit{The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2018.00132}{doi:10.3389/fphar.2018.00132}.
\item Barnby JM, Mehta MA (2018). \textit{Psilocybin and Mental Health-Don't Lose Control.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2018.00293}{doi:10.3389/fpsyt.2018.00293}.
\item Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, Thomas CD, Hetzel SJ, Henriquez KM, Ribaudo AS, Hutson PR (2017). \textit{Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.}. Clinical pharmacokinetics. [published; PubMed]. \href{https://doi.org/10.1007/s40262-017-0540-6}{doi:10.1007/s40262-017-0540-6}.
\item Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV (2017). \textit{Psychedelic Drugs in Biomedicine.}. Trends in pharmacological sciences. [published; PubMed]. \href{https://doi.org/10.1016/j.tips.2017.08.003}{doi:10.1016/j.tips.2017.08.003}.
\item Carhart-Harris RL, Goodwin GM (2017). \textit{The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.}. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. [published; PubMed]. \href{https://doi.org/10.1038/npp.2017.84}{doi:10.1038/npp.2017.84}.
\item Jonathan Nash (2017). \textit{Navigating Psychedelic Medicines through (Inter)national Regulation}. Northumbria Research Link (Northumbria University). [published; OpenAlex]. \href{http://nrl.northumbria.ac.uk/id/eprint/31692/1/\_\_Client\_H\%24\_Documents\_Breaking\%20Convention\%202017\%20Final.pptx}{source link}.
\item Stephen Bright, M.L. Williams, David Caldicott (2017). \textit{Should addiction researchers be interested in psychedelic science?}. Drug and Alcohol Review. [published; OpenAlex]. \href{https://doi.org/10.1111/dar.12544}{doi:10.1111/dar.12544}.
\item Thomas W. Flanagan, Melaine N. Sebastian, Charles D. Nichols (2017). \textit{Anti-inflammatory effects of serotonin 5-HT2A receptor activation in ovalbumin-induced allergic asthma models}. The FASEB Journal. [published; OpenAlex]. \href{https://doi.org/10.1096/fasebj.31.1\_supplement.820.4}{doi:10.1096/fasebj.31.1\_supplement.820.4}.
\item Barrett FS, Robbins H, Smooke D, Brown JL, Griffiths RR (2017). \textit{Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions.}. Frontiers in psychology. [published; PubMed]. \href{https://doi.org/10.3389/fpsyg.2017.01238}{doi:10.3389/fpsyg.2017.01238}.
\item Thomas K, Malcolm B, Lastra D (2017). \textit{Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2017.1320734}{doi:10.1080/02791072.2017.1320734}.
\item Roseman L, Nutt DJ, Carhart-Harris RL (2017). \textit{Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.}. Frontiers in pharmacology. [published; PubMed]. \href{https://doi.org/10.3389/fphar.2017.00974}{doi:10.3389/fphar.2017.00974}.
\item Rucker JJ, Jelen LA, Flynn S, Frowde KD, Young AH (2016). \textit{Psychedelics in the treatment of unipolar mood disorders: a systematic review.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881116679368}{doi:10.1177/0269881116679368}.
\item Patra S (2016). \textit{Return of the psychedelics: Psilocybin for treatment resistant depression.}. Asian journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.ajp.2016.08.010}{doi:10.1016/j.ajp.2016.08.010}.
\item Michael P. Bogenschutz, Alyssa A. Forcehimes (2016). \textit{Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism}. Journal of Humanistic Psychology. [published; OpenAlex]. \href{https://doi.org/10.1177/0022167816673493}{doi:10.1177/0022167816673493}.
\item Howland RH (2016). \textit{Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor.}. Journal of psychosocial nursing and mental health services. [published; PubMed]. \href{https://doi.org/10.3928/02793695-20160616-09}{doi:10.3928/02793695-20160616-09}.
\item Dos Santos RG, Osório FL, Crippa JA, Riba J, Zuardi AW, Hallak JE (2016). \textit{Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/2045125316638008}{doi:10.1177/2045125316638008}.
\item Tylš Filip, Páleníček Tomáš, Kadeřábek Lukáš, Lipski Michaela, Kubešová Anna, Horáček Jiří (2016). \textit{Sex differences and serotonergic mechanisms in the behavioural effects of psilocin}. Behavioural Pharmacology. [published; Crossref]. \href{https://doi.org/10.1097/fbp.0000000000000198}{doi:10.1097/fbp.0000000000000198}.
\item Tyls F, Michaela Viktorinova T, Prokopcova D, Korcak J, Androvicova R, Brunovsky M, Horacek J. (2016). \textit{PM506. Psilocybin Clinical Trial: Acute Effects and its relationship to the brain activity as measured by quantitative EEG}. The international journal of neuropsychopharmacology. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC5616440}{source link}.
\item Filip Tylš, Michaela Viktorinová, Dominika Prokopcova, Jakub Korčák, Renata Androvičová, Martin Brunovský, Jiřı́ Horáček (2016). \textit{PM506. Psilocybin Clinical Trial: Acute Effects and its relationship to the brain activity as measured by quantitative EEG}. The International Journal of Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1093/ijnp/pyw041.506}{doi:10.1093/ijnp/pyw041.506}.
\item Nichols DE (2016). \textit{Psychedelics.}. Pharmacological reviews. [published; PubMed]. \href{https://doi.org/10.1124/pr.115.011478}{doi:10.1124/pr.115.011478}.
\item Bogenschutz MP, Johnson MW (2016). \textit{Classic hallucinogens in the treatment of addictions.}. Progress in neuro-psychopharmacology \& biological psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.pnpbp.2015.03.002}{doi:10.1016/j.pnpbp.2015.03.002}.
\item Stephen Mo Hanan (2015). \textit{The Psyche in Psychedelic}. Tikkun. [published; OpenAlex]. \href{https://doi.org/10.1215/08879982-3328661}{doi:10.1215/08879982-3328661}.
\item Jochen Gartz, Georg Wiedemann (2015). \textit{Discovery of a new caerulescent Psilocybe mushroom in Germany: Psilocybe germanica sp.nov.}. Drug Testing and Analysis. [published; OpenAlex]. \href{https://doi.org/10.1002/dta.1795}{doi:10.1002/dta.1795}.
\item Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ (2015). \textit{Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/0269881114565144}{doi:10.1177/0269881114565144}.
\item Halberstadt AL (2015). \textit{Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.}. Behavioural brain research. [published; PubMed]. \href{https://doi.org/10.1016/j.bbr.2014.07.016}{doi:10.1016/j.bbr.2014.07.016}.
\item Baumeister D, Barnes G, Giaroli G, Tracy D (2014). \textit{Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/2045125314527985}{doi:10.1177/2045125314527985}.
\item Rick Doblin (2014). \textit{Stanislav Grof's Contributions to FDA Drug Development Research with Psychedelics}. CIIS Digital Commons (California Institute of Integral Studies). [published; OpenAlex]. \href{https://digitalcommons.ciis.edu/stanislavgrof2014/12}{source link}.
\item Nichols DE (2014). \textit{The Heffter Research Institute: past and hopeful future.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2014.873688}{doi:10.1080/02791072.2014.873688}.
\item Burdick BV, Adinoff B (2013). \textit{A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment.}. The American journal of drug and alcohol abuse. [published; PubMed]. \href{https://doi.org/10.3109/00952990.2013.811513}{doi:10.3109/00952990.2013.811513}.
\item Young SN (2013). \textit{Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.}. Journal of psychiatry \& neuroscience: JPN. [published; PubMed]. \href{https://doi.org/10.1503/jpn.120128}{doi:10.1503/jpn.120128}.
\item Bogenschutz MP (2013). \textit{Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin.}. Current drug abuse reviews. [published; PubMed]. \href{https://doi.org/10.2174/15733998113099990002}{doi:10.2174/15733998113099990002}.
\item Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, Hobden P, Sharp DJ, Evans J, Feilding A, Wise RG, Nutt DJ (2012). \textit{Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin.}. The British journal of psychiatry: the journal of mental science. [published; PubMed]. \href{https://doi.org/10.1192/bjp.bp.111.103309}{doi:10.1192/bjp.bp.111.103309}.
\item Frecska E, Luna LE (2006). \textit{The adverse effects of hallucinogens from intramural perspective.}. Neuropsychopharmacologia Hungarica: a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology. [published; PubMed]. \href{https://pubmed.ncbi.nlm.nih.gov/17211054/}{source link}.
\item Riba J, Rodríguez-Fornells A, Barbanoj MJ (2002). \textit{Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-002-1237-5}{doi:10.1007/s00213-002-1237-5}.
\end{enumerate}
\end{document}
